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SUMMARY
1) Phenobarbitone (PB) was administered to male C3H/He and 
C57B1/5 strain mice (high and low incidence of spontaneous 
hepatic nodule formation respectively), and to Sprague-DawTey 
rats at several dose levels for up to 14 days. Maximal 
stimulation of hepatic microsomal cytochrome P-450 content and 
some associated enzyme activities occurred at doses ^7 5  mg/kg/day 
to mice and ^ 125 mg/kg/day to rats.
2) A maximally stimulating dose of PB (85 mg/kg/day) was 
administered in the diet to C3H/He mice for up to 90 weeks, and 
aspects of liver growth and enzyme induction were measured. 
Synthesis of DNA accompanied an increase of liver size. After 
the initial growth period liver size remained constant until the 
development of large hepatic nodules, which were readily 
dissectable after 70 weeks of treatment. Activities of both 
Phase I and Phase II xenobiotic metabolising enzymes were 
induced by PB treatment, and remained stimulated throughout the 
entire period of PB administration. Enzyme activities in 
nodular tissue were similar to those in host tissue, and 
induction was reversible on cessation of treatment. PB appeared 
to induce similar form(s) of cytochrome P-450 in both nodules 
and host tissue.
3) The inductive effect of short term PB treatment to the rat 
and two mouse strains on aspects of glutathione metabolism was 
investigated. Similarly the metabolism and excretion of 
[^"^c]PB was investigated. No differences between species and 
strains were detected that might explain the differing 
susceptibilities to hepatic nodule formation.
4) The effect of prolonged dietary administration of the 
hepatocarcinogen o-aminoazotoluene, at a concentration of 
0.03%, on hepatic xenobiotic metabolising enzymes was 
investigated in the two mouse strains. During nodule formation 
enzyme induction was noted, although induction was not seen 
when a higher dose of the carcinogen was used.
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21 INTRODUCTION
1.1 Hepatic Xenobiotic Metabolism
1.1.1 Liver Structure
In the developing mouse the liver derives from endodermal 
cells and develops as a bud off the foregut at 9^ days 
(Rugh 1964). In the adult the liver consists of four 
major lobes; the left, median, right and caudate. 
Arterial blood is supplied by the hepatic artery, but 
a further afferent supply via the portal vein brings 
venous blood from the spleen, stomach, small and large 
intestine and pancreas. Thus nutrients and anutrients 
present in the blood after absorption are transported 
directly to the liver. In the liver the conducting 
portal veins, hepatic arterioles and bile ducts lie 
together in portal triads, separate from the terminal 
hepatic vein, giving rise to the concept of the liver 
lobule. Three schemes have been used to describe 
histological and functional units of the liver and 
although different, these concepts are not necessarily 
in conflict (Jones and Spring-Mills 1977).
The classic lobule is seen as a roughly hexagonal area 
with a portal triad at each apex, equidistant from a 
central vein. Blood flows from the portal vein and 
hepatic artery through blood sinusoids lined with
hépatocytes and past the parenchymal cells to the 
central vein. This lobule concept illustrates the 
endocrine function of the liver and, by demarcation 
of periportal, midzonal and centrilobular areas, has 
been used to describe certain lesions e.g. centrilobular 
necrosis.
In contrast the portal lobule is a triangular area 
with the central vein at each apex and a portal triad 
within. Bile is moved in the opposite direction to 
blood flow, that is from the central area to the bile 
canniculus in the portal triad. This scheme demonstrates 
the exocrine functions of the liver lobule.
The liver acinus is the smallest unit of the liver and 
comprises a roughly oval shaped area formed between two . 
central veins and encompassing the two interposing portal 
triads. The acinus has been divided into three metabolic 
zones called Rappaport areas 1, 2 and 3 (Rappaport et al 
1954). Area 1 surrounds the terminal branches of the 
portal vessels and is exposed to high concentrations of 
oxygen. Oxygen tension declines towards area 3 and this 
fact may have some significance in toxic effects across 
the lobule (Rappaport 1969). However some workers have 
disputed the Rappaport delineation of oxygen gradients 
(Matsumoto et al 1979). Rappaport areas 1, 2 and 3 
compare approximately to periportal, midzonal and
4centrilobular areas respectively, of the classic lobule. 
However some parts of Rappaport area 3 may closely 
approach the portal triad.
1,1.2 Distribution of Hepatic Xenobiotic 
Metabolising Enzymes.
The liver acinus has been defined by Rappaport (see 1.1.1) 
as having regions of different oxygen tension. Other 
differences in morphological and biochemical characteristics 
of cells within the lobule have been identified (Gumcicio 
and Miller 1982). In the centrilobular regions cells are 
smaller than those of the periportal area, have less 
glycogen stored, have more smooth endoplasmic reticulum 
and more numerous, but smaller mitochondria. Distribution 
of enzymes including alcohol dehydrogenase (Greenberger 
1965), 7-ethoxycoumarin 0-deethylase (Ji et al 1981), 
glucuronidase and sulphatase (Ullrich et al 1984;
Conway et al 1982), and epoxide hydrolase (Bentley et al 1979) 
have been studied in rats by a variety of techniques 
including histochemistry, fluorescence and immunochemistry. 
Some components of the microsomal electron transport 
chain, including cytochrome P-450 and cytochrome c (P-450) 
reductase, have also been extensively studied to map 
their intralobular distribution. Both direct measurement 
and immunohistochemical techniques show twice the 
cytochrome P-450 content in centrilobular cells of 
untreated rats as in periportal cells (Gooding et al 1978;
5Baron et al 1978). More recent work in the rat has 
demonstrated that phenobarbitone (PB) inducible 
cytochrome(s) P-450 is present in a concentration 
gradient, maximal in the centrilobular region and 
declining through the midzonal to the periportal areas, 
in all liver lobes (Baron et al 1981). However the 
20-methylcholanthrene inducible cytochrome(s) P-450 
(cytochrome "P-448"), whilst greatest in the centrilobular 
area is similar in the midzonal and periportal areas.
After 20-methylcholanthrene treatment, cytochrome P-450 
levels were induced to a greater extent in midzonal and 
periportal cells than in centrilobular cells (Baron et al 
1982).
It has been suggested that the centrilobular localisation 
of detoxifying enzymes, such as epoxide hydrolase and 
glutathione S-transferase, distant from the portal 
localisation of cytochromes often involved in the 
activation of carcinogens, could be an important factor 
in the susceptibility of certain regions to chemical 
carcinogens (Wolf et al 1984).
Enzymes are further compartmentalised within the cell.
Early work by DeDuve and coworkers (1955) utilised 
differential centrifugation to isolate subcellular 
organelles and thereby investigate their enzymology.
A summary of the subcellular locations of some xenobiotic 
metabolising enzymes is shown in Table 1.1. The microsomal
6Table 1.1. Subcellular distribution of xenobiotic
metabolising enzymes
Enzyme
Subcellular fraction
Nuclei Mitochondria Microsomes Cytosol
Cytochrome P-450 + + +++
Epoxide hydrolase + +-H- +,
Conjugation with:
“ glucuronic acid + -H-f-
sulphate +
- reduced glutathione + + 4- +++
- amino acids +
Monoamine oxidase +-H- +
Alcohol and aldehyde
dehydrogenases + + +
Relative enzyme concentration is indicated by the number of 
crosses.
7fraction mainly represents rough and smooth endoplasmic 
reticulum, which forms vesicles upon homogenisation 
(Claude 1969). However simple centrifugation results 
in the presence of plasma membrane fragments, lysosomes 
and peroxisomes as contaminants.
Cytochrome P-450, and thus its associated enzyme activities, 
is largely associated with the microsomal fraction, 
Conjugative enzymes are mainly present in both microsomal 
and cytosolic fractions. Indeed, with certain exceptions, 
it may be seen that the majority of xenobiotic metabolism 
occurs in these two subcellular fractions.
1.1.3 Xenobiotic Metabolism.
The xenobiotic metabolising enzymes are part of a homeostatic 
mechanism involved in the metabolism of various endogenous 
compounds such as steroids, fatty acids, and vitamins.
However these enzymes can also metabolise foreign 
compounds that may be absorbed such as bacterial, fungal 
^nd plant toxins. Recent technological advances in 
organic chemistry have added thousands of synthetic 
anutrient molecules to those that may be encountered of 
natural origin.
In general, nonpolar xenobiotics are potentially toxic 
(Remmer 1970), as nonpolar molecules are reabsorbed in
8the kidney tubule. Thus the strategy to eliminate 
xenobiotics is one that increases water solubility.
Portal blood from the gut enables the liver to metabolize 
molecules before they reach other organs and although the 
gut epithelium, kidneys and lungs may also participate, 
the liver is the major metabolic site of xenobiotics.
The metabolism of xenobiotics has been divided by 
Williams (1959) into two phases; the first phase 
comprising metabolic transformation reactions and the 
second phase conjugation or synthetic reactions. A 
simple example is the conversion of benzene to phenol 
(Phase I) and the conjugation of phenol to form 
phenylglucuronide and phenylsulphate (Phase II). It 
should be noted that not all compounds are subject to 
both phases of metabolism and that conjugate formation 
does not preclude subsequent Phase I metabolism. Some 
of the pathways associated with Phase I and Phase II 
metabolism are shown in Table 1.2. Of all the Phase I 
reactions the most important are those transformations 
catalysed by the microsomal cytochrome P-450 complex.
This enzyme system is often referred to as mixed function 
oxidase (m.f.o.) as both reducing (NADPH) and oxidising 
(molecular oxygen) equivalents are required. A xenobiotic 
may thus be metabolised by the following scheme:
Cytochrome P-450 ^
RH + NADPH + H + 0^ ------------  ► RGH + NADP + H^O
9Table 1.2. Reactions of Phase I and Phase II Metabolism.
PHASE I METABOLIC REACTIONS
Oxidation by microsomal enzymes
e.g. hydroxylation of aromatic and aliphatic 
compounds, epoxidation, N-hydroxylation, N-oxidation, 
S-oxidation, dealkylation, deamination and 
desuIphuration.
Reduction by microsomal enzymes
e.g. reduction of nitro and azo compounds.
Non-microsomal oxidation
e.g. oxidation of alcohols and aldehydes, deamination.
Non-microsomal reduction
e.g. reduction of aldehydes and ketones.
Hydrolysis
e.g. hydrolysis of esters and amides by microsomal 
and non-microsomal enzymes.
2,
PHASE II METABOLIC REACTIONS
Epoxide hydration
Conjugation with: D-glucuronic acid, reduced glutathione,
sulphate, amino acids , acetate, methyl groups, phosphate 
and D-glucose.
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Whilst cytochrome P-450 dependent enzymes catalyse 
many types of transformation a common mechanism of 
hydroxylation is involved (Parke 1975) (Table 1.3).
Cytochrome P-450 is a collective term for a family of
haemoproteins with broad, but overlapping substrate
specificities. A simplified scheme showing the
mechanism of cytochrome P-450 catalysed oxidations
is shown in Fig. 1.1. The substrate (RH) binds to
the oxidised form of the cytochrome, which is then
reduced by the introduction of one electron derived from
NADPH via an NADPH-dependent flavoprotein (Fp) reductase
enzyme. In further steps a second electron (from either
NADPH or NADH via a NADH-dependent flavoprotein
reductase and cytochrome b^) and molecular oxygen
are introduced, and finally the oxidised xenobiotic
and water are released. The precise participation of
cytochrome b^ in this electron transport chain and the
exact structure of the enzyme system has not been fully
elucidated (Alvares 1982). The system itself is located
largely in the smooth endoplasmic reticulum with each
cytochrome P-450 reductase molecule in the lipid
membrane surrounded by perhaps 20 cytochrome P-450
molecules (Estabrook et al 1977). However, small
amounts of cytochrome P-450 have been located in the
nucleus and mitochondria (Jernstrom et al 1976;
Bresnick et al 1977).
Table 1.3. Cytochrome P-450.Dependent Hydroxylation.
Aromatic hydroxylation
CgHsR
(0)
HOCgH^R
Aliphatic hydroxylation
RCH.
(0)
- ►  R C H 2 O H
0-Dealkylation
ROCH,
(0)
'IrOCH oh]— ►  ROH + HCHO
N-Dealkylation
RNCH.
(0)
Deamination
R.
R
CHNH^
(0) R ^
, C(0H)NH - ►  CO + NH.
Sulphoxidation
RSR
(0)
-►[r s o h r J - ►  RSOR: + H"*"
N-Oxidation
/ // 
RRRN
(O)
►  [r r r n o h]"^ — ► rreIn o  + h ‘
1 2
OU)
IQ.
0)
E
o
JZ
o
o
>
Ü
E
Q)
(A>
(/)
O0)
LU
O)
il
O
CD
4— "
a
L_
4— >
CO
JD
D
(D
X
cc
Xo
<
CL
Q
<
1 3
Synthetic (Phase II) reactions commonly involve 
binding of endogenous molecules such as glucuronic 
acid, amino acids, glutathione, sulphate and glucose 
to a polar group of xenobiotic (Caldwell 1982).
Epoxide hydrolase (E.C.3.3.2.3) conjugates water with 
an epoxide group. Thus the substrate is frequently 
a product of Phase. 1 metabolism. The conjugate is 
usually more polar and acidic than its precursor, 
favouring urinary excretion. Glucuronic acid 
conjugation, a major Phase 11 pathway in rodents, is 
a microsomal enzyme associated with the lipid membrane. 
However a major group of isozymes, the glutathione 
S-transferases,which are ubiquitous in mammalian 
tissues, are located largely in the cytosolic fraction 
of the liver. However significant microsomal and 
mitochondrial activity has also been detected 
(Mukhtar et al 1981).
1.1.4 Factors Affecting Xenobiotic Metabolism.
Many factors influence metabolic processes, including 
diet, age, sex, genotype, endocrine status, diurnal 
variations, disease states and chemical induction or 
inhibition, and these have been extensively discussed 
(Lake and Gangolli 1981; Zimmerman 1978).
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The effects of variation of dietary macronutrients 
such as protein, carbohydrate and lipid, as well as 
micronutrients such as vitamins and minerals have been 
reviewed by Campbell and Hayes (1974). Fasting must 
be distinguished from prolonged treatment with 
specifically deficient diets. In addition to affecting 
some enzyme activities fasting leads to depletion of 
glutathione, a compound that has a role in detoxification 
of certain molecules (see Chapter 6). High intake of 
various sugars has been shown to increase sleeping time 
in mice (Strother et al 1971). High dietary protein 
content can result in enzyme induction (Kappas et al 1975). 
Conversely protein deprivation leads to depressed m.f.o. 
enzyme activity (McLean and McLean 1969; Campbell and 
Hayes 1974) in rats, but the degree of protein deficiency, 
and indeed other factors including sex (Cram et al 1970), 
species and stress (Campbell and Hayes 1974) may affect 
enzyme activities. Bock et al (1973) cautioned that as 
liver weight and microsomal protein content are both 
changed during fasting the method of expression of 
enzyme activities may influence the effects seen.
Dietary anutrients possibly represent the greatest source 
of exposure to foreign compounds. Vfliile certain food 
additives (e.g. the antioxidant butylated hydroxytoluene,
1 5
Gilbert and Golberg 1955) and contaminants 
(e.g. the pesticide DDT, and polychlorinated biphenyls, 
Alvares and Kappas 1977; Hart and Pouts 1953) are known 
to induce xenobiotic metabolism in animals, à number 
of naturally occurring compounds are also capable of 
enzyme induction. For example the natural anutrients 
safrole (Crampton et al I977i), caffeine (Mitoma et al 
1959), flavones and related compounds (Wattenberg 
et al 1958) and indoles (Kappas et al 1975) have been 
shown to stimulate hepatic and extrahepatic xenobiotic 
metabolism in experimental animals.
Drug metabolising enzymes in mammals do not develop 
until the principal organs have acquired some degree 
of functional competence (Pelkonen 1982). In rodents 
a pattern of enzyme development has been noted, 
notwithstanding variability between laboratories 
(see review. Short et al 1975). Typically some enzyme 
activities, including N-demethylation and aliphatic 
and aromatic hydroxylation, rise from a low or undetectable 
level at parturition to adult levels in about 30-40 days. 
UDP-Glucuronyltransferase (E.G.2.4.1.17) enzymes have 
been classified into two groups according to their 
stage of development, that is "late foetal” or "neonatal" 
(Wishart 1978). Smooth endoplasmic reticulum and thus 
m.f.o. enzyme activity was not seen until after birth in 
the mouse (Peters et al 1953).
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In senescence, animals show a different pattern of 
xenobiotic metabolism. Cytochrome P-450 content is 
often depressed as are many, but not all, m.f.o. 
enzyme activities. This may indicate a changing 
complement of cytochromes as well as reduced total 
cytochrome P-450 content. Senescent rats and mice are 
still able to respond to some extent to inducing agents 
(Birnbaum and Baird 1978; Birnbaum 1980; Rikans and 
Notley 1982).
Consistent sex differences in drug metabolism between 
male and female rats have been demonstrated. Male rats 
are able to metabolise many drugs faster than females, 
and this is apparently due to qualitative rather than 
quantitative changes in the cytochrome P-450 complement 
(see review, Kato and Kamataki 1982). The mouse however 
does not exhibit the sex differences seen in the rat 
(Kato and Kamataki 1982).
Large changes in the rates of xenobiotic metabolism 
may be achieved as a result of treatment with chemical 
inducing agents. This enhancement is usually associated 
with increased liver size and proliferation of smooth 
endoplasmic reticulum. Induction of m.f.o. enzyme 
activities was first demonstrated by Conney et al (1956) 
using polycyclic hydrocarbons. Later the potent inducing 
action of barbiturates was demonstrated (Remmer 1959).
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Although both Phase I and Phase II metabolism can be 
induced, most information is available on the induction 
of the m.f.o. system. Inducers have been categorized 
into two main classes; typified by either phenobarbitone 
or polycyclic hydrocarbons such as 20-methylcholanthrene. 
The major features of induction in each class including 
processes not dependent on cytochrome P-450 are summarised 
in Table 1.4. Certain compounds such as polychlorinated 
biphenyl mixtures induce both these cytochrome types 
(Ryan et al 1977), and other inducers such as safrole,
rifampicin and clofibrate apparently induce individual
\
forms of cytochrome P-450 (Tredger et al 1981; loannides 
et al 1981; Gibson et al 1982). Several different 
cytochrome P-450 forms have been isolated, and this 
subject has been reviewed by Lu and West (1980).
It is probable that the various catalytic activities 
attributed to cytochrome P-450 are accounted for by the 
existence of multiple forms of the cytochrome which 
exhibit different but overlapping substrate spécificités 
(Paine 1981). In this thesis the form(s) specifically 
induced by PB is referred to as "P-450" and that induced 
by polycyclic hydrocarbons as "P-448".
It has been noted that many known carcinogens are capable 
of induction, particularly of "P-448" and that this 
induction process differs from that typified by PB,
1 8
Table 1.4. Some characteristics of PB or
20-Methylcholanthrene induction
PB
Physical character
Molecular weight
Soret peak, of CO-reduced 
cytochrome complex
Ethylisocyanide interaÆion 
spectra. Peak height ratio 
455 : 430nra
Enzyme activities
Metabolism of; 
benzphetamine 
ethylmorphine 
7-ethoxycoumarin 
7-ethoxyresorufin 
benzo(a)pyrene 
testosterone
Glucuronyltransferase ;
Late foetal group 
subs trates-l-nap&thol
-4-methyl umbelliferone 
Neonatal group 
substrates-4-hydroxybiphenyl 
-morphine
Epoxide hydrolase
48,000 
450 nm
20-Methylcholanthrene
53,000 
448 nm
t
t I 
f t 
ft 
t
I or no change
no change
t
I or no change 
I or no change
f t 
t t 
t t 
t”
t
no change
no change
^ 16-Hydroxylation 
^ 7-Hydroxylation
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in that there is little proliferation of endoplasmic 
reticulum and the onset of induction takes several 
days (Parke 1981). Induction of cytochrome "P-448" 
can change the direction of metabolism, for example 
favouring 2-hydroxylation of biphenyl rather than 
4-hydroxylation (Nebert et al 1977). It has been 
suggested that prolonged treatment with certain weak 
carcinogens may result in ligand binding of reactive 
metabolites to cytochrome P-450, and that such loss 
of activity, or damage, results in enhanced cytochrome 
”P-448” activity, and thus cytotoxic processes that may 
lead to neoplasia (Parke 1981).
1.1.5 Consequences of Xenobiotic Metabolism.
Clearly the process of metabolic transformation of a 
molecule will also change its effects on a biological 
system. As previously discussed metabolism tends to 
render a molecule more polar and thus more water soluble 
(see section 1.1.3). This facilitates urinary and/or 
biliary excretion.
However metabolism may alter the pharmacological potency 
(if any) of a molecule. Metabolic activation of 
imipramine to desmethylimipramine, an antidepressant.
2 0
is mediated by the liver. Similarly inactivation may 
occur, as seen when the tranquillizer meprobamate 
is metabolised to hydroxymeprobamate.
A further consequence of metabolism is altered toxicity 
of a molecule. Metabolic processes generally result 
in reduced toxicity, by deactivating reactive groups 
and promoting excretion. However metabolism in some 
cases also generates reactive metabolites. It has 
been considered that chemically reactive metabolites may 
be the cause of serious forms of toxicity, including 
necrosis, mutagenesis and carcinogenesis (Williams 1977).
The production of reactive intermediates by the cytochrome 
P-450 m.f.o. system has often been demonstrated and 
Fig. 1.2 shows two pathways of activation of benzo(a)- 
pyrene. The generation of highly reactive molecules 
within the cell may lead to covalent binding of the 
metabolites with cell macromolecules. Such binding 
was initially shown using azo-dyes (Miller and Miller 1947), 
but more recently radioisotopes have been used to 
demonstrate binding both in vivo and in vitro (Lake 1984; 
Gillette 1974). It has also been demonstrated that in 
certain instances conjugative metabolism, usually 
regarded as a detoxification pathway,may generate 
reactive molecules. For example 2-acetylaminofluorene
2Fig.1.2 Two Pathways of Benzo(a)pyrene (BP) Metabolism, 
Showing Formation of Reactive Interm ediates
1 2 t
BP-4,5-oxide  
(covalent binding)
P - 4 5 0
OIO
OIO
EH
OIO
OIQ
7 ,8 -ox ide OH
OH
BP-4,5-dihydrodiol
BP-7,8-dihydrodiol
4 5 0
O.
oip.c3g
| p - -
BP-7,8-d ihydrodio l-9 ,10-epoxide  
(covalent binding)
P-450,cytochrom e P -4 5 0  
EH,epoxide hydrolase 
K,K-region 
B,bay-region
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is first hydroxylated by m.f.o. enzymes but subsequent 
sulphation produces the ultimate carcinogen (Weisberger 
and Williams 1975). A schematic representation of 
possible toxification and detoxification pathways, 
with some specific examples is shown in Fig. 1.3.
Whilst all toxicity may not be a result of covalent 
binding of reactive molecules to cell components, it 
seems that interaction with DNA or RNA is a prerequisite 
of a genotoxic carcinogen. Although total binding of a 
chemical carcinogen does not correlate well with 
carcinogenic potency, due probably to the multiplicity 
of reactive metabolites and binding sites (Miller and 
Miller 1977), the identification of specific carcinogen 
adducts with informational molecules may prove fruitful. 
For example at least 12 sites of alkylation of DNA have 
been identified under physiological conditions, and 
repair enzymes have been identified for 4 of these 
(Pegg 1984).
A further consequence of xenobiotic metabolism is the 
generation of active oxygen species. Some of the oxygen 
consumed by microsomal drug oxidation in vitro is released 
in the form of H 2 O2 (Gillette et al 1957;Nordblom and 
Coon 1977). This is apparently formed from superoxide 
radicals by superoxide dismutase (E.C.1.15.I.1). The
2 3
F ig .1.3 Pathways of Xenobiotic  Metabolism -  Toxification  
and D etoxification
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superoxide radicals may be generated by either
redox cycling (see Chapter 6) or inefficient oxidation
of cytochrome P-450 substrates (Wendel and Feuerstein
1981). Furthermore it has been proposed that a form 
of cytochrome P-450, inducible by benzene and ethanol, 
specifically generates superoxide radicals,, and thus 
hydroxyl radicals, which may then participate in 
hydroxylation of certain xenobiotics (including 
benzene and ethanol) (Ingleman-Sundberg and Hagbjork
1982). Normally active oxygen species are detoxified 
by superoxide dismutase, catalase (E.C.1.11.1.6) and 
glutathione peroxidase (E.C.1.11.1.9), but under certain 
conditions these reactive molecules can be shown to result 
in peroxidation of lipids (Wendel 1980; Wendel and 
Feuerstein 1981). Indeed certain hypolipidaemic agents 
which cause peroxisome proliferation may, by way of 
increased p-oxidation and concomitant H 2 O2 generation, 
result in membrane damage such as lipid peroxidation;
it has been found that several peroxisome proliferators 
increase hepatic tumour numbers in rats and mice 
(see review, Reddy and Lalwani 1983). Thus reactive 
oxygen molecules may provide a mechanism of damage to 
cellular informational molecules.
25
1.2 Hepatic Tumoriqenesis
1.2.1 Nomenclature of Carcinogenesis.
As many different types of tumour have been described 
in both animals and man the precise meaning of many 
terms has become confused (Pitot 1978). For example 
due to clinical use ’’cancer”, ’’tumour”, ’’neoplasia” 
and ’’malignancy” have all come to mean a metastais isingj [
neoplasia. Definitions of the terms used in this 
thesis follow suggestions of Pitot (1978). Hypertrophy 
is an increase in cell size. Hyperplasia is an increase 
in cell number and/or genetic material (Shulte-Hermann 
1974). Hyperplasia normally refers only to increases 
in cell number, but the ability of hepatic cells to 
readily exist in polyploid states confuses normal 
histological assessment of hyperplasia. Hyperplasia 
is neither a unique characteristic nor an absolute 
requirement of neoplasia. A hyperplastic nodule is an 
area of hyperplasia that is macroscopically distinct 
from surrounding tissue. A tumour is any mass of tissue 
different from normal physiological growth, and thus 
does not infer benign or malignant activity. For example 
scar and callus tissue are tumours. A neoplasm is 
defined as a ’’relatively autonomous growth of tissue” .
The degree of autonomy is variable, but not total,and 
the rate of growth may be less than, similar to, or more 
than that of host tissue. Cancer and carcinogenesis
are used in their clinical sense as referring to 
malignant neoplasia. The principal behaviour of both 
benign and malignant neoplasms are shown in Table 1.5.
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Table 1.5. Characteristic Behaviour of Benign 
and Malignant Neoplasms
BENIGN MALIGNANT
Encapsulated Non encapsulated
Not invasive Invasive
Highly differentiated Poorly differentiated
Rare mitoses More common mitoses
Slow growth Rapid growth
Little to no anaplasia Variable anaplasia
No métastasés Métastasés
(after Pitot,H.C. (1978) , Fundamentals of Oncology,
Marcel Dekker Inc., New York.)
These definitions are largely subjective. A metastasis 
(secondary growth at a site different to the primary 
neoplasm) where seen positively identifies malignancy. 
However other changes are open to histological 
interpretation and thus to different diagnoses.
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1.2.2 Classification of M o u æ Hepatic Nodules.
In a paper dealing with the toxicology of dieldrin 
Walker et al (1972) classified mouse hepatic nodules 
as Type A, a simple nodular growth of liver paranchymal 
cells, or Type B, areas of papilliform and adenoid 
growth. This nomenclature has been used by many 
investigators; Type A nodules regarded as benign 
adenomas and Type B nodules, often associated with 
métastasés» as carcinoma. Furthermore the studies of 
Walker et al (l972) and others (Ward 1980? Lipsky et al 
1981; Thorpe and Walker 1973) suggest that Type A 
nodules are the precursors of Type B. Gellatly (1975) 
classified mouse hepatic paranchymal nodules into 3 types; 
Type 1 being highly differentiated, acidophilic and 
not transplantable. Type 2 of variable differentiation, 
weakly acidophilic to intensely basophilic and of 
variable transplantability and Type 3, moderately to 
poorly differentiated, basophilic and frequently 
transplantable. Vesselinovitch et al (1978) classified 
primary liver lesions into hyperplastic nodules, 
adenomatous nodules and trabecular nodules of which 
only the last was considered to be carcinoma.
Recently Becker (1982) presented a new classification 
of four morphologically separable lesions, of which
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I and II are comparable to Walker's Type A and 
III and IV are Walker's Type B. Becker found Types 
I and II only in a strain of mouse predisposed to 
spontaneous nodule formation, suggesting that these 
nodule types do not precede Types III and IV.
1.2.3 Spontaneous Hepatic Nodules.
The variation in susceptibility of the mouse to hepatic 
nodule formation including the occurrence of "spontaneous" 
nodules in untreated animals has led to problems of 
interpretation in^toxicity and carcinogenicity studies 
(Grasso and Crampton 1972). Heston and Vlahakis (1955) 
demonstrated that sex, genotype and body weight influenced 
spontaneous hepatoma formation. Generally, in a given 
strain, such hepatomas are more frequent in males than 
females (Turusov and Takayama 1979). Inbred strains 
of mouse have differing rates of spontaneous hepatoma, 
the C3H strain generally displaying a high rate and 
the C57 strain a low rate (Table 1.5).
Several other factors have been shown to affect the 
frequency of spontaneous nodule formation in mice.
For example, tumour numbers were increased by housing 
mice on sawdust bedding compared to filter paper bedding. 
Furthermore the tumour incidence was reduced by feeding 
a purified (semi synthetic) diet (Tennekes and Wright 1978).
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Table 1.6. Spontaneous Murine Hepatic Tumours
Mouse Strain
Number 
of Animals Tumour incidence %
(Sub strain) d' Î d' $
C3H 461 10 37 0
(y/Aa) 94 - 88 -
(Hep) 323 - 32
BALB/C 49 51 0 0
Charles River 137 144 2 1.5
C57(B1) 143 171 1 1
ASH CS l 429 420 5 0 -
CBA 285 229 41 27
For references see Grasso, P. and Hardy, J., (1975), 
in Mouse Hepatic Neoplasia, eds. Butler, W.H. and 
Newberne, P.M., Elsevier Publishing Company, Amsterdam.
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These factors appeared to operate independently of each 
other. Occurrence of nodules is reduced by caloric 
restriction (Tucker 1979; Tannenbaum 1959) lowered 
dietary protein (Tannenbaum and Silverstone 1949) and 
lowered dietary fat (Tannenbaum 1942). Also nodule 
incidence may be modified by presence or absence of 
gut flora (Roe and Grant 1970, Mizutani and Mitsuoka 
1979).
1.2.4 Chemical Carcinogenes is.
One of the first clear descriptions of chemical 
carcinogenesis dates from 1775 when Percival Pott, 
by clinical observation, associated contact with soot 
sustained by child chimney sweeps with subsequent 
development of adult scrotal cancer.
The first experimental hepatic tumours were reported 
following administration of o-aminoazotoluene to mice 
(Yoshida 1932). Identification of a polycyclic 
hydrocarbon as a skin carcinogen stimulated work on 
the carcinogenicity of this molecular species (Kennaway 
1955; Miller 1978). Potent carcinogens are commonly 
found in some other groups of organic chemicals including 
the nitrosamines, aflatoxins and steroids. Indeed simple 
aliphatic coumpounds such as ethyl carbamate, ethionine 
and carbontetrachloride are carcinogenic in rodent 
species (see Zimmerman 1978). Thus the question arises
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whether such a diverse range of chemicals have a common 
mechanism of action.
Most carcinogens are metabolised to what has been 
termed the "ultimate carcinogen", that is the actual 
molecule that initiates the carcinogenic lesion. The 
metabolic pathway leading to formation of the ultimate 
carcinogen may not be the major route of metabolism, 
and furthermore may be affected by the factors 
previously discussed (Section 1.1.4). Ultimate 
carcinogens have frequently been demonstrated to be 
reactive molecules. For example polycyclic hydrocarbon 
metabolism results in epoxide formation (Fig.1.2)
(Sims and Grover 1974). Although K-region epoxides 
have been demonstrated, non K-region epoxides are 
assumed by identification of dihydrodiols. Conney (1982) 
has reviewed the evidence that bay-region diol-epoxides 
are ultimate carcinogens of polycyclic hydrocarbons.
This hypothesis has been effective in predicting 
carcinogenic activity, although some carcinogenic 
polycyclic hydrocarbons have no bay region (Harvey 1980). 
Other carcinogenic compounds are capable of biological 
alkylation after metabolism (Ross 1962). For example 
nitrosamines are metabolised by an as yet undefined 
mechanism to give the alkyl carbonium ion (Zimmerman 1978).
Such reactive electrophilic metabolites permit reaction 
with nucleophiiic centrefs (Sarma et al 1975;
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Miller 1978; Magee 1983) which may be found on 
cell macromolecules including DNA (Fig. 1.4). Binding 
of carcinogens to macromolecules was first shown by 
Miller and Miller (1947) who demonstrated that during 
hepatocarcinogenesis azo dyes became bound covalently 
to liver proteins, but not to neoplasm proteins. 
Subsequently binding to DNA and RNA was demonstrated 
(Lawson 1970). Synthetic epoxides of benz(a)anthracene 
and benzo(a)pyrene covalently bind to nucleotides 
in vitro and these have been compared to DNA adducts 
obtained from in vivo exposure (Sims 1977). K-region 
epoxides apparently react preferentially with poly(G) 
compared to poly(A) (Swaisland et al 1974), but do not 
bind to apurines. The ultimate carcinogen of 
2-acetaminofluorene has been found to bind to DNA and 
RNA, with a preference for guanine moieties (Warwick 
1971). There is evidence that alkylation of guanine 
to 0^-methylguanine is significant in the carcinogenic 
process as opposed to the formation of, for instance,
7- and 3-methylguanine (Pegg 1984). There are several 
repair processes that can excise damaged bases and 
repair DNA with new bases, so carcinogenesis can be 
considered as a result of failure of these systems 
(Thielmann 1984).
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Fig. 1.4 Nucleophiiic Centres of Nucleotides That React With 
Electrophilic M etabo lites  of Carcinogens
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1.2.5 Two Stage Model of Carcinogenesis.
The concept that carcinogenesis may be divided into 
two stages ; initiation and promotion, was suggested 
many j ' years ago (Berenblum and Shubik 1947). The 
theory suggests that cells may be irreversibly altered 
by a short, sometimes single dose, exposure to an 
initiating agent. Subsequently these altered cells 
may be stimulated into uncontrolled growth by prolonged 
exposure to a promoting agent (Fig. 1.5).
Although much early work on initiation of tumours was 
performed using the mouse skin model much data relating 
toxic chemicals to hepatic carcinoma is available.
Most known carcinogens are not active by themselves but 
are metabolised to one or more active metabolites. As 
the liver is the major site of metabolism, it is 
particularly susceptible to chemical carcinogenesis.
The reactive metabolites of most known carcinogens 
are positively charged apd thus have affinity for 
electron dense areas (Miller 1978). Carcinogen binding 
to DNA has been extensively studied due to the probable 
role of altered DNA in carcinogenesis (Rajalakshmi et al
1982), although other macromolecules may be involved.
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Fig. 1.5 Stages of initiation and Promotion During 
Hepatic  Carcinogenesis
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If a dose of carcinogen (initiator) is not followed 
within about two days by cell division the initiation 
does not occur. Thus it is probable that the putative 
lesion in DNA can be repaired. Indeed Cleaver (1969) 
found that cells derived from xeroderma pigmentosum 
patients, who are genetically predisposed to sunlight 
induced skin cancer, demonstrated impaired excision 
of ultraviolet induced DNA lesions. If cell division 
does occur before repair the damage to a single strand 
of DNA can be incorporated into double stranded DNA, 
and thus not subject to repair processes (Farber 1983).
Thus a permanent change is made in some hepatocytes.
If no selective stimulation of initiated hepatocytes 
occurs the initiated cells may exist in a quiescent 
state for long periods. If stimulated the initiated 
cells divide to form small foci and larger hyperplastic 
nodules. The majority of these nodules undergo a 
retrodifferentiation process called neodifferentiation 
{Farber and Cameron 1980), changing to resemble both 
structurally and histochemically normal tissue (Farber 
1976). These nodules are not apparently neoplastic 
(Farber and Cameron 1980). However a minority of such 
nodules may not remodel and with further stimulation 
may again change behaviour and become a true hepatocellular
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carcinoma (Fig. 1.5). The number and nature of these 
changes are as yet unknown but prolonged administration 
of promoting agents, not in themselves carcinogenic, 
can effect the transformation of initiated hepatocytes 
into frank carcinoma.
1.2.6 Enzyme Inducers and Nodule Formation.
Several known carcinogens are capable of stimulating 
hepatic enzyme induction to some extent. The degree of 
induction may be great as with 20-methylcholanthrene, 
or small and transient as with 3-methyl-4-dimethyl 
aminoazo benzene and Ponceau MX (Hutterer et al 1969j 
Crampton et al 19771), Other potent inducers of xenobiotic 
metabolism have been shown to be capable of promoting 
the lesions initiated by genotoxic carcinogens. Such 
compounds include sex steroids, certain hypolipidaemic 
agents, drugs including PB and pesticides and contaminants 
such as DDT, hexachlorocyclohexane and 2,3,7,8-tetra- 
chlorodibenzo-p-dioxin (Peraino et al 1975; Pitot et al 
1980; Schulte-Hermann and Parzefall 1981; Taper 1978).
Furthermore certain m.f.o. enzyme inducers can lead to 
increased hepatic tumour incidence in rodents without 
prior exposure to initiating agents. Such increased 
tumour incidence requires long term treatment at a high
53
dose, and thus investigations of such aspects such
' -
as dose response relationships have been poorly 
researched. These compounds do not give positive 
results in mutagenicity assays and thus have been 
classed as epigenetic carcinogens (Williams 1981); 
that is their mode of action does not include direct 
attack on DNA. This is in contrast to genotoxic 
carcinogens that directly affect DNA (Williams 1980).
The precise mechanism of action of epigenetic carcinogens 
is as yet unknown but theories of altered cell 
communication (Williams 1981), aiding the expression 
of preexisting oncogenic factors (Boutwell 1974) 
and the promotion of spontaneous or 
previously formed preneoplastic lesions (Schulte- 
Hermann et al 1983b; Telang et al 1982) have been 
suggested. Schulte-Hermann (1979) suggested that 
enzyme induction may not be sustained over long periods 
in animals susceptible to tumour formation. Alternatively 
prolonged metabolism of m.f.o. enzyme substrates and 
concomitant generation of active oxygen species could 
cause oxidative damage to informational intracellular 
molecules and/or intracellular membranes and thence 
tumour formation.
In the mouse the susceptibility of an inbred strain 
to tumour formation by enzyme inducers is linked to the
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rate of spontaneous nodule formation. For example 
Becker (1982) reported that in contrast to the C3H 
mouse strain where both spontaneous and induced 
nodules were found, the C57 strain did not develop 
spontaneous nodules or form nodules in response to 
phenobarbitone. Similarly the rat has a low rate of 
spontaneous hepatic nodule formation (for example 
about 2% in the Wistar strain, Schulte—Hermannet_aj. 
1983a) and is relatively resistant to tumour formation 
following enzyme inducers. Thus the elucidation of 
the mechanism of tumour formation in response to 
enzyme inducers may lie in the comparison of
i ,
susceptible and resistant mouse strains.
1.3 Aims of This Thesis.
This thesis sets out to compare and contrast the effects 
of PB, a compound that results in hepatic enzyme 
induction with short term treatment and hepatic 
tumours in varying numbers with prolonged treatment, 
after acute and chronic administration to two mouse 
strains and a strain of rat. The responses of both 
species and strains, particularly with relation to 
enzyme induction were studied for differences that 
might be relevant to nodule formation.
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Specific approaches to this work were:
1) Investigation of the effect of stock and 
semisynthetic diets on hepatic enzymes involved in 
the metabolism of xenobiotics in a rat strain and 
two strains of mouse. To determine a dose of PB
that maximally induced hepatic m.f.o. enzyme activities 
in both species and strains, and to find the most 
suitable method for chronic delivery of the maximally 
stimulating dose.
2) To investigate the effect of prolonged administration 
of the maximally stimulating dose of PB on several 
hepatic parameters including hepatic growth and 
xenobiotic metabolism in the C3H/He strain mouse.
3) To compare the metabolic fate of [^^c]PB in a rat 
strain and two mouse strains with and without previous 
enzyme induction by PB. Similarly to compare the 
response of enzymes of glutathione metabolism that
are responsible for cellular protection from reactive
■-.Î
molecules.
4) To study the process of enzyme induction by the 
known carcinogen o-aminoazotoluene during tumourigenesis jV 
in two mouse strains.
CHAPTER 2
MATERIALS AND METHODS
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MATERIALS AND METHODS
2.1 Substrates
The following compounds were used as substrates in enzyme 
assays and were obtained from the sources stated;
Aniline - British Drug Houses.
Benzo(a)pyrene - Aldrich Chemical Co.
Biphenyl - Sigma Chemical Co.
DL-Carnitine - Sigma Chemical Co.
l-Chloro-2,4=dinitrobenzene - Fisons Scientific Equipment. 
Cytochrome c - Sigma Chemical Co.
1.2-Dichloro-4-nitrobenzene - Aldrich Chemical Co.
1.2-Epoxy-3-(£-nitrophenoxy)propane - Sigma Chemical Co. 
7-Ethoxycoumarin - Aldrich Chemical Co.
7-Ethoxyresorufin - Pierce and Warrinner UK Ltd.
Ethylmorphine hydrochloride - May and Baker Ltd. 
Glucose-6-phosphate - Sigma Chemical Co.
Glutathione (oxidised and reduced) - Sigma Chemical Co. 
L-*-Glutamyl-7-amino-4-methylcoumarin - Uniscience Cambridge Ltd. 
4-Hydroxybiphenyl - Sigma Chemical Co.
Nitrobenzyl chloride - Aldrich Chemical Co.
Sodium Succinate - Sigma Chemical Co.
2.2 Standards
Albumin (bovine fraction IV), 4-aminophenol, 7-amino-4-methylcoumaD 
DMA (calf thymus), glutathione, 4-hydroxybiphenyl and 
7-hydroxycoumarin were obtained from the Sigma Chemical 
Co.. Formaldehyde (38% w/v) and sodium dihydrogen 
orthophosphate were purchased from Fisons Scientific Equipment 
Ltd., and resorufin was the generous gift of ICI Pharmaceuticals 
Ltd.
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2.3 Cofactors and Enzymes
Cofactors and purified enzymes listed below were obtained 
from the Sigma Chemical Co.;
Acetyl Coenzyme A.
p-Glucuronidase (B.C.3.2.1.31) from mollusk.
Cytochrome c .
Glutathione (oxidised and reduced).
4-Iodonitrotetrazolium violet.
DL-isocitric acid.
Isocitrate dehydrogenase (E.C.1.1.1.42).
NAD , NADH, NADP, NADPH.
Sulphatase (E.C.3.1.6.1) from mollusk.
UDP-glucuronic acid.
2.4 Isotopes
The following isotopes were obtained from Amersham 
International pic.
6 Thymidine, 26 Ci/mmol specific activity (98.8% pure).
Pheno [2-1 ^ ^c] barbitone, 2 3mC i/mmol specific activity (98% pure).
Ring-U-C^^clAcetaminophen, 1.27mCi/mmol specific activity 
{98% pure), was synthesised at BIBRA (Lake et al 1981).
2.5 Other Chemicals^
All other reagents were of the highest purity available.
2.6 Gases
Carbon monoxide and oxygen free nitrogen were purchased from 
the British Oxygen Company Ltd., Morden, UK.
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2.7 Ethyl Isocyanide
Ethyl isocyanide was synthesised according to the method of 
Jackson and McKusick (1955) and stored in sealed containers 
at -20°C.
2.8 Inducing Agents
Sodium Phenobarbitone (5-ethyl-5-phenyl sodium barbiturate)
>98% pure was obtained from British Drug Houses.
p-Maphthoflavone ( 5,5-benzof lavone) was obtained from Aldrich 
Chemical Co.
Q-Aminoazotoluene (4-amino-2, ^ -dimethylazobenzene,OAT) was 
obtained from Sigma Chemical Co.
2.9 Inhibitors
o<-Naphthoflavone (7,8-benzoflavone) was obtained from the 
Aldrich Chemical Company.
Metyrapone (2-methyl-1,2-bis- (3-pyridyl)-1-propanone) was the 
generous gift of CIBA Laboratories, Horsham, Sussex.
2.10 Buffers
Ammediol (2-amino-2-methyl propane-1,3-diol), cacodylic acid, / 
glycine. Tris, Tris maleate and -sodium phosphate were used 
as buffers. The concentration and pH used are given with details 
of individual assays. Adjustments of pH were made using 
1. OM HCl or l . O A l  NaOH, at room temperature.
2.11 Animals
Male C3H/Heola and C57Bl/6ola strains of mice were obtained 
from OLAC 1976 Ltd. (Bicester, Oxon, UK) at 3-4 weeks of age. 
Male Sprague-Dawley rats were obtained from the same source 
at 6-8 weeks of age.
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2.12 Animal Housing
Rats and mice were housed 4 per cage in plastic cages with 
stainless steel wire grid floors and lids. Tap water was 
available ad lib. Food was available ad lib, and was formulated 
as described below (2.13). Animals were housed in rooms 
containing no other species and were maintained at a 
temperature of 20 - 2°C and a relative humidity of 55-10%.
To standardise the effects of circadian variations the animal 
rooms were subjected to a 24 hour light-dark cycle with the 
light phase from 0700 to 1900 hours GMT.
Mice receiving OAT in the diet were housed in similar cages 
in a positive pressure filtered air plastic isolator.
2.13 Animal Diet
Mice and rats were fed either semisynthetic or stock (LAD2,
Spratts Ltd., Barking, Essex) diet. Two different formulations 
of semisynthetic diet were used. For the long term administration 
of PB to C3H/He mice the diet designated RHM (Labsure Animal 
Foods, Poole, Dorset) was used. For all other studies the 
diet designated SS2 (mixed at BIBRA) was used. The differences 
between the two semieynthetic diets ar-e shown in Tables 2.1 and 2.2
2.14 Administration of Test Compounds
2.14.1 When PB was administered in the diet, food and water 
consumption and body weight were monitored on a representative 
number of specifically designated cages of control and test 
mice, initially every week. After 10 weeks data was collected 
for 1 week in every 4 and after 40 weeks 1 week in 8; The 
mean body weight and food intake of the test group was used 
to calculate the concentration of PB in the diet that would give
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Table 2.1 Semisynthetic diets - major components.
Component
Proportion in 
SS2
the diet (% w/w) 
RHM
Casein 21.5 20
DL-Methionine 0 0.2
Corn Starch 58 55
Corn Oil 10 5
Fibre 4.5 13.8
(Solka floe BWlOO)
Minerals^ 5 5
Vitamins^ 1 1
^ BP Nutrition
Table 2.2 Semisynthetic diets - mineral mix.
Element SS2 RHM
Ca 6
a
g 10 g
P 4 g 5 g
Na 0.5 g 0.5 g
. Cl 0.2 g 0.2 g
Mg 0.4 g 2 g
K 5 g . 5 g
Fe 35 mg 35 mg
Cu 5 mg 5 mg
Mn 50 ,mg 50 mg
Zn 15 mg 15 mg
I 0.2 mg 0.2 mg
Se 0.1 mg 0.1 mg
Cr 0.3 mg 0.3 mg
Values are the weight/kg in the diet.
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the appropriate daily dose. Wasteage by scattering diet from 
the cage was estimated to be less than 5% of that consumed and 
no allowance for this was made when calculating PB concentration 
in the diet.
The measured weight of PB was initially mixed with 10% of the 
diet for 20 minutes in a rotary mixer. This premix was 
subsequently mixed with the remaining diet for 20 minutes. 
Concentration of PB in the diet was checked at BIBRA by gas 
chromatography using the method of Brochmann-Hanssen and 
Oke (1969) . The diet was remixed if the analysed concentration 
differed from the expected concentration by more than 10%.
2.14.2 When OAT was administered in the diet a concentration 
of either 0.03 or 0.04% (w/w), was used. The OAT was dissolved 
in corn oil and then mixed with the diet for 20 minutes in a 
twin cone mixer.
2.15 In Vivo Metabolism Studies
The metabolism and elimination of (^^c] PB by rats and mice was 
investigated. Pheno[2-^^cjbarbitone was administered orally, 
at a dose of 85 mg/kg (6ja-Ci/animal) to mice or 150 mg/kg 
(7.5^Ci/animal) to rats. Both rats and mice were housed 
individually in the appropriate size of "Metabowl” (Jencons 
Ltd., Hemel-Hempstead); an all glass metabolism cage designed 
for the free collection of urine, faeces and expired CO 2 .
Sample collection continued for up to 7 days. CO2 was collected 
by pumping air from the Metabowl through a trap containing 
ethoxyethanol/ethanolamine (80:20 v/v).
9Urine was collected into flasks containing a small quantity 
(approx. O.lg) of NaF as preservative.
Faeces were homogenised in a convenient volume of water 
using an Ultra-Turrax homogeniser.
Aliquots of the collected samples were used for determination 
of radioactivity as described below (2.16).
After collection of urine and faeces, animals were killed by 
cervical dislocation and designated organs removed and 
combusted in a Packard sample oxidiser and collected radioactivity 
determined as described below (2.16).
2.16 Scintillation Spectrometry
Samples ( 1 ml) for determination of radioactivity were mixed 
with 10 ml of ethoxyethanol/toluene 1:1 (v/v) containing 
0.4% (w/v) 2,5-diphenyloxazole. Samples were stored in a
refrigerator for at least 2 hours to eliminate chemiluminescence 
and then radioactivity determined in a Packard (Caversham,
Bucks, UK) Tri-Carb Model 2650 liquid scintillation spectrometer. 
Correction for quenching was by the external channels ratio 
method. Highly coloured samples such as blood were decolourised 
by addition of a small volume of H^O^. When colour was 
eliminated, chemiluminescence was reduced by addition of 1.0 ml 0.5M HCl.
2.17 Preparation of Liver Homoqenates and Subcellular Fractions 
Animals were killed by cervical dislocation, the livers 
immediately excised, rinsed in ice cold isotonic (0.154 M) KCl
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containing 50 mM Tris-HCl pH 7.4, blotted dry, weighed and 
homogenised using a Potter type. Teflon/glass motor driven 
homogeniser (A.H. Thomas, Pennsylvania, USA). When large 
readily dissectable liver nodules were present these were 
separated from the surrounding host tissue and treated as a 
separate tissue pool. When necessary small nodules were combined 
to make one tissue pool. Mouse liver homogenates were prepared 
at a concentration of 0,1 g fresh tissue/ml homogenising 
medium. Rat liver homogenates were prepared at a concentration 
of 0.25 g fresh tissue/ml (Chapter 3) or at 0.1 g fresh 
tissue/ml (Chapter 5),
Liver homogenates were centrifuged at 10,OOOg (MSB, Crawley, 
Sussex, UK, High Speed 18, 8 x 50 ml rotor) for 20 minutes at 
4°C. The postmitochondrial supernatant was decanted and 
further centrifuged at 158,OOOg (MSB Prepspin 65, 8 x 14 ml 
rotor 50,000 r.p.m.) for 41 minutes at 4^C.
The 158,000g supernatant, or cytosol, was aspirated into fresh 
containers using a Pasteur pipette to avoid contamination by 
the surface fat layer. The microsomal pellet was resuspended 
in homogenising medium and resedimented as described above.
The washed microsomal fraction was resuspended in homogenising 
medium to the original concentration of 0.1 or 0.25 g fresh 
tissue/ml.
The preparation of tissue homogenates and subcellular fractions 
was carried out as rapidly as possible, using ice cold containers 
and buffer. Fractions were kept in ice, and were used on the 
day of preparation. Whole liver homogenates were stored frozen
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at -20°C for the subsequent measurement of V-glutamyl 
transpeptidase and carnitine acetyltransferase (see sections 2.24 
and 2.25).
2.18 Estimation of Non-protein Sulphydryl.
Hepatic non-protein sulphydryl levels, shown to largely consist 
of reduced glutathione (Moron et al 1979), were measured by 
the method of Ellman (1959) with the modifications of Sedlak 
and Linsay (1968). To 0.5 ml of whole liver homogenate was 
added 1.0 ml of cold 10% (w/v) trichloroacetic acid (TCA) 
containing 10 mM ethylenediaminetetraacetic acid (EDTA) and 
the precipitate was sedimented by centrifugation at 1200g 
(MSB Coolspin 2000 r.p.m.) for 10 minutes at 4°C. To duplicate 
0.5 ml aliquots of the supernatant was added 5.0 ml of 0.2 M 
phosphate buffer pH 8.2, into which was thoroughly mixed 
50 ^1 of 5,5-dithiobis-(2-nitrobenzoic acid) (Bllman's reagent), 
dissolved in methanol. Blank tubes received methanol alone. 
Aqueous solutions of freshly prepared reduced glutathione 
(0-t).l pmol) were used as standards for every set of estimations. 
Absorption was measured at 412nm after 30 minutes using a 
Cecil CE272 spectrophotometer (Cecil Instruments, Cambridge,
UK). The efficiency of the assay was estimated by adding 
aliquots of glutathione to some test samples and was found 
to be greater than 95%.
2.19 Bstimation of Protein
Protein measurement was carried out by the method of Lowry 
et al (1951). Samples were initially diluted with 0.5 M NaOH. 
Some proteins were not readily soluble, such as whole homogenate 
and TCA precipitates, and these were incubated overnight in 
stoppered tubes at 37°C. Aliquots were taken into test tubes
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and made to 1.0 ml with 0.5 M NaOH. 5 ml of freshly prepared 
reagent C (100 parts 2%(w/v)Na2C0^, 1 part l%(w/v)CuSO^.SH^O 
and 1 part 2%(w/v)Na/K tartrate) was added. After at least 
10 minutes 0.5 ml of Folin and Ciocalteau's Phenol reagent 
(diluted 1 in 3 with distilled water; equivalent to about IN) 
was added and thoroughly mixed. After 30 minutes tube contents 
were mixed and the absorption at 720nm measured using a Cecil 
CE272 spectrophotometer. Suitable blanks (1.0 ml 0.5 M NaOH) 
and standards (50-200 pg of Fraction V bovine serum albumin) 
were also assayed.
2.20 Estimation of DNA
Hepatic DNA content was measured by the method of Kissane and 
Robins (1958) as modified by Setaro and Morley (1976). To 1 ml 
aliquots of whole homogenate (equivalent to 0.1 g wet tissue) 
were added 4 ml 10%(w/v) TCA, mixed and centrifuged at 1200g 
for 3 minutes (MSB Coolspin). The supernatant was discarded 
and the pellet washed a further 2 times with 10%(w/v) TCA.
The pellet was then drained well and resuspended in 2 ml 
ethanol and left at room température for ID minutes. The sample 
was centrifuged at 1200g for 3 minutes and the ethanol discarded. 
The pellet was resuspended in 2 ml of 0.1 M potassium acetate 
in ethanol and incubated at 60°C for 15 minutes with the tubes
•-Î
stoppered. The pellet was resedimented at 1200g for 3 minutes, 
the ethanol fully drained off and resuspended in 2 ml 1 M 
perchloric acid. Tubes were stoppered and incubated at 85°C 
for 30 minutes to extract the DNA. After incubation tubes were 
centrifuged at 1200g for 3 minutes and 20 pi samples of the 
supernatant used for estimation of DNA. Calf thymus DNA was 
used as standard in a range from 0 to 8 pg. DNA was assayed
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by addition of 100 pi of 300 mg/ml diaminobenzoic acid, 
mixing and incubation at 60°C for 30 minutes. Perchloric 
acid (0.5 M) was added to give a final volume of 2 ml and 
fluorescence determined at 520 nm with excitation 420 nm 
with a Perkin-Elmer (Beaconsfield, Bucks., UK) MPF3L 
fluorescence spectrometer.
2.21 Incorporation of P h ]Thymidine into DNA
Synthesis and repair of DNA was measured by the incorporation 
of P h ]thymidine into DNA in vivo in mice. Animals were given 
ImCi 6-ipHjthymidine/kg body weight 1 hour before sacrifice. 
Radioactivity in the perchloric acid ENA extract was determined 
as described in 2.16,
2.22 Measurement of Enzyme Activities
The enzyme assays described below were all checked to ensure 
that activity was a linear function of time of incubation and 
tissue concentration. Furthermore, where possible, optimal 
cofactor and substrate concentrations and pH were used to 
ensure maximal activity. These conditions have on occasions 
differed between the rat and the mouse. Many of the problems 
of determination of in vitro rates of drug metabolising enzymes 
have been discussed by Fouts (1970).
2.23 Measurement of Succinate Dehydrogenase (E.C.1.3.99.1) 
Incubation mixtures were set up on ice in 10 ml screw top tubes 
(V.A. Howe, London), and consisted of 0.7 ml 0.2 M phosphate 
buffer pH7.8 containing 0.5 mg 4-iodonitrotetrazolium violet 
and 0.1 ml of whole homogenate diluted 1 in 10 with unbuffered 
0.154 M KCl. Tube contents were mixed, and after 2 minutes 
preincubation at 37°C, 0.2 ml of 0.3 M sodium succinate 
(adjusted to pH7.8) was quickly added and the assay mixtures
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were incubated in a shaking waterbath at 37°C for 2-4 minutes, 
when a visable colour developed. Reactions were stopped by 
the addition of 1.5 ml 10% w/v TCA. Succinate was added to 
blank tubes, and 5.0 ml ethyl acetate was added to all tubes, 
screw caps fastened and tubes shaken vigorously by hand for 
approximately 10 seconds. Tubes were then centrifuged at 
300g (MSB Coolspin) for 3 minutes at 4°C to separate the 
phases. The upper ethyl acetate layer was aspirated into 
clean, dry, glass cuvettes and the extinction determined on a 
Cecil CE272 spectrophotometer at 491 nm, employing ethyl acetate 
to zero the instrument. Results were calculated using an
O  O  _  1
extinction coefficient 20,1x10 .cm .mol for reduced 
4-iodonitrotetrazolium violet. '
2.24 Measurement of Carnitine Acetyltransferase (E.C.2.3.1.7) 
Carnitine acetyltransferase was measured by modification of 
the method of Solberg et al (1972). Aliquots of whole liver 
homogenate were frozen and thawed 4 times before use in order 
to ensure maximum activity. Incubation mixtures contained 
0.156 mM Ellman's reagent, 0.25 mM acetyl coenzyme A, 0.25 mM 
EDTA, liver homogenate equivalent to 0.5 mg fresh liver,
30 mM Tris-HCl pH8.2 in a total of 1.0 ml. Incubations were 
performed at 37°C. After preincubation for 2 minutes the 
reaction was started by the addition of 3.125 pmol DL-carnitine 
and the increase in absorbance at 412nm recorded using a 
Perkin-Elmer Hitachi Model 557 spectrophotometer.
2.25 Measurement of y-Glutamyl Transpeptidase (E.C.2.3.2.2)
The most frequently used method for the measurement,of Y- 
glutamyl transpeptidase (GGT) is by monitoring the release of | 
p-nitroanilide from t-glutamyl-p-rtitroanilide. This method was
5found to be unsatisfactory for the rapid measurement of several 
hepatic whole homogenate samples. The sensitive fluorimetric 
method of Smith et al (1979) was modified to an end point 
assay for these experiments.
A stock (10 mM) solution of L-^-glutamyl-7-amino-4-methylcoumarin 
was prepared in methoxyethanol. Sonication was required for up 
to 1 minute to ensure complete solubilisation. A buffer/substrate 
solution was made consisting of 0.1 M ammediol, 20 mM glycylglycim 
0.1% Triton X-100 and stock substrate solution to give 0.2. mM 
substrate/ ^ % methoxyethanol and adjusted to pH8.5 with 
0.1 M HCl. This solution was kept ice cold and 0.5 ml samples 
added to plastic tubes kept on ice. Whole liver homogenate 
equivalent to 1 -5 mg fresh tissue, was added and the total 
incubation volume made up to 0.7 ml with unbuffered 0.154 M .
KCl pH7.4. Tube contents were mixed, incubated at 37°C for 
10 minutes and the reaction stopped with 1 ml 5%(w/v)ZnS0^ 
and 1 ml saturated BafOH)^' Blanks and standards were stopped 
at zero time. The mixtures were centrifuged at 1200g (MSE, 
Coolspin) for 5 minutes and 1.0 ml of the supernatant mixed 
with 2.0 ml 0.5 M glycine-NaOH buffer pH10.5.
Fluorescence of the 7-amino-4-methyl coumarin product was 
measured at 440nm with excitation at 370nm on a Perkin-Elmer 
MPF3L fluorescence spectrometer.
2.26 Measurement of Glutathione S-Transferase (E.C.2.5.1.18) 
Glutathione S-transferase describes a group of enzymes found 
predominantly in the cytosolic fraction of mammalian liver, 
that catalyse the conjugation of reduced glutathione to a range
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Of substrates, usually electrophilic <, of diverse chemical 
structure (Jakoby 1978). Although some of the transferase 
enzymes can be recognised by their pattern of activity with 
different substrates, these enzymes are best described as 
having overlapping substrate specificity.
Activity to four substrates was measured using the conditions 
set out in Table 2.3. Substrates were; l-chloro-2,4- 
dinitrobenzene (CDNB), 1,2-dichloro-4-nitrobenzene (DCNB),
nitrobenzyl chloride (NBC), and 1,2-epoxy-3-(p-nitrophenoxy) 
propane (ENPP). Measurements were performed using a Perkin- 
Elmer Model 557 dual beam spectrophotometer. Substrates were 
dissolved in ethanol and added to both test and reference 
cuvettes. Ethanol concentration did not exceed 2%. As some 
non-enzymic conjugation occurred, both reduced glutathione and 
substrate were present in both test and reference cuvettes.
After preincubation to equilibrate cuvettes at 37°C cytosol was 
added to the test cuvette and the rate of increase in extinction 
compared to the reference cell recorded. These methods are 
based on those described in Habig et al (1974a).
2.27 Measurement of Glutathione Reductase (E.C.1.6.4.2)
The reduction of (oxidised) glutathione disulphide to the 
reduced form was measured using the method of Carlberg ahd 
Mannervik (1975). Test and reference cuvettes contained 0.1 M 
phosphate buffer pH7.6, 0.5 mM EDTA, 0.1 mM NADPH and 1 mM 
oxidised glutathione in a total volume of 2.0 ml. After 
preincubation at 37^C for 2 minutes the reaction was started 
by the addition of 50 pi cytosol, and the decrease in extinction  ^
at 340 nm recorded using a Perkin-Elmer Model 557 spectrophotometer.'
Table 2.3 Conditions of assay of 
glutathione S-transferase
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Substrate^
Condition CDNB DCNB NBC ENPP
Wavelength (nm) 340 345 310 360
Temperature (®C) 37 37 37 37
Buffer; Tris - - - 50mM
phosphate O.IM O.IM O.IM -
pH 7.0 7.8 7.4 8.2
glutathione 
concentration (mM)
1 5 5 5
Substrate
concentration (mM)
2.5 1.2 1 0.5
Cytosol (pi)
- mouse 10(1 in 20)b 50 50 50
- rat 50(1 in 20)b 30 50 50
^ For substrate names see section 2.26 
^ Cytosol was diluted with unbuffered 0.154 M KCl
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2.28 Measurement of Glucose-6-Phosphate Dehydrogenase (E.C . 1.1.1. 49) 
Glucose-6-phosphate dehydrogenase (G5PDH) was measured by 
modification of the method of Noltmann et al (1951), Test and 
reference cuvettes contained 50 mM Tris-HCl pH 7.5, 0.4 mM
EDTA, 1 mM glucose-6-phosphate and cytosol equivalent to 
10 mg of fresh tissue in a total volume of 2.5 ml. After 
preincubation at 37°C for 2 minutes in the heated cell block 
the reaction was started by the addition of 0.8 mM NADP, and the 
increase in extinction at 340 nm recorded using a Perkin-Elmer 
Model 557 spectrophotometer.
2.29 Measurement of Mixed Function Oxidase Enzymes
Several m.f.o. enzymes were measured both in the rat and mouse.
The conditions of assay are tabulated in Table 2.4 A and B. 
Incubation mixtures were made up on ice either in glass tubes 
with a teflon sealed screw cap when a solvent extraction was 
performed, or in plastic tubes when protein precipitation was 
used to stop the reaction. All incubations were done in a 
shaking (100 cycles/minute) water bath at 37°C. Assays were 
performed in duplicate, with single blanks to which the substrate 
was not added until the reaction was stopped. Internal 
standardisation was carried out where possible by adding a known 
quantity of authentic product to triplicate blank tubes.
Further details of individual assays are described below.
2.29.1 Ethylmorphine N-demethylase.
Déméthylation of ethylmorphine is achieved by an initial 
hydroxylation forming an unstable hydroxymethyl intermediate 
which breaks down with the release of formaldehyde, which is 
estimated by means of the Hantzsch reaction as described by ;
Nash (1953). This assay was first described by Holtzmann 
et al (1968). Incubation mixtures contained 7.5 mM semicarbazide
5 9
(U
CO
3
0
T3C
(0
CO
I
N
a
0)
U-(
o
oj
CO
CO
cd
u
oCH
T )
<V
CO
3
gO
•H
4-1
•H
3.OO
COV4
o
4-1ocd
C4-,
ocj
CO<u3
3
4JX
•H
S
3
O
•H
4-1
3jO
3
O
3
CO
O
a§CD
PQ r3
PL, 0
I—)
O
3 i=H
3 0
3
O
CJ
<f
o
c/2
00
S
3
3
3 3
4-> 3
3 3
3 00 3
O 3
U 3 .3
•3 TJ 3
O >> 3
o rC
w 3
M T>
3
3
4J
3X5
3
C/2
3 '3 
3 3 
U-i H  4-1
3 S m ^
o
m
3
3 0
3 >.
3 N
0 32 W
CN
o o
o
o
in
0 m m
m
0 CM
m
0 CM CO
0 0 0 0 0 0 0 0 0
m m
m r~- m m m en m
CO CO CO r>- CO C'­ C'­
en in in in in in m m in
0 0 0 0 0 0 0 0 0 0
m
o
o
o
m
00
CO
m m 0 r-4 0 m m
0 CM m 0 0 in 0 CM m
vO 0 MO - f
CO
(N
CO
3 Po
3 3 X
3 3 0
rH 3 3
Po r4 TO
3 X Po Po 3
•3 0 X x: •3
3 3 3 0 13
3 3 3 TO 3 3 3 3
3 3 0 3 Po TO 3 3 3
3 i3 3 3 ,3 ÎO 3 0 3
•3 >> 3 rH 1 X 3 3 r3
0 >, 1 Po 3
CL 3 0 X -d" CL • 3 X
3 3 %  3 T—4 P'.3 3
0 0 X 3 Po 3 3 X 3 0
0 3 0 3 3 3 0 3 Po
rH TO -3 TO 3 •3 0 X TO 3 N
1 3 1 r3 N 3 1 3 3.
j3 2 w  0 CL •3 3 M 0 ci W
3 1 •3 3 3 }
W C'- P5 <3 PQ C'.
«S
o
m
CM 00 CM 00
00 r - . C'-
3
3
3
I—(
Po
X 3
3 3 3
3 3 3
0 r3 3
3 Po i3
TO X Po
1 3 0 ■ X
2 •3 3 0
3 3 TO 3
3 3 3 Po TO
3 0 3 xo
•3 3 iH 1 X
X 0 Po 1
CL 0 X -d"
3 P>^ 3 r -|
0 X 3 Po 3
0 0 3 3 3
f-4 X  TO 3 •3
Po 3 1 JC r4
X w  0 CL .3
3 1 •3 3
w PQ <
6 0
3
3
a
o
3
O
3
U
•H
S
3
3
>
2
2
3
3
3
O
0
2
d
3
3
3
3
d
•H
3
3
0
PO
N
d
3
O
2
0
2
O
PO
3
3
3
3
3
O
2
2
3
3
3
3
d
o
2
3
•H
2
d
O
CJ 3
3
3
3
-d" 2
3
CM O
O
3 3
2 CL
X
3 Po
H 33
3
<
PQ
C
O
•H
3
U
3
3
3
P
d
o
Po •rH /O
3 3 0
3 3 d
3 •H
3 0
0
3 W
3
d
3
U d
3 o
3 2
3 X
O 3
3 , X a
2 2  d
Ph o w
X
w
3
O
d Po
3 3
X  3 0 CM O
3 3 d 2 m
O 3 <r X
3
X
<
3
X
d
3 3
00 CM X< 2 3
o  3
00 3 X
d X  X
2 W
p -d"
p O  2
o X CJ
X d 3
CO CM 2P
3
Po 0
3 3 ,2
3 1—4 03 o
C >
d
o
2
X d
3
X 0
3
O
d
2
d
o
-rH
X
3
X d
3 •rH
O 0
d
2
3
3PL
>,
3
3
3
<
CM O
m o
'd'
O
m
CM
00
m
I2
3 3
C 3 'L cd X <-1 
CL >, 3 X 
O 3 
B 3 —I 6 
Po 3 
X  "O 
3 
W
3
3
3
r-4PO
X
O
u
X
p>\
X
c
<
o o
00 o
co m
CM2O
3
«
<fO
co
c
CM
3 3
3 3
e 3
O >> 
a X3
X 3
0 3 
X  TO 
3 I
p  o1
g
<r
B
m
3
3
3r3
PO
X
o
3
T3
PO
X
PO
c
3
X
CL
m
(T>ro
S
O
3
C 3 
3 33 (d 
PO '—I 
CL PO 
^  X 
3 O 
/ 3 
O TO 
N Po 
C X 
3 PÛ
m
couo
CM
2
O
3
«
"d"
O
CO
C
CM
C
•H34
3 3 
3 3
O 3 
3 i3 
3 Po 
3 X 
Po 3 
X 3
0 3 
X  2
3 IW O
1
C'-
300
3
C
3
U
Po
X
2
3
C
X
o
3
§
c
3
3
3
C
3
3
CL
3
3
2
3
3
•3
C
•H
3
3
O
3
CL
3
P
CM
2
O
3
X
2
3
3
3
3
3
3
3 . 
3
f—* O
o
Po U  
X
2  W
3 CO3 2 
O ^
V* IL ûO( 
O o
4-4 O  
CM 
-d''—' 
O
CO
d
CM
5-2uO
3
3
X
3
2
3
2
2
3
3
3
00
m
3
3
O
X
3
O
3
2
4-,
O
c
3
3
cr
2
c
3
3
O2
00
d
2 3
3 3 
00 X 
d 3 
3 32P 2
3
3 *2 
X  6 
3
3 O 
d
o PO •H X 
3
3 2  
X  3 
3 3 
U O 
d 2
-rH |2
o
3  4-1
X
H
6 1
adjusted to neutral pH to trap the formaldehyde generated.
After the reaction was completed according to Table 2.4 A and B
2 . 0  ml of the deproteinised supernatant was mixed with 2 . 0  ml 
of Nash reagent (4M ammonium acetate containing 0.6% (v/v) 
glacial acetic acid, freshly mixed with 0.4 ml acetylacetone 
per 100 ml) and colour developed at 37°C for one hour. Tubes 
were cooled, mixed and the extinction measured at 420nm using 
a Cecil CE272 spectrophotometer. The concentration of a 
standard formaldehyde solution (1 in 1 0 0 0 0 ) was determined using 
an extinction coefficient of 8x 1 0 ^,cm^,mol  ^ and approximately 
2 jamol was added to blank incubations to calibrate the assay.
2.29.2 Aniline 4-hydroxylase.
This enzyme was measured by modifications of the method of Kato 
and Gillette (1965) using the colour development method of 
Nakanishi et al (1971). Before incubation the aniline substrate 
was adjusted to neutral pH. For assay conditions see Table 2.4 
A and B. After the reaction was stopped the 4-aminophenol 
product was extracted into 1 0 ml ether for 1 0 minutes using a 
flatbed shaker. 5 ml of ether was transferred to -screw top 
tubes and mixed by shaking for 10 minutes with 4 ml of phenol 
reagent (0.5M tripotassium orthophosphate containing 1% (w/v) 
phenol). Tubes were left for a further 60 minutes to complete 
colour development, the ether layer aspirated and extinction 
measured at 630nm using a Cecil CE272 spectrophotometer.
Authentic 4-aminophenol was used as standard.
2.29.3 7-Ethoxycoumarin 0-deethylase.
Production of highly fluorescent 7-hydroxycoumarin by dealkylation 
of 7-ethoxycoumarin was measured by the method of Lake et al •
(1982). Enzyme substrate was dissolved in 50 mM Tris pH7.6 
by heating. After incubation (Table 2.4 A and B) 1.0 ml of
6 2
deproteinised supernatant was mixed with 2 ml 0.5M glycine- 
NaOH buffer pH10.5 and fluorescence of 7-hydroxycoumarin 
determined using a Perkin-Elmer MPF3L fluorescence spectrometer. 
Authentic 7-hydroxycoumarin (5 mM in ethanol and diluted 1 in 
50 with distilled water) was used as standard.
2.29.4 Biphenyl 4-hydroxylase.
Biphenyl 4-hydroxylase was measured in washed microsomal 
fractions by the method of Creaven et al (1955). Stock 
biphenyl substrate (10 mM) was prepared in unbuffered 0.154 M 
KCl containing 3% w/v Tween 80. After incubation (Table 2.4 A 
and B) reaction products were extracted into 7 ml n-heptane 
(containing 1.5% v/v isoamyl alcohol to prevent foaming) for 
10 minutes on a flat bed shaker. After shaking the two phases 
were separated by brief centrifugation (300g for 2 minutes MSE, 
Coolspin) and 2 ml of the heptane phase added to a screw cap 
glass tube containing 5 ml 0.1 M NaOH. After 10 minutes shaking, 
the phases were separated by centrifugation, the heptane 
aspirated and fluorescence of the aqueous phase measured.
Authentic 4-hydroxybipheny1 was dissolved 3 mM in ethanol 
and diluted to 0.3 mM for use as standard.
2.29.5 Benzo(a)pyrene hydroxylase.
Benzo(a)pyrene is hydroxylated in several positions but the 
fluorescence assay used detects mainly 3-hydroxybenzo(a)pyrene. 
Benzo(a)pyrene is a known carcinogen and thus all manipulations 
were performed in a fume cupboard and wearing gloves. Furthermore 
the hydroxylation products are light sensitive so assays were 
performed as rapidly as possible and avoiding direct light.
Benzo(a)pyrene itself was dissolved in acetone and added 
directly into incubation mixtures containing 0 .8 mg bovine serum
6 3
albumin to aid solubility and prevent denaturisation of sample 
tissue by acetone. Acetone concentration in the assay was 
1.25% v/v.
After the reaction was stopped (see Table 2.4 A and B) 6 ml 
n-hexane was added and tubes shaken on a flat bed shaker for 
10 minutes. The phases were separated by centrifugation 
(MSE Coolspin 300g for 5 minutes), 4 ml of hexane added to 
4 ml 1,0 M NaOH and extracted in the same way. The hexane 
was then aspirated and the fluorescence of the aqueous solution 
determined, using a Perkin-Elmer MPF3L fluorescence spectrometer. 
As 3-hydroxybenzo(a )pyrene for standardisation was not available 
extraction efficiency was assumed to be 67% (Kuntzman et al 
1966). External standardisation was achieved using a 0.3 pg/ml 
solution of quinine sulphate in 0.05 M # 2 8 0 ^, observing 
fluorescence at 445nm with excitation at 340nm. 1 p.g quinine
sulphate was taken to be equivalent to 42.05 pmol of
3-hydroxybenzo(a)pyrene (Kuntzman et al 1966).
2.29.6 7-Ethoxyresorufin 0-deethylase.
The direct measurement of 7-ethoxyresorufin 0-deethylase was 
described by Burke and Mayer (1974). For these experiments 
an end point assay was developed. All manipulations were 
carried out in subdued light as this substrate is light sensitive
7-ethoxyresorufin was dissolved in methanol and then the methanol 
was evaporated under a stream of N 2 . This procedure facilitated 
subsequent dissolution into Tris-HCl buffer pH8.2, which also 
required prolonged sonication in an ultrasonic water bath 
(Sonicor Instrument Corp., Copiague, New York, USA). The 
substrate solution was scanned in a spectrophotometer (Perkin-
6 4'
Elmer Model 557) from 900 to 300nm and the extinction at
480nm measured. Using an extinction coefficient of 
3 2 — 122.5x10 .cm .mol the solution was diluted to 5 nmol/ml.
A stock solution of resorufin was scanned (Perkin-Elmer Model 
557) from 900 to 500nm and the extinction at 570nm used with 
an extinction coefficient of 0.04x10 .cm .mol to determine 
the concentration. The stock solution was diluted with water 
to about 2 nmol/ml and used as standard.
Incubations were performed as described in Table 2.4 A and B 
using a covered shaking water bath. After incubation 1 ml of 
deproteinised supernatant was mixed with 2 ml of glycine-NaOH 
buffer pH8.5 and fluorescence measured at 582nm with excitation 
at 535nm using a Perkin-Elmer MPF3L fluorescence spectrometer.
2.30 Measurement of UDP-glucuronyltransferase (E.C.2.4.1.17)
This enzyme of phase II metabolism was measured as described 
by Bock et al (1980) using 4-hydroxybiphenyl as the aglycone. 
Activity was measured in the presence and absence of Tween 80, 
as detergents can activate enzyme activity. Incubation mixtures 
containing 50 mM Tris-HCl buffer pH7.6, 10 mM MgSO^, 0.5 mM 
4-hydroxybiphenyl,0 or 0.2% Tween 80 and washed microsomal 
suspension equivalent to 10 mg of control or 5 mg of test 
tissue, were prepared on ice in screw top glass tubes. Substrate 
(10 pi, dissolved in acetone) was added by microlitre syringe 
directly into incubations and mixed at once to ensure complete 
solubilisation. After 2 minutes preincubation at 37°C the 
reaction was started with 3 mM UDP-glucuronic acid, and 
stopped after 10 minutes with 1 ml 1.0 M TCA. The biphenyl 
glucuronide was extracted into 5 ml CHCl^ by shaking for
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10 minutes. After separating the two phases by centrifugation 
(300g for 5 minutes MSE, Coolspin), 1.0 ml of the upper aqueous 
layer was mixed with 2 ml 1.5 M glycine-NaOH buffer pHlO.5 
and the fluorescence measured at 325nm with excitation at 
287nm.
As no authentic standard was available the fluorescence of a 
standard fluorescent block at the wavelength stated in the 
method was determined. This provided a correction factor 
for variations in the fluorimeter between assays. To calibrate 
the assay further additional incubations were performed for 
40 minutes to ensure that significant substrate conjugation had 
occurred. After stopping the reaction with 1 ml of 1.0 M TCA, 
and centrifugation at 300g for 5 minutes to sediment the 
protein precipitate, aliquots were taken either for estimation 
of remaining substrate or determination of fluorescence in the 
manner previously described. The remaining substrate was 
estimated by means of Folin and Ciocalteau's phenol reagent. 
Aliquots of the post-incubation supernatant were mixed with 
1 ml of 1 M NaOH and distilled water to a total volume of
1.5 ml. After the addition of 1 ml Folin and Ciocalteau's 
phenol reagent (diluted 1:7 with distilled water) colour was 
developed for 30 minutes and extinction measured at 720nm 
using a Cecil CE272 spectrophotometer. Loss of substrate was 
calculated by means of a standard curve, which was linear to at 
least 30 pmol of 4-hydroxybiphenyl. Loss of substrate equated 
to increased fluorescence at 0.76 pmol per fluorescence unit.
2.31 Measurement of NADPH-dependent Lipid Peroxidation. 
NADPH-dependent lipid peroxidation was determined by measurement 
of thiobarbiturate reacting substances, assumed to be largely
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malondialdehyde. Incubation mixtures were set up in plastic
tubes on ice, and contained 0.05 mM FeClg.6H20 (prepared
immediately before use), 2 mM ADP, washed microsomal fraction
equivalent to 30 mg fresh tissue in 50 mM Tris-HCl pH7.2,
in a total volume of 1 ml. After 2 minutes preincubation at
37°C in a shaking waterbath duplicate test reactions were
initiated by the addition of 0.4 mM NADPH. After 10 minutes
incubation the reactions were stopped with 2 ml 10% w/v TCA,
and NADPH added to blank incubations. After centrifugation
at 1200g for 10 minutes (MSE, Coolspin), 2 ml of deproteinised
supernatant was mixed with 2 ml 30% (w/v) TCA, 0.25 ml 4 M
HCl and 2 ml of 0.75% (w/v) thiobarbituric acid and heated in
a boiling waterbath for 15 minutes. Tubes were sealed with
aluminium foil to prevent evaporation. After cooling and
mixing, thiobarbiturate reacting substances were measured at
528nm on a Cecil CE272 spectrophotometer. An extinction
3 2 —1coefficient of 156x10 .cm .mol for malondialdehyde was used 
(Ernster and Nordenbrand 1967).
2.32 Measurement of Glucose-6-Phosphatase (E.C.3.1.3.9)
Activity of glucose-6-phosphatase in washed microsomal fractions 
was measured by the method of DeDuve et al (1955). Incubation 
mixtures, prepared on ice, contained 1 mM EDTA, 65 mM 
cacodylate buffer pH6.5 and washed microsomal preparation 
equivalent to 5 mg fresh tissue. After preincubation at 37°C 
for 2 minutes in a shaking waterbath 100 mM glucose-6-phosphate 
was added to start the reaction. After 10 minutes the reaction 
was stopped with 1.0 ml 10% TCA, and substrate added to blank 
tubes. After centrifugation (1200g MSE, Coolspin) 0.5 ml of 
the deproteinised supernatant was assayed for phosphate by
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mixing with 1.0 ml 2% (w/v) metol/3% (w/v) sodium bisulphite,
1.0 ml 1.875% (w/v) ammonium molybdate in 0.75 M H^SO^ and
2.5 ml water. Extinction was determined after 30 minutes 
at 580nm using a Cecil 272 spectrophotometer. Standard 
phosphate solutions over a range of 0-0.75 pmol were assayed 
simultaneously.
2.33 Measurement of NADPH-cytochrome c reductase (E.C.1.6.2.4) 
NADPH-cytochrome c reductase was measured by modification of the 
method of Williams and Kamin (1962). Cuvettes were prepared 
containing 0.1 M phosphate buffer pH7.6, 1.2 mM KCN, 1.55 mg 
cytochrome c and washed microsomal fraction equivalent to 5 mg 
fresh tissue in a total volume of 2.5 ml. After preincubation 
at 37°C for 2 minutes, 0.4 mM NADPH was added to the test cell 
and the reduction of cytochrome c recorded at 550nm. An 
extinction coefficient of 18.7x10^.cm^.mol  ^ (Holtzman et al 
1968) was used.
2.34 Estimation of Cytochrome P-450 Content and Wavelength Maxima, 
Cytochrome P-450 content of washed microsomal fractions was 
measured according to the method of Omura and Sato (1964), using
a Perkin-Elmer Model 557 spectrophotometer. Microsomal fractions 
were diluted 1 in 4 with 0.2 M phosphate buffer pH7.4 and a 
small amount of sodium dithionite (about 0.1 g) dissolved in 
the mixture, which was then divided into reference and test 
cuvettes. The test cuvette was bubbled with CO for 2 minutes and 
the difference spectrum recorded from 500 to 400nm. Cytochrome 
P-450 content was calculated from the increase in extinction 
from 490 to 450nm using an extinction coefficient of 
91x10^.cm^.mol  ^ (Omura and Sato 1964).
The wavelength of maximum absorption of cytochrome(s) P-450
6 ^u
may change as the complement of isoenzymes changes with certain 
treatments. To assess this wavelength accurately the 
procedure of Mailman et al (1975) was used. Concentrated 
microsomal suspensions were used to reduce the signal: noise 
ratio, the chart scale was expanded by x20 and the recording 
made at 6nm/minute. Each spectrophotometric trace was 
calibrated by use of a holmium filter crystal utilising the 
absorbtion peak at 453.2nm.
2.35 Ethyl Isocyanide Binding Spectra.
The binding of ethyl isocyanide to hepatic haemoproteins
was measured by the method of Omura and Sato (1964), at
pH7.0 and 7.4. IMl of washed microsomal fraction was diluted
with 4 ml 1 M Tris maleate buffer and reduced with sodium
dithionite. 2.5 ml was transfer/ed to a test cuvette and
1 pi ethyl isocyanide was added. After 1 minute the difference
spectra was recorded from 490 to 410nm. Results were expressed
as the ratio of peak heights at 430:455nm.
2.36 Measurement of NADPH-Dependent Covalent Binding of
^^C]Phenobarbitone and C^ "^ c] Paracetamol to Hepatic 
Microsomal Proteins.
The covalent binding of [^^clphenobarbitone to hepatic microsomal
proteins was measured in both control and phenobarbitone treated
mice. Single microsomal preparations were obtained from the
combined livers of 4 control or 3 treated mice. The
concentration of the microsomal preparations was adjusted to
2.5 mg protein/ml in buffer.
Assay mixtures were prepared on ice in plastic tubes and 
contained 2.5 mg microsomal protein, 0.5 mM NADP , 7.5 mM 
isocitric acid, 1 unit isocitrate dehydrogenase, 5 mM MgSO^ and
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0.1 M phosphate buffer pH7.4, in a volume of 2 ml. Blank
incubations contained no NADP, isocitric acid or isocitrate
dehydrogenase. Some incubations (see Table 4.3) contained
3,3,3-trichloropropylene oxide (TCPO), 0.1 mM in the assay
added in 5 pi acetone. Appropriate controls with 5 pi acetone
alone were performed. 2-[^^c]Phenobarbitone, specific
activity 23,pCi/pmol, was diluted with stock PB to give 5 mM
14and 0.15 pCi in each incubation. Ring-U-[ CJParacetamol 
(specific activity 1.27 mCi/mmol), used as a positive control; 
was diluted with stock paracetamol to give 1.0 mM and 2.2 pCi 
in each incubation. After 5 minutes preincubation the appropriate 
substrate was added and incubated for 5 minutes in a shaking 
waterbath at 37°C (paracetamol binding in PB treated mice),
7.5 minutes (paracetamol binding in control mice) or 30 minutes 
(phenobarbitone binding). The incubation was stopped with 
2 ml 10% (w/v) TCA, the precipitate sedimented by centrifugation 
at 1200g for 5 minutes (MSB Coolspin) at 18°C. The pellet was 
resuspended twice in 5 ml 5% TCA, then 6 times in 80% (v/v) 
methanol/water to remove all unbound radioactivity. The final 
pellet was dissolved in 0.5 M NaOH and aliquots used for 
protein estimation and determination of radioactivity by 
scintillation spectrometry.
CHAPTER 3
THE DETERMINATION OF THE MAXIMALLY 
STIMULATING DOSE OF PHENOBARBITONE 
FOR THE INDUCTION OF HEPATIC XENOBIOTIC 
METABOLISING ENZYME ACTIVITIES IN THE 
RAT AND TWO MOUSE STRAINS AND THE 
EFFECT OF DIET FORMULATION ON THESE 
ACTIVITIES-
n 0
INTRODUCTION
Induction of xenobiotic metabolism was first reported by 
Conney et al (1956) who found a dose dependent increase in 
metabolism of dimethylaminoazobenzene following treatment 'of' 
rats with 20-methylcholanthrene. Later other compounds including 
benzo(a)pyrene, phenobarbitone (PB), aminopyrine and 
phenylbutazone were also found to stimulate azo dye déméthylation 
(Murphy and DuBois, 1958; Conney and Burns 1959). Subsequently 
these drugs were found to increase activity of various other 
hepatic microsomal enzymes (Conney et al 1960). Remmer
(1959) independently observed the ability of PB to stimulate 
microsomal hexobartitone metabolism in rats and rabbits.
Since these early experiments a wide variety of drugs, pesticides, 
food addittives, industrial and household chemicals, polycyclic 
hydrocarbons and other xenobiotic compounds have been shown to 
increase activities of microsomal drug metabolising enzymes 
(Conney, 1967; Schulte-Hermannl974). Furthermore it has been 
established that prolonged administration of some enzyme 
inducers may result in formation of hepatic nodules in 
susceptible mouse strains. It has been suggested that prolonged 
stimulation of the hepatic mixed function oxidase (m.f.o.) 
system may eventually lead to dysfunction of the system and 
a resultant focal hyperplasia (Schulte-Hermannl979), and that 
certain species and strains may be less capable of mounting 
such a prolonged adaptive response. Alternatively high doses 
of m.f.p. substrate over prolonged periods may result in 
accumulation of damage from either toxic metabolites or the 
release of active oxygen species. If such mechanisms result
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in nodule formation a dose of inducing agent that maximally 
stimulates hepatic m.f.o. enzyme activities could be used to 
study both effects of short term treatment in susceptible and 
resistant species and strains, and also the generation of 
nodules with chronic treatment.
Surprisingly few dose-response studies of enzyme induction have 
been performed. Initial studies reported the maximum stimulation 
of smooth endoplasmic reticulum in rats with 3 to 5 daily i.p. 
doses of 80 mg/kg PB (Remmer and Merker 1965). Hart and Fouts 
(1965) reported 2 daily doses of 40 mg/kg for 3 days as 
stimulating maximum enzyme induction in rats. The dose of 
80 mg/kg/day for 4 days has subsequently been used as a maximally 
stimulating dose of m.f.o. enzymes (Kao and Hudson 1980).
Valerino and coworkers (1973, 1974) studied ethylmorphine 
N-demethylase, aniline 4-hydroxylase and cytochrome P-450 content 
in rats given 2.5, 25, 50 and 100 mg/kg/day PB for up to 
15 days. Animals given 200 mg/kg/day died after 2 days. These 
parameters (expressed per mg of microsomal protein) were 
stimulated by 3 days and thus 100 mg/kg/day was determined as 
maximally stimulating, although differences between other doses 
were not tested for significance.
There is little data available of either i.p. or dietary PB 
administration to the mouse. Wright et al (1972) fed PB in 
the diet to CFl mice at concentrations equating to daily doses 
of 1.2, 12 and 120 mg/kg, for up to 40 weeks. The highest dose 
resulted in greatest proliferation of smooth endoplasmic 
reticulum and stimulation of m.f.o. enzymes. Poland et al
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(i960) found that PB maximally stimulated aminopyrine 
déméthylation at doses above the maximum tolerated dose 
(100 mg/kg/day for 3 days) in female mice.
The present experiments were conducted in order to determine 
the maximally inducing dose of PB in the rat and two strains of 
mouse with either low (C57B1/6) or high (C3H/He) incidence of 
spontaneous hepatoma (see Table 1.6). Initially the effect 
of stock or a semisynthetic diet on hepatic xenobiotic 
metabolising enzymes was assessed to determine the contribution 
of dietary factors to enzyme induction. The maximally inducing 
dose of PB was then determined over a 14 day treatment period 
in order to continue challenge beyond the initial proliferative 
phase. Finally studies were conducted to establish a route 
of PB administration suitable for long term treatment.
MATERIALS AND METHODS
Male Sprague-Dawley rats (6 weeks old) and C3H/He and C57B1/6 
mice (4 weeks old) were housed according to Chapter 2 for 
2 weeks prior to use. Enzyme assays were performed as described 
in Chapter 2.
Comparison of stock and semisynthetic diet
Animals were fed stock (Spratts LAD2) diet for 2 weeks, after 
which some animals were fed semisynthetic (SS2) diet for up to 
2 (rats) or 3 (mice) weeks. Cytochrome P-450 content and some 
microsomal m.f.o. enzyme activities were measured at weekly 
intervals.
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Estimation of the maximally stimulating dose of PB 
Animals were fed semisynthetic (SS2) diet for two weeks prior 
to treatment in order to acclimatise them to experimental 
conditions. Animals were given by daily i.p. injection
0.9% w/v saline (0.5 ml/lOOg body weight to rats, 1.0 ml/lOOg 
body weight to mice) (control) or PB dissolved in saline 
vehicle at the dose shown in Tables 3.4 (rats) and 3.5 (mice) 
for up to 14 days. Measurement of hepatic microsomal cytochrome 
P-450 content and activity of ethylmorphine N-demethylase and 
aniline 4-hydroxylase was made on groups of 4 control and 
3 treated mice at 3, 7, 10 and 14 days of treatment.
Comparison of the effects of PB administration in either 
drinking water or the diet
PB was administered to rats at a dose of 1 5 0  mg/kg/day and to mice 
at a dose of 85 mg/kg/day, either in the drinking water or the 
diet. Concentration of PB was calculated according to body 
weight and food or water intake. Drinking water concentration 
was adjusted twice a week, dietary concentration once in 
2 weeks. Food and water consumption were monitored, and after 
10 weeks hepatic microsomal cytochrome P-450 content was 
measured.
RESULTS
Comparison of stock and semisynthetic diet
The effect of feeding semisynthetic diet to rats for 1 and 2 
weeks is shown in Table 3.1. Both at 1 and 2 weeks there was 
no change in liver size, microsomal protein and cytochrome P-450 
content, and in the four microsomal m.f.o. enzymes measured.
n 4
In C3H/He (Table 3.2) and C57B1/6 (Table 3.3) mice feeding was 
continued for up to 3 weeks. In the C3H/He strain relative 
liver weight, microsomal cytochrome P-450 content and the 
microsomal activity of 4 m.f.o. enzymes were significantly 
reduced below control at all times. Microsomal protein content 
was also reduced after 1 week but not at 2 or 3 weeks. In the 
C57B1/5 mouse relative liver weight was reduced at 1 and 3 
weeks only. Microsomal cytochrome P-450 content and the 
activities of aniline 4-hydroxylase, ethylmorphine N-demethylase 
and biphenyl 4-hydroxylase, but not 7-ethoxycoumarin 0-deethylase, 
were reduced below control levels. Microsomal protein content 
was reduced in mice fed semisynthetic diet, but this was only 
significant at 1 and 2 weeks.
Estimation of the maximally stimulating dose of PB
The effect of 14 days PB treatment of rats, at 4 dose levels
on liver size and microsomal protein and cytochrome P-450 content
is shown in Table 3.4. PB increased all these parameters, at
all doses, above control levels. PB doses greater than
175 mg/kg/day caused fatalities in the rat (data not shown).
Treatment of C3H/He and C57B1/5 mice with PB (50 to 100 mg/kg/day) 
increased liver weight and microsomal protein and cytochrome 
P-450 content above control levels (Tables 3.5 and 3.6 
respectively). In both the C3H/He and C57B1/6 mouse microsomal 
protein and cytochrome P-450 content per g liver of animals 
given 50 mg/kg/day was significantly less than in animals given 
70 mg/kg/day. Doses of over 100 mg/kg/day resulted in fatalities 
to both strains of mouse (data not shown), and the slightly 
increased relative liver weight in C3H/He mice, and the
significant increase in C57B1/5 strain mice given 100 mg/kg/day 
reflects a reduced body weight at this dose.
Microsomal m.f.o. enzyme activities and cytochrome P-450 content 
are often expressed per weight fresh tissue or per mg protein.
As PB treatment increases both these parameters the effect of 
different PB doses from 3 to 14 days of treatment on hepatic, 
microsomal cytochrome P-450 content was investigated in both 
mouse strains. Cytochrome P-450 content is shown expressed 
as nmol per lOOg body weight (Fig. 3.1), per g liver (Fig. 3.2) 
and per mg protein (Fig. 3.3). Cytochrome P-450 content per 
lOOg body weight of mice given the lowest dose of PB was 
significantly less than that of animals given all other doses 
of PB at 10 and 14 days of treatment in both mouse strains.
There was no difference at earlier times. Expressed per g liver 
cytochrome P-450 content at the lowest dose was significantly 
different from all other doses at 14 days in the C57B1/6 mice 
only. Expressed per mg microsomal protein cytochrome P-450 
content in mice given the lowest dose of PB was not significantly 
different from that of mice given all other doses at any time.
Microsomal m.f.o. enzyme activities were also measured and 
are shown in Figs. 3.4 and 3.5 for C3H/He and C57B1/6 mice 
respectively, expressed as enzyme activity per lOOg body weight. 
Activity of aniline 4-hydroxylase in C3H/He mice given the 
lowest dose of PB was less than all other doses at all times, 
and this difference was significant at 7 and 14 days. Activity 
of ethylmorphine N-demethylase in C3H/He mice given the lowest 
PB dose was less than in mice given any other dose of PB, but 
the differences were not statistically significant.
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In the C57B1/6 mouse animals given the lowest PB dose had 
significantly lower activities of aniline 4-hydroxylase and 
ethylmorphine N-demethylase after 14 days of treatment.
A similar experiment performed using the rat showed that activity, 
of aniline 4-hydroxylase and ethylmorphine N-demethylase in 
animals given the lowest dose of PB was significantly below 
activities in animals given higher doses at 10 and 14 days 
of treatment (Fig. 3.6)
Comparison of the effects of PB administration in either 
drinking water or diet
Administration of PB at a dose of 150 mg/kg/day to rats in the 
drinking water resulted in a reduced weight gain by 10 weeks 
(Table 3.7), During the study period body weight and water 
consumption increased in control animals. In test animals 
water consumption fell. This factor combined with a rising 
body weight resulted in a progressively higher concentration 
of PB in the water from 1*1 to 4.5 mg/ml. Body weight of 
test rats was reduced at 10 weeks.
■ /
In both mouse strains administration of PB at a daily dosé 
of 85 mg/kg/day in drinking water for 10 weeks did not affect 
either body weight or water consumption (Table 3.8).
Concentration of PB in water was 0.60 or 0.82 mg/ml according 
to strain, and was not increased during the treatment period.
The effect on liver size, microsomal protein and cytochrome 
P-450 content of PB given either in the diet or in the drinking 
water is shown in Table 3.9. Route of administration did not 
significantly affect the degree of induction in either mouse strain
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DISCUSSION
Previous investigations have shown that environmental factors 
such as bedding and diet can affect levels of some hepatic 
enzyme activities and hepatoma incidence in untreated mice 
(Tennekes and Wright 1978; Tennekes et al 1979). In order 
to minimise the effects of bedding both rats and mice were 
maintained in plastic cages with wire mesh floors in all studies 
reported in this Thesis. The feeding of a semisynthetic diet 
has been shown to lower hepatic enzyme activities in the mouse 
(Tennekes and Wright 1978; - Brown et al 1954), rabbit
(Tredger and Chabra 1980) and rat (McLean and Driver 1977 )» 
However in the rat other workers have reported 
little or no change (Brown et al 1954; Billings and Wattenberg 
1972). The present study shows that feeding a semisynthetic 
diet to mice results in a reduction of hepatic m.f.o. enzyme 
activities within 1 week, in agreement with previous studies. 
Feeding the same semisynthetic diet to rats did not reduce 
hepatic m.f.o. enzyme activities.
Certain dietary anutrients have been found to stimulate hepatic 
xenobiotic metabolism including additives, such as the anti­
oxidant butylated hydroxytoluene (Gilbert and Golberg 1965), 
contaminants, such as the pesticide DDT (Hart and Fouts 1963) 
and several naturally occurring compounds. These include 
safrole, caffeine, flavones and various indole derivatives 
(for references see Lake and Gangolli 1981),
Enzyme activities are often expressed per unit of microsomal 
protein, per unit of cytochrome P-450 or per unit of fresh
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tissue. As PB treatment affects all these units of expression 
cytochrome P-450 content, calculated as total hepatic activity 
per lOOg body weight, showed the absolute stimulation of this 
parameter normalised for body weight. Using this method of 
calculation both hepatic microsomal cytochrome P-450 content 
and activities of ethylmorphine N-demethylase and aniline
4-hydroxylase show that 50 mgPB/kg/day was not a maximally 
inducing dose in either mouse strain. Doses ^70 mgPB/kg/day 
did maximally stimulate these parameters over the 14 day 
treatment period. A similar study in the rat showed that 
75 mg/kg/day did not maximally induce hepatic microsomal 
ethylmorphine N-demethylase and aniline 4-hydroxylase, but 
doses ">125 mg/kg/day were maximally stimulating over the 
14 day treatment period. It has been shown in the rat that 
recovery of cytochrome P-450 in washed microsomal fractions 
was not affected by pretreatment of animals with PB (Massey 
and Butler 1979).
For long term administration to large numbers of animals i.p. 
dosing is unsatisfactory and impractical. Valerino et al (1974) 
found no difference in stimulation of cytochrome P-450 content 
and associated m.f.o. enzyme activities by oral compared to
i.p. dosing. Therefore, efficacy of administration of PB in 
either drinking water or diet was investigated. The concentration 
of PB required to give 150 mg/kg/day to rats was apparently 
unpalatable. In the mouse no palatability problems were seen 
with administration in either drinking water or diet.
Comparison of inductive effects in the two mouse strains did 
not show a difference between the potency of 85 mg/kg/day PB
7 9
given in either drinking water or diet and therefore the diet 
was used to deliver PB in the chronic PB study (Chapter 4).
Errors in the estimation of the dose received occur when 
animals scatter powdered diet or water. Weighing scattered 
diet indicated waste (and thus underdosing) to be approximately 
5% (data not shown).
In summary hepatic m.f.o. enzyme activities were reduced by 
feeding semisynthetic diet to mice, but not to rats. In both 
mouse strains the maximally inducing dose of PB was ^70 mg/kg/day 
over 14 days. For subsequent experiments a dose of 85 mg/kg/day 
was considered as a maximally inducing dose. In the rat 
maximal induction was seen at a dose ^125 mg/kg/day for 
14 days and thus 150 mg/kg/day was considered as a maximally 
inducing dose for later experiments. Administration of PB 
could be satisfactorily achieved in. the diet.
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Eig. 3.1 The .Effect of Phenobarbitone On Microsomal Cytochrome
P-450 Content in C3H/He (A) and C57B1/5 (B) Mice.
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Phenobarbitone was administered by daily i.p. injection of 
50 (O), 70 (a ), 80 (a), 90 (■), or lOO (□) mg/kg/day.
Control mice (•) received saline alone (l.Oml/lQOg body weight) 
Results are presented as the mean of 4 control or 3 treated 
mice. Points marked *, significantly different from all other 
doses (Student's t-test P<0.05).
8Fig. 3.2 The Effect of Phenobarbitone On Microsomal Cytochrome
P-450 Content in C3H/He (A) and C57B1/5 (B) Mice.
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mice. Points marked *, significantly different from all other 
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Phenobarbitone was administered by daily i.p. injection of 
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Fig. 3.4 The Effect of Phenobarbitone On Microsomal Aniline
4-Hydroxylase (A) and Ethylmorphine N-Demethylase (B)
in C3H/He Mice.
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Phenobarbitone was administered by daily i.p. injection of 
50 (O), 70 (a )', 80 (i), 90 (■), or 100 (□) mg/kg/day.
Control mice (•) received saline alone (l.Oml/lOOg body weight) 
Results are presented as the mean of 4 control or 3 treated 
mice. Points marked *, significantly different from all other 
doses (Student's _t-test P<0.05).
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Fig. 3.5 The Effect of Phenobarbitone On Microsomal Aniline .
4-Hydroxylase (A) and Ethylmorphine N-Demethylase (B)
in C57B1/5 Mice.
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Phenobarbitone was administered by daily i.p,. injection of 
50 (o), 70 (a ), 80 (A), 90 (■)> or lOO (□) mg/kg/day.
Control mice (•) received saline alone (l.Oml/lOOg body weight) 
Results are presented as the mean of 4 control or 3 treated 
mice. Points marked *, significantly different from all other 
doses (Student's t-test P<0.05).
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Fig. 3.6 The Effect of Phenobarbitone On Microsomal Aniline
4-Hydroxylase (A) and Ethylmorphine N-Demethylase (B)
in Sprague-Dawley Rats.
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Phenobarbitone was administered by daily i.p. injection of 
75 (O), 125 (A), 150 (a ), or 175 (■) mg/kg/day. Control 
rats (•) received saline alone (0.5ml/100g body weight). 
Results are presented as the mean of 4 Control or 3 treated 
rats. Points marked *, significantly different from all 
other doses (Student's t-test P<0.05).
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Table 3.1 The effect of feeding either stock or semisynthetic diet 
(SSD) on some hepatic parameters in the Sprague-Dawley rat
Parameter Diet
Weeks of 
1
feeding^
2
L
Relative liver weight Stock 4.62 ± O.lic 4.56 i 0.11
(g/lOOg body weight) SSD 4.36 ± 0.11 4.57 i 0.17
(94) (100)
Aniline 4-hydroxylase^ S tock 94 ± 5 77 ± 6
SSD 88 ± 5 78 ± 2
(94) (101)
7-Ethoxycoumarin 0-deethylase^ Stock 143 ± 10 122 i 3
SSD 151 ± 6 127 ± 14
(106) (104)
Ethylmorphine N-demethylase^ Stock 630 ± 50 948 ± 54
SSD 721 36 920 ± 52
(114) (97)
Biphenyl 4-hydroxylase^ Stock 165 ± 31 130 ± 4
SSD 157 ± 6 123 ± 3
(95) (95)
Cytochrome P-450 S tock 0.96 ± 0.05 1.10 ± 0.05
(nmol/mg microsomal protein) SSD 0.93 ± 0.04 0.96 ± 0.05
(97) (87)
Microsomal protein Stock 32.9 ± 0.7 36.2 ± 0.5
(mg/g liver) SSD 29.2 ± 2.0 31.6 ± 1.3
(89) (87)
^ Rats were acclimatised to stock diet for 2 weeks, and then fed 
either SSD or stock diet for 1 or 2 weeks.
^ In units of nmol/hr/mg microsomal protein.
 ^ Data is presented as mean t S.E.M. of 4 animals with values from 
rats fed SSD expressed as a percentage of values from rats fed 
stock diet in parentheses. Feeding SSD did not change any 
parameter significantly from stock fed values (Student's test; 
P>0.05).
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Table 3.4 Effects of different doses of PB on some hepatic parameters
in the Sprague-Dawley rat
PB Treatment^ 
(mg/kg/day)
Relative liver weight 
(g/lOOgbody weight)
Microsomal Protein 
(mg/g liver)
Cytochrome P-450 
(nmol/g liver)
0(Control) 3.35 ± O.igb 28.4 ± 2.1 30.3 ± 1.1
75 4.35 ± 0.15 
(130)
41.6 i 1.9 
(146)
102 ± 4 
(337)
125 4.98 ± 0.36 
(149)
42.3 ± 1.8 
(149)
104 ± 3 
(343)
150 4.94 ± 0.12 
(147)
46.5 i 1.2 
(164)
118 i 3 
(389)
175 5.78 ± 0.38 
(173)
45.4 ± 2.4 
(160)
115 ± 3 
(380)
^ Rats were fed 
days either 
stated dose
semisynthetic diet, and 
0.9% saline (0.5 ml/100 
of PB.
received by daily i.p. injection for 14 
g body weight) or saline containing the
^ Data is presented as mean i S.E.M. of 4 control or 3 test animals with
percentage of control values in parentheses. All test values are 
significantly different from the appropriate control value (Student's 
t-test; P <0.01).
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Table 3.5 Effect of different doses of PB on some hepatic
parameters in the C3H/He mouse
PB Treatment^ Relative liver weight Microsomal Protein Cytochrome P-450
(mg/kg/day) (g/lOOgbody weight) (mg/g liver) (nmol/g liver)
0(Control) 3.86 ± 0.07b 14.3 ± 0.7 10.7 ± 1.1
50 4.95 ± 0.25 19.1 ± 0.4d 31.3 ± 1.9c
- (128) (134) (293)
70 5.56 ± 0.08 23.6 ± 0.5 45.8 ± 3.1
(144) (165) (428)
80 5.44 ± 0.11 20.8 i 1.5 38.1 i 2.7 .
(141) (145) (356)
90 5.67 ± 0.14 20.7 ± 0.1 37.7 ± 2.0
(147) (144) (371)
100 6.05 ± 0.02 20.1 i 0.6 38.9 i 0.7
(157) (141) (364)
^ Mice were fed semisynthetic diet, and received by daily i.p . injection for 14
days either 0.9% saline (1.0 ml/100 g body weight) or saline containing the
stated dose of PB.
^ Data is presented as mean i S.E.M. of 4 control or 3 test animals with 
percentage of control values in parentheses. All test values are 
significantly different from the appropriate control value (Student’s 
_t-test; ^<0.01).
^ Significantly different (Student's jt-test) from the next highest dose;
P <0.05.
Significantly different (Student’s t-test) from the next highest dose; 
P <0.01. ~
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Table 3.6 Effect of different doses of PB on some hepatic
parameters in the C57B1/6 mouse
PB Treatment^ 
(mg/kg/day)
Relative liver weight 
(g/lOOgbody weight)
Microsomal Protein 
(mg/g liver)
Cytochrome P-450 
(nmol/g liver)
O(Control) 3.76 ± 0.09b 13.8 ± 0.5 9.85 ± 0.45
50 4.73 ± 0.07 20.0 ± 0.3c 30.8 ± 3.1c
(126) (145) (313)
70 4.57 ± 0.10 26.2 ± 0 . 9 45.9 ± 0.9
(122) (190) (466)
80 5.03 ± 0 . 1 0 25.1 ± 0.7 45.0 ± 1.2
(134) (182) (457)
90 4.91 ± 0.16d 23.6 ± 1 . 4 43.2 ± 5.0
(131) (171) (439)
100 5.64 ± 0.13 23.4 ± 1.1 45.9 ± 3.6
(150) (170) (466)
^ Mice were fed seraisynthetic diet, and received by daily i.p. injection for 14 
days either 0.9% saline (1.0 ml/100 g body weight) or saline containing the 
stated dose of PB.
b Data is presented as mean i S.E.M. of 4 control or 3 test animals with 
percentage of control values in parentheses. All test values are 
significantly different from the appropriate control value (Student's 
_t-test; 2  <0.01).
c Significantly different (Student's _t~t^st) from the next highest dose;
P <0.01.
Significantly different (Student's _t“ test) from the next highest dose; 
P <0.05. ~~
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Table 3.9 The effect of 85 mg/kg/day PB in the drinking water or diet 
for 10 weeks on some hepatic parameters in C3H/He and C57B1/6 mice
Parameter
Cytochrome
Relative liver Microsomal P-450 content
weight (g/ICO g) protein content (nmol/mg
Mouse strain Vehicle body weight) (mg/g liver) microsomal protein)
C3H/He Diet 137 ± 7^ 145 ± 10 225 ± 1 5
C3H/He Water 147 ± 3  154 ± 3 208 ± 3
C57B1/6 Diet 122 ± 6 125 ± 3 215 ± 8
C57B1/6 Water 125 ± 4 134 ± 5 199 ± 7
^ Results are presented as the mean ± S.E.M. of 4 PB treated mice expressed as 
a percentage of 4 untreated mice. All values are significantly increased 
(Student's ^-test) above control (_P<0.05). Route of treatment did not 
significantly (Student's t-test) affect percentage change (JP >0.05 ).
CHAPTER
THE EFFECT OF PROLONGED PHENOBARBITONE 
ADMINISTRATION ON SOME HEPATIC XENOBIOTIC 
METABOLISING ENZYME ACTIVITIES IN C3H/He MICE
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INTRODUCTION
Several xenobiotics of diverse chemical structure 
have been found to produce liver tumours after prolonged 
administration to rats and mice. These compounds include 
drugs such as phenobarbitone (PB) (Butler and Hempsall 
1978; Peraino et al 1973; Ponomarkov et al 1976;
Rossi et al 1977), steroids such as cyproterone acetate 
(Schuppler and Gunzel 1979), hypolipidaemic drugs such 
as nafenopin (Reddy and Lalwani 1983), organochlorine 
compounds such as DDT, dieldrin and x-hexachlorocyclo- 
hexane (Rossi et al 1977; Schulte-Hermann and Parzefall 
1981; Walker et al 1972) and other industrial chemicals 
including di(2-ethylhexyl)phthalate (Kluwe et al 1982). 
Acute administration of these compounds results, to 
varying degrees, in similar hepatic effects; that is 
increase in liver size, proliferation of smooth 
endoplasmic reticulum and induction of xenobiotic 
metabolising enzyme activities (Schulte-Hermann 1974).
The production of liver nodules by these compounds is 
often dependent upon long term administration at a high 
dose. Some experiments that failed to generate tumours 
may have had an inadequate duration of treatment 
(Wright et al 1972).
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It has been suggested that enzyme inducers promote a 
pre-existing oncogenic factor present in susceptible 
strains (Tennekes et al 1981; Peraino et al 1973).
It has also been suggested that liver growth itself may 
be responsible for tumourigenesis following enzyme 
inducers (Schulte-Hermann 1978). Thus if a liver cell 
has been initiated resulting in derestriction of growth 
control mechanisms, liver growth following treatment 
with an inducer will favour the proliferation of these 
initiated cells (Farber 1984; Schulte-Hermann 1978).
Liver growth without treatment with enzyme inducers 
can be stimulated by partial hepatectomy. It has been 
shown that such a regenerating liver is most susceptible 
to carcinogens at times when DMA synthesis occurs, as 
altered DMA may be incorporated into the cell before 
repair processes have operated (Craddock 1978).
Thus while liver growth is a factor in nodule formation, 
do induced enzyme activity and smooth endoplasmic 
reticulum proliferation have a role? Liver enlargement 
without enzyme induction has been demonstrated, and this 
was associated with hepatic damage (Grasso et al 1974).
It has also been shown that some compounds, including dieldrin,
3-methyl-4-dimethylaminoazobenzene, Ponceau MX and safrole, 
known to result in tumour formation, may with prolonged 
administration result in only a transient induction of
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hepatic■mixed function oxidase (m.f.o.) (Hutterer 
et al 1969; Crampton et al 1977/1)). Although enzyme 
activity may fall liver size remains elevated. Thus 
a failure to sustain enzyme induction may be associated 
with hepatocellular damage including nodule formation.
As the proliferated smooth endoplasmic reticulum persists 
the term hypoactive, hyperplastic has been used (Hutterer 
et al 1969). Grasso (1979) has contrasted such damage 
with work hypertrophy, characterised by hyperactive 
hyperplastic smooth endoplasmic reticulum;that is sustained 
liver enlargement and enzyme induction.
It has been considered that enzyme induction is an 
adaptive response that results in some protection of the 
liver (Schulte-Hermann 1974; Remraer and Merker 1965;
Wright et al 1972) . Only at high doses of xenobiotic, 
when the liver is unable to respond further, are toxic 
effects manifest (Hutterer et al 1969). Schulte-Hermann 
(1979) suggested that prolonged stimulation of the 
hepatic drug metabolising enzyme system may lead to 
dysfunction of that system and presumably various species 
and strains have different susceptibilities. A study on 
rats (Crampton et al 1977a) showed that administration of 
PB for up to 80 weeks at 2500ppm in the diet resulted 
in maintained induction of m.f.o. enzymes and cytochrome 
P-450 and protein content which was reversible. In mice 
PB has been reported to stimulate hepatic m.f.o. activity
1 0 0
for up to 40 weeks of treatment (Wright et al 1972).
Thus although failure of the hepatic m.f.o. enzyme 
system was not demonstrated, these studies did not 
report nodule formation.
In this study the effect of continuous administration 
of PB was investigated, using a dose of 85 mg/kg body 
weight/day in the diet on C3H/He mice, a strain highly 
susceptible to "spontaneous" heptoma formation 
(see Chapter 1.2.3). Treatment was continued throughout 
the period of nodule formation and a range of biochemical 
parameters measured to assess enzyme induction. Mice 
were housed in grid floored plastic cages and fed a 
semisynthetic diet to minimise extraneous environmental 
influences on hepatic enzyme induction and nodule 
formation (Tennekes and Wright 1978).
MATERIALS AND METHODS 
Treatment of Animals
Male C3H/He mice were fed semisynthetic diet as described 
in Chapter 2.13. Test animals were given PB (>98% pure) 
in the diet at a dose of 85 mg/kg body weight/day as 
described in Chapter 2.14, for up to 90 weeks.
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Studies on Mice Treated For Up To 70 Weeks With PB 
Enzymes of xenobiotic metabolism were measured after 
4, 10, 25, 40, 55 and 70 weeks of PB treatment. DNA 
content was measured at these times and also after 
1 week of treatment. Assay methods are described in 
Chapter 2.
After 4 and 10 weeks of PB treatment the covalent 
binding of Q^^c JPB to hepatic microsomes was measured 
in treated and control mice, using the method described 
in Chapter 2.35. Binding of L^^cl paracetamol was 
measured as a positive control.
Histological Examination
Histological examination of livers from control and mice 
treated for 4 and 70 weeks with PB was kindly performed 
by Dr. J.G. Evans at B.I.B.R.A. Livers were fixed in 
neutral buffered formalin. Sections were stained with 
haematoxylin and eosin and examined by light microscopy.
Studies on. Hepatic Nodules
Some mice, after 70 and 90 weeks of PB treatment, and 
untreated mice (102 weeks old) had liver nodules that 
could be easily dissected free from surrounding (host) 
tissue. These nodules were treated as separate tissue 
preparations. In some cases several nodules were pooled 
to form one tissue preparation.
0 2
After 72 weeks of treatment the apparent kinetic 
constants of hepatic Y-glutamyl transpeptidase (GGT) 
were measured in control, host and nodular tissue.
The inhibition of microsomal 7-ethoxycoumarin 0-deethylase 
by metyrapone and «.-naphthof lavone (ANF) was 
investigated in host and nodular tissue from PB treated 
mice, in similarly aged untreated mice and in mice 
treated with p-naphthoflavone (BNF). BNF was administered 
by daily i.p. injection, dissolved in corn oil, at a 
dose of 40 mg/kg/day for 3 days.
Xenobiotic metabolising enzymes were measured in host 
and nodular tissue from mice treated for 90 weeks with 
PB, and in similarly aged controls. Enzyme activity was 
compared to similarly aged mice given BNF (3 daily doses 
of 40 mg/kg/day) and in young mice of both the C3H/He 
and C57B1/6 strains given either 1 dose of BNF (80 mg/kg), 
48 hours prior to sacrifice, or 3 daily doses of either 
40 or 80 mg/kg/day, the last dose 24 hours prior to 
sacrif ice.
Some hepatic enzyme activities were measured in nodules 
and host tissue of mice fed PB for 60 weeks and then 
stock diet for 34 weeks, and in similarly aged untreated 
mice.
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Clearance of PB from Blood and Liver in vivo
Mice treated for 70 weeks with PB and similarly aged 
controls were given a single 0.42 mg/kg (0.ImCi/kg) 
i.p. dose of C^^^cU PB and the total radioactivity 
determined in the blood and liver at various times. 
Where appropriate test livers were divided into host 
tissue and large nodules.
RESULTS
Hepatic Effects of Up To 70 Weeks PB Treatment 
Relative liver weight was increased by PB treatment 
at all times measured (Fig 4.1). After the initial 
response at 1 week relative liver weight was constant 
from 4 to 25 weeks, but from 40 to 70 weeks a further 
progressive increase was seen.
The DNA content of test livers expressed per lOOg body 
weight was increased at all times with the percentage 
increase larger at later times of treatment (Fig 4.2). 
Expressed per g. of liver DNA content was not markedly 
changed from 10 to 70 weeks but a significant decrease 
was recorded at 1 and 4 weeks. Incorporation of 
j^ H^ J thymidine into hepatic DNA was raised to 200% of 
control value after 1 week of treatment. There was a 
smaller, but significant increase at 10 weeks, and no 
change was noted at 4 weeks, or from 25 weeks onwards.
1 04
Histological examination of the livers revealed 
hypertrophy of the centrilobular cells of the liver 
lobule in PB treated animals (Fig 4.3.A).
Mitochondrial enzymes succinate dehydrogenase and 
carnitine acetyltransferase, when expressed as enzyme 
activity per g . liver were reduced at all times of 
PB treatment (Table 4.1). The same data expressed 
a.s enzyme activity per lOOg body weight showed both 
activities unchanged from control levels, except for 
succinate dehydrogenase which was slightly stimulated 
at 4 and 25 weeks and further increased at 70 weeks.
The effect of PB treatment on microsomal m.f.o. enzyme 
and NADPH-cytochrome c reductase activities and 
cytochrome P-450 content, expressed per mg protein is 
shown in Fig 4.4. There was a significant increase in 
all parameters at all times of treatment. Aniline
4-hydroxylase and NADPH-cytochrome c reductase activities 
and cytochrome P-450 content responded to a similar 
extent, with the degree of increase remaining fairly 
constant. 7-Ethoxycoumarin 0-deethylase, after a higher 
initial stimulation remained induced to about 400% of 
control activity until weeks 55 and 70 where further 
increases were evident. Ethylmorphine N-demethylase was 
highly induced 6 to 10 fold with treatment, and there was 
an apparent trend of continued increase from 25 to 70 weeks.
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Enzyme activities of Phase II metabolism during PB 
administration are shown in Fig. 4.5 expressed per 
mg protein. Glutathione S-transferase activity to 
l-chloro-2,4-dinitrobenzene (CDNB) was not affected by 
PB treatment until after 10 weeks, when there was an 
increase to about 130% of control. Activity to 
1, 2-epoxy-3-(p^-nitrophenoxy) propane (ENPP) was induced 
throughout treatment. Hepatic levels of non-protein '
sulphydryl groups were not- changed with treatment 
(data not shown). UDP-Glucuronyltransferase was 
induced throughout treatment. There was no change in 
the degree of stimulation with either time or with the 
addition of detergent to activate the enzyme.
PB treatment had a variable effect on NADPH-dependent 
lipid peroxidation (Table 4.2), when small but 
significant increases were measured at 25, 40 and 70 weeks.
The control rate of NADPH-dependent lipid peroxidation 
increased nearly 10 fold from 4 to 25 weeks and declined 
slightly thereafter.
The covalent binding of PB or its metabolites to
liver microsomes of both test and control mice at 4 and 
10 weeks was not detected (Table 4.3). As a positive 
control covalent binding of paracetamol was assayed
identically using the same tissue preparations. The rate 
of binding was nearly doubled in PB treated mice at both times
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Studies on Hepatic Nodules of 70 Week PB Treated-Mice 
At 70 weeks of treatment the livers of about 70% of 
treated mice bore visable hepatic nodules. In about 
half of these animals nodules were of sufficient size 
to be dissected free from host tissue and treated as 
a separate tissue preparation. Typically such nodules 
were similar in colour to surrounding tissues. 
Histological examination revealed either small basophilic 
nodules or nodules consisting of large eosinophilic cells 
containing bizarre nucleii (Fig. 4.3.B). Nodules of 
this type were often extremely large and probably 
represented the form dissected free for biochemical 
determinations. Livers of control mice contained 
nodules of the basophilic type only.
The DNA content of both large nodules and host tissue 
was not significantly different from control values 
(Table 4.4). However, while in host tissue the rate of 
incorporation of C^n]thymidine into DNA was the same 
as control, in large nodules the rate was significantly 
increased.
•)
Non-protein sulphydryl levels were unchanged from control 
in both host tissue and large nodules (Table 4.5).
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Succinate dehydrogenase .activity in the liver of PB 
treated mice was reduced, and to a greater extent in 
large nodules (52%) than in host tissue (73%).
GGT was induced over 2 fold in host tissue but to 
30 fold in large nodules. To further investigate the 
large stimulation of this enzyme in nodular tissue, 
that was not seen in host tissue, the apparent kinetic 
constants were determined in test and control tissues 
(Table 4.6). The apparent of GGT was increased by 
a small non-significant extent in PB treated tissue 
The enzyme in nodular tissue had a slightly higher 
apparent Km than that in host tissue and significantly 
higher than control values. The Vmax of GGT in host 
tissue was double that of control tissue, but that of 
nodular tissue was about 50 fold greater than control 
values.
Glucose-6-phosphate dehydrogenase activity was not 
significantly raised in host tissue but was doubled in 
nodular tissue (Table 4.5).
Glutathione reductase was increased above control in 
host tissue and further increased in large nodules. 
Glutathione S-transferase activity to CDNB was not 
significantly increased in host tissue, but was increased
108
2 fold in large nodules. Activity to ENPP was increased 
in both host liver and large nodules.
There was no significant change in microsomal NADPH- 
dependent lipid peroxidation in either host or nodular 
tissue (Table 4.7).
Host tissue microsomal 7-ethoxycoumarin and 7-ethoxyresorufin 
0-deethylase activities were increased 4-5 fold, but 
10 and 25 fold respectively in large nodules (Table 4.7). 
Ethylmorphine N-demethylase activity was increased 
10 fold above control in both host tissue and large 
nodules. Cytochrome c reductase activity was also 
induced to a similar level in both tissues, but to about 
250% of control. Microsomal cytochrome P-450 content was 
also similar in both the tissues, induced to about 300% 
of control values, with no detectable shift in the 
wavelength of maximal absorbance in nodules. Ethyl 
isocyanide spectra showed a reduction in the ratio of 
peak heights, which was greater in large nodules than 
host tissue.
To further investigate the nature of the cytochromes 
present in nodular tissue, the effect of the specific 
inhibitors ANF and metyrapone on microsomal 7-ethoxycoumarin 
0-deethylase was investigated. 7-Ethoxycoumarin 
0-deethylation is catalysed by both cytochrome "P-448"
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and "P-450". The cytochrome "P-448" inhibitor ANF 
(Wiebel et al 1971) did not affect the enzyme from 
control, PB treated host tissue or PB induced nodules 
(Fig. 4.5.A) but did inhibit the enzyme from BNF 
pretreated mice. In contrast the cytochrome "P-450" 
inhibitor, metyrapone, depressed 7-ethoxycoumarin 
0-deethylation in tissue from PB treated host tissue 
and nodules, but not in control or BNF treated livers 
(Fig, 4.5,B).
Clearance of PB from Blood and Liver in vivo
The levels of radioactivity remaining in the blood and 
liver of mice given C^'^clPB (0.1 m Ci/kg, 0.43 mg/kg 
bodyweight) are shown in Fig. 4.7.A and Fig. 4.7.B 
respectively. In control animals the clearance was 
log-linear for 24 hours with a half-life of 10.7 and
9.4 hours for blood and liver respectively. In test 
animals clearance was linear for at least 8 hours and 
half-lives in blood, host liver and large nodules were 
3.5, 3.1 and 3.0 hours respectively.
Studies on Hepatic Nodules of 90 Week PB Treated Mice 
Some hepatic parameters of mice fed PB for 90 weeks, 
untreated control mice of the same age and similarly 
aged control mice treated with BNF are shown in Table 4.8 
Glutathione S-transferase activity to CDNB was induced 
by PB treatment to a greater extent in large nodules 
than in host tissue. BNF pretreatment did not change
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glutathione S-transferase activity. Glutathione 
reductase responded in a similar fashion.
Microsomal protein content was increased in both host 
tissue and large nodules, but not with BNF treatment.
Four m.f.o. enzyme substrates were more rapidly 
metabolised by PB treated host tissue and large nodules 
than by control tissue, including the cytochrome "P-448" 
substrates 7-ethoxyresorufin and benzo(a)pyrene.
BNF treatment raised metabolism of 7-ethoxyresorufin 
and benzo(a)pyrene to a lesser degree than PB treatment. 
The change in 7-ethoxyresorufin 0-deethylation is 
illustrated in Fig. 4.8 which shows activity in control, 
host and nodular tissue after 70 and 90 weeks of PB 
treatment and after BNF treatment in old and young mice.
At 90 weeks control activity was raised compared to 
control activity at 70 weeks. After 90 weeks of treatment 
host tissue and large nodules exhibited similar activities 
whereas after 70 weeks host tissue activity was 
considerably less than that of large nodules. BNF 
treatment increased enzyme activity to similar levels 
as those seen in large nodules, but young mice apparently 
responded more than old.
Cytochrome P-450 content was significantly raised in 
both host tissue and large nodules from PB treated mice, 
but not with BNF treatment (Table 4.8). A drop in the
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ethyl isocyanide spectra peak height ratio was seen 
with PB treatment in both host tissue and nodules, 
whilst an increase followed BNF treatment. However, 
these changes were not statistically significant.
As the BNF treatment used did not result in the high 
degree of cytochrome "P-448" induction expected 
(i.e. large increase in benzo(a)pyrene hydroxylation 
and cytochrome P-450 content), three different dosing 
regimens were tested, using 8 week old mice. Both 
C3H/He (Table 4.9) and €57 Bl/6 (Table 4.10) mice 
were tested. It may be seen comparing the effect of 
BNF treatment (3 x 40 mg/kg) in 98 week old mice to 
that in 8 week old mice that younger mice are somewhat 
more responsive, having increased cytochrome P-450 
content, benzo(a)pyrene hydroxylase, 7-ethoxycoumarin 
0-deethylase and cytosolic glutathione S-transferase 
enzyme activities. Ethylmorphine N-demethylase and 
microsomal protein were not affected by treatment 
in young mice.
Comparing the effect of different doses of BNF in the 
C3H/He strain it was clear that 1 x 80 mg/kg and 
3 X 40 mg/kg were not maximally stimulating doses, as 
greater induction was achieved with 3 x 80 mg/kg. Also 
the C57B1/6 mouse was more responsive to BNF than the
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C3H/He strain. At the highest dose cytochrome P-450 
content, and activity of cytochrome "P-448" linked 
enzymes were higher in the C57B1/6 strain. In this 
strain there was a hypsochromic wavelength shift of 
cytochrome P-450 of about 2 nm, whereas this was about
1.5 nm in the C3H/He strain with BNF treatment (data 
not shown).
Studies on Hepatic Nodules Induced By PB Treatment,
After 34 Weeks Without PB
After 60 weeks of PB treatment some mice were fed control 
diet for 34 weeks to investigate the reversibility of 
the effects of PB (Table 4.11). Microsomal protein 
content of large nodules and host tissue from these 
animals was not different from tissue from control mice. 
Cytochrome P-450 content was reduced in host tissue but 
slightly raised in 2 nodules. Three enzymes frequently 
used as histochemical markers were measured, glucose-6- 
phosphate dehydrogenase, glucose-6-phosphatase and GGT. 
There was no consistent change from control in host tissue 
or large nodules. However, of the three nodule 
preparations one had a highly elevated (620%) GGT level.
Studies on Hepatic Nodules From Untreated Mice.
At 102 weeks of age some control mice (about 30%) had 
nodules that were large enough to be excised from 
surrounding host tissue. These nodules were generally
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liver coloured and appeared similar.to those seen 
after prolonged PB treatment.
Microsomal protein (Table 4.12) and cytochrome P-450 
content did not differ from control values in these 
nodules. GGT was,raised in one nodule preparation 
but not in two others. Glucose-6-phosphate dehydrogenase 
was highly induced to nearly 4 fold control (host tissue) 
levels.
In two of these nodule preparations some other enzymes 
were measured (Table 4.13). Cytosolic glutathione 
S-transferase activity to CDNB was elevated in these 
nodules, but glutathione reductase was less so. The
three m.f.o. substrates tested generally showed a
 fsimilar rate of metabolism in the nodules as to ^ control 
tissue.
DISCUSSION.
There is extensive information available on the effects 
of short term PB administration in rodents (see Chapters 3, 
5 and 6).
In this study the effects of PB were monitored from 
short term to prolonged administration. Parameters of 
liver growth and enzyme induction were measured to assess 
their potential role in nodule formation.
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As PB is an epigenetic carcinogen in mice (Williams 1981) 
and thus may not directly damage DNA it is important 
to discover when and how cells are eventually directed 
into less restricted growth with prolonged treatment. 
Biochemical data shows that liver size was initially 
(1 week) increased without proportional increase of 
DNA, although at this stage DNA synthesis was higher 
than control levels. By 4 weeks the increase in liver 
size was accompanied by increased total DNA, although 
DNA concentration was somewhat reduced. At 10 weeks 
DNA concentration was similar in test and control mice. 
Thus initial hypertrophy followed by hyperplasia could 
be postulated. However, histological examination 
reveals centrilobular hypertrophy at all treatment 
times. Thus the hyperplasia is at least partly due 
to increased ploidy of cells. This point serves as a 
demonstration that liver homogenates provide an overall 
value of all different Cell types present. Detailed 
morphometric analysis of nuclear size would be needed 
for a definitive answer to this problem.
It has been reported that in rats liver enlargement 
following PB was entirely due to hypertrophy (Schulte- 
Hermann et al 1980). Wright et al (1972) said that 
liver cell hyperplasia as shown by increased hepatic 
DNA in response to PB occurred in the mouse but not
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the rat. Certainly hyperplasia was a contributory . 
factor in liver enlargement in the mouse (Wright et al 
1972, Thorpe and Walker 1973, Tennekes and Wright 1978, 
Tennekes et al 1979). In this study DNA synthesis, 
estimated by thymidine incorporation, was only
raised at 7 days of PB treatment. It has been noted 
in other studies that after several weeks of PB 
administration to mice C t h y m i d i n e  incorporation 
into DNA was not raised (Cans et al 1976). It is 
probable that once the initial response to PB is made 
a normal steady state of DNA turnover is maintained.
Thus it seems that PB and other enzyme inducers do not 
exert a tumorigenic effect by increasing DNA turnover 
and thereby increasing the chance of incorporating 
errors into DNA by either chemically mediated or random 
mechanisms.
Mitochondrial function might play an important role in 
livers that are subject to a high oxidative load.
Succinate dehydrogenase, an enzyme of the tricarboxylic 
acid cycle, provides a measure of the ability of the 
mitochondria to provide reduced nicotinamide-adenine 
dinucleotides. These dinucleotides are cofactors 
required for the cytochrome P-450 electron transport 
chain and thus needed for microsomal xenobiotic metabolism, 
Activity calculated per g fresh liver of mitochondrial
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enzymes showed significant depression with PB treatment. 
When calculated as total activity as a percentage of 
body weight succinate dehydrogenase was at control
C
level, or occasionally stimulated by treatment. Thus 
the total enzymic capability was not changed, although 
liver size was increased. This may indicate that numbers 
of mitochondria per unit cell volume were reduced or 
mitochondria became less active with treatment. Detailed 
morphometric analysis of livers would give an answer to 
the former point. Mitochondria have been studied as a 
possible key site of damage following hepatotoxins such 
as CCl^, but such damage occurs after that to other 
organelles and thus a role has been discounted (Recknagel 
and Glende 1973).
The response to PB treatment of hepatic smooth endoplasmic 
reticulum proliferation and increased enzyme activities 
is well known (Remmer and Merker 1965). This study 
demonstrates that induction of hepatic microsomal m.f.o. 
and MADPH-cytochrome c reductase activities and cytochrome 
P-450 content was maintained for at least 70 weeks with 
continual PB challenge. Furthermore, there was some 
indication of greater increases in some m.f.o. enzyme 
activities from 40 to 70 weeks. At this time relative 
liver weight in treated mice also increased. Increase 
in liver size over this time may be the physical 
consequence of nodule formation. It is certain, however.
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that nodule formation is not coincident with either 
dysfunction of the m.f.o. enzyme system or "hypoactive, 
hyperplastic endoplasmic reticulum" (Hutterer et al 1959) 
Thus PB apparently acts differently from some other 
enzyme inducers such as 3-methyl-4-’aminoazobenzene, 
safrole and Ponceau MX (Crampton et al 1977b; Hutterer 
et al 1969) but in a similar manner to dieldrin 
(Tennekes and Wright 1978; Tennekes et al 1981).
Conjugative enzymes, both cytosolic and microsomal 
showed no reduction of activity with continued PB 
treatment. The similar ratio of activated to unactivated 
UDP-glucuronyltransferase throughout treatment indicated 
that the enzyme does not become more or less membrane 
bound during prolonged PB treatment. It is known that 
UDP-glucuronyltransferase activity to 4-hydroxybiphenyl 
is PB inducible and indeed largely centrilobular in 
location (Ullrich et al 1984), so it would be of interest 
to know if activity of the enzyme form(s) not induced by 
PB are changed with prolonged treatment.
As no change of NADPH-dependent lipid peroxidation was 
seen in vitro with PB treatment and as no detrimental 
effects on the microsomal membrane (as assessed by m.f.o. 
enzyme activity) were noted it is probable that activated 
oxygen species were not involved in the lesion(s) leading 
to nodule formation. Indeed some drug substrates can be
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in vitro inhibitors of lipid peroxidation (Miles 
et al 1980).
The presence of a reactive metabolite of PB was not 
detected in incubations of liver microsomes, cofactors 
and C^^c Ip b , although the system used was capable of 
detecting reactive products formed from paracetamol. 
Incubations in the presence of the epoxide hydrase 
inhibitor 3,3,3-trichloropropylene oxide (Oesch 1974) 
which would prevent the enzymic breakdown of an arene 
oxide to the dihydrodiol and thus potentiate reaction 
with cellular macromolecules also did not increase 
binding. Thus there is no evidence from these studies 
that PB is metabolised via an arene oxide. Failure to 
detect covalent binding of PB metabolites has been 
previously reported by Corsini et al (1972). The 
generation of a reactive metabolite cannot yet be 
discounted without evidence to demonstrate that the 
in vitro system used does indeed metabolise PB. Such 
confirmation might be obtained by the detection of 
4-hydroxy— PB in incubation mixtures. Crayford and 
Hutson (1980) have reported the refractory nature of 
PB to in vitro metabolism, whereas Kapetanovic and 
Kupferberg (1981) have identified by gas chromatography both 
3- and 4-hydroxy PB in NADPH-dependent microsomal 
incubations. The covalent binding of radiolabelled
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metabolites to cellular macromolecules has been used 
as a method of detecting reactive intermediates of 
several xenobiotics (Lake 1984; Potter et al 1974;
Sun and Dent 1980).
After 70 weeks of PB treatment the large nodules 
present in some test livers were used for biochemical 
determinations. The DNA content per g weight of large 
nodules was similar to control tissue, but DNA synthesis 
in the nodules was increased. The rate of DNA synthesis 
has been used as an index of the speed of growth and 
hence deviation of hepatomas (Lea et al 1966), and by 
this criterion these nodules were very slow growing.
The increased rate was less than that found in liver 
treated for 7 days with PB. In spite of increased DNA 
synthesis and unchanged DNA content per g liver 
histological studies revealed large bizarre nuclei 
and multinucleate cells in large nodules. Thus cell 
division was possibly inhibited in some way.
The in vivo uptake and elimination of a C^^c]pB dose 
by large nodules was the same as host tissue; that is 
similar uptake and more rapid elimination compared to 
control. Thus large nodules have the potential to 
participate in hepatic metabolic processes.
In nodules of PB treated mice enzymes associated with 
Phase I drug metabolism showed in vitro levels of induction
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similar to that of host tissue. In many respects the 
pattern of induction and the response of nodular tissue 
to enzyme inhibitors was typical of PB induction.
High m.f.o. enzyme activity has been reported in nodules 
resulting from chronic administration of dieldrin to mice 
(Tennekes et al 1979, 1981). However there are certain 
dissimilarities between the actions of dieldrin and PB, 
such as the reduction of hepatic GSH content in dieldrin 
induced nodules not seen with PB. Also dieldrin reduced 
glucose-6-phosphatase activity only in nodules, whereas 
activity was reduced in all PB treated hepatic tissues. 
Enzyme induction by dieldrin in nodular and non-nodular 
tissue was reversible on cessation of dieldrin treatment 
(Tennekes et al 1979) as was cytochrome P-450 content with 
PB induced nodules and host tissue.
Enzymes of Phase II metabolism were also induced in nodules 
arising from both dieldrin and PB. Furthermore the limited 
data obtained from spontaneous nodules shows microsomal 
protein and cytochrome P-450 content and m.f.o. enzyme 
activities similar to control (host) tissue. Thus nodules 
arising either spontaneously or from chronic exposure to PB 
appear to behave in a similar manner to normal tissue.
In general the cytochrome P-450 content and m.f.o. enzyme 
activities of hepatomas induced by various carcinogens and 
including transplantable types are acknowledged to be less
than control or host tissue levels (Adamson and Pouts 1961;
Astrom et al 1983; Denk et al 1980; Eriksson et al 1983;
Kaneko et al 1980; Strobel et al 1978).
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In transplantable hepatomas the loss of some enzyme 
activities was related to the degree of differentiation 
with the minimal deviation tumours having normal activity 
(Rogers et al 1967). Nodules resulting from long term 
administration of PB, whilst not transplantable, have 
minimally deviant xenobiotic metabolising enzymes.
However, the large increase in 7-ethoxyresorufin 
dééthylation in nodules of PB treated animals (not 
found in control nodules) was unexpected. This enzyme 
was considered to be a specific marker for cytochrome 
"P-448" (Burke and Mayer 1975), and thus only inducible 
by polycyclic hydrocarbons such as BNF. However short 
term PB treatment to mice induces this enzyme activity 
by 3-4 fold (M. Collins, unpublished observations).
Aryl hydrocarbon hydroxylase (benzo(a)pyrene 3-hydroxylase) 
was also stimulated about 3 fold in both responsive and 
non-responsive mice following acute PB treatment 
(Tukey et al 1982). Similar increases were seen in 
benzo(a)pyrene hydroxylation in both host tissue and 
nodules from PB treated mice at 90 weeks. The change 
in activity to 7-ethoxyresorufin in PB treated host 
tissue from 70 to 90 weeks suggests a changing population 
of cytochromes at this time. Enzyme activity in nodular 
tissue was similar to that achieved by BNF treatment.
This result may represent a small qualitative change 
in cytochrome(s ) present resulting in large quantitative
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changes, for other data such as ethyl isocyanide 
spectra, wavelength of maximum absorption of the 
reduced cytochrome P-450-CO complex and inhibition 
by metyrapone but not by ANF of 7-ethoxycoumarin 
0-deethylase confirm typical "P-450" induction.
In the presence of massive induction of this cytochrome
type, cytochrome "P-448" may not influence these
parameters sufficiently to be detected. It would
thus be of interest to investigate the nodular cytochromes
by such techniques as PAGE-electrophoresis, where changes
may be directly visualised. Other workers have reported
various changes in m.f.o. enzymes in senescent
compared to young or adult rodents. Birnbaum and
Baird (1978) reported no change in microsomal cytochromes,
but a decrease in ethylmorphine N-demethylation and
benzo(a)pyrene hydroxylation in 30 month old rats.
Rikans and Motley (1982) recently reported a reduction 
of cytochrome P-450 content and a hypsochromic wavelength 
shift in the CO-cytochrome P-450 spectra of 0.8 nm in 
24 month old rats, alongside reduced benzphetamine 
N-demethylation and increased nitroanisole 0-demethylation. 
Enzyme activities in senescent rodents were apparently 
still fully inducible by various agents (Birnbaum and 
Baird, 1978). In 25 month old mice Birnbaum (1980) 
reported decreases in benzphetamine and ethylmorphine 
N-demethylation but increases in benzo(a)pyrene and
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7-ethoxycoumarin metabolism. Thus age related changes 
in the cytochrome complement are known, but the large 
changes seen in PB induced nodules remain unexplained.
It would be of interest to know the activity of 
7-ethoxyresorufin 0-deethylase in nodules formed 
by PB treatment but after prolonged withdrawal of 
the inducer.
Other enzyme activities of nodular tissue demonstrate 
some differences between nodules and host tissue.
For example in large nodules glutathione S-transferase 
activity to CDNB was considerably raised above host 
tissue levels at 70 and 90 weeks of treatment. Similar 
differential induction of enzymes of Phase II metabolism 
has been previously reported in nodules resulting from 
2-acetylaminofluorene (Astrom et al 1983) with reduction 
of Phase I metabolism (Cameron et al 1976; Eriksson 
et al 1983). Low levels of monooxygenase activity 
found in tumour cells might reduce the quantity of 
reactive metabolites produced within the cell. Coupled 
with high levels of conjugative enzymes the reduced 
toxic load may enable selective growth of cells altered 
in this way (Eriksson et al 1983). Certainly it seems 
that hepatoma cells are less susceptible to some 
chemical toxins (Farber et al 1976).
2Other enzymes studied in nodular tissue included
often used histochemical markers GGT and glucose-6-
phosphate dehydrogenase. There was marked stimulation
of glucose-5-phosphate dehydrogenase in control nodules,
perhaps indicating a fundamental difference from PB
induced nodules. GGT was slightly stimulated by
PB treatment in host tissue at 70 weeks. This might
be due to the presence of numbers of small enzyme
altered foci, for the induction in PB induced nodules
at this time was massive. In both nodules from mice
fed PB for 50 weeks and then stock diet for 34 weeks,
and nodules from untreated animals there appeared to
be at least two nodule types; either with high or
low stimulation of GGT. Examination of the apparent
kinetic constants of GGT from the various tissue
types suggests that the increased activity was due
to synthesis of new enzyme rather than increased
affinity for the substrate which, if anything, was
reduced. GGT activity has been considered as a marker
for very early, as well as late, putative preneoplastic
lesions in rats (Cameron et al 1978), but in the mouse
findings have been inconsistent and Essigmann and
Newberne (1981) suggest that activity may be a function
of necrosis and/or hyperplasia rather than a
neoplastic process. The apparent reversibility of
this enzyme stimulation supports this view. Histochemically
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negative GGT in spontaneous nodules but positive 
GGT in nodules resulting from PB treatment of C3H 
mice has been reported (Kitagawa et al 1980), although 
Fiala et al (1972) reported some spontaneous hepatomas 
with slightly elevated GGT., It would be of interest 
to see if GGT of spontaneous nodules could be induced 
by short term PB treatment to a similar degree as that 
seen in nodules resulting from long term PB administration.
These studies show that during prolonged administration 
of PB to C3H/He mice enzymes of both Phase I and Phase II 
metabolism were stimulated and that the stimulation was 
maintained. Nodules arose in both control and treated 
mice, but greater numbers were found in the treated 
group and these extra nodules had different staining 
characteristics. Enzymes measured in large nodules 
from treated mice were generally similar to host tissue 
and the nodules were thus apparently capable of 
participating in metabolism. Thus nodules did not 
arise from a failure to maintain high levels of m.f.o. 
enzyme activities and nodules themselves closely 
resembled normal PB treated tissue.
Fig. 4.1 The Effect of PB on Liver Size of C3H/He-Mice
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Mice were fed semisynthetic diet (o) or diet containing 
PB (•) at a dose of 85 mg/kg/day. Results are the 
mean - S.E.M. of 6 animals.
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Fig. 4.2 The Effect- of PB Administration On Hepatic
DNA Content And Incorporation of Thymidine
in C3H/He Mice.
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PB was administered in the diet at a dose of 85 mg/kg/day 
to C3H/He mice. Hepatic DNA content (•), total hepatic 
DNA (o) and incorporation of [^Hjthymidine into DNA (a ) 
were determined and results are presented as the mean - S.E.M. 
of 6 treated mice expressed as a percentage of 6 untreated mice. 
Typical control values are 2.8 mg DNA/g liver, 10.2 mg DNA/lOOg 
body weight and 7400 d.p.m./mg DNA respectively.
Fig. 4.3
Section of liver stained with haematoxylin and 
eosin from C3H/He mice fed 85 mg/kg/day PB for 
(A) 4 weeks, showing slight cellular and 
nuclear hypertophy in the immediate vicinity 
of an hepatic vein, X130; (B) 70 weeks,
showing the edge of a large nodule formed of 
large eosinophilic cells with large, open, 
vesicular nuclei. The nuclei often contain 
prominent nucleoli. There is slight compression 
of the surrounding parenchyma and the border 
between the parenchyma and nodule is quite . 
distinct, X55.
Fig. 4.4
The effect of administration of 85 mg/kg/day 
PB in the diet on microsomal ethylmorphine 
N-demethylase (a ), 7-ethoxycoumarin 0-deethylase 
(•), aniline 4-hydroxylase (■), NADPH-cytochrome 
c reductase (O) and cytochrome P-450 (X).
Results are presented as mean - S.E.M. of 
6 test animals expressed as a percentage 
of 6 control animals. Typical control values 
for the activities measured (expressed per unit 
of microsomal protein) are shown in Table 4.7.
Fig. 4.4 The Effect of PB on Some Hepatic Microsomal
Parameters in C3H/He Mice.
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Fig. 4.5
The effect of administration of 85 mg/kg/day
PB in the diet on microsomal UDP-glucuronyltransferase
either unactivated (A) or detergent activated (A)
and on cytosolic glutathione S-transferase
activity to CDNB (O) and ENPP (•). Results
are presented as the mean - S.E.M. of 6 test
animals expressed as a percentage of 5 control
animals. Typical control values for unactivated
and activated UDP-glucuronyltransferase are 39 and
52 nmol/hour/mg microsomal protein respectively
and for glutathione S-transferase activity to
CDNB and ENPP 7.0 and 0.38 )imol/min/mg cytosolic
protein respectively.
Fig. 4.5 The Effect of PB on Some Hepatic Enzymes of
Phase II Metabolism in C3H/He Mice.
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Fig. 4.6
Inhibition of hepatic 7-ethoxycoumarin 
0-deethylase by (A) ANF and (B) metyrapone. 
Washed microsomal fractions were prepared 
from control C3H/He mice (•) or mice fed a 
diet containing 85 mg/kg/day PB for 70 weeks. 
Livers from treated animals were separated 
into large nodules (a) and surrounding host 
tissue (■). Some control mice were given 
40 mg/kg/day BNF for 3 days by i.p. injection 
(□) or corn oil vehicle alone (o). Results 
are expressed as a percentage of the appropriate 
control i.e. in the absence of metyrapone or 
in the presence of 5 p.1 acetone for ANF. Each 
point represents the mean - S.E.M. of 3 tissue 
preparations.
Fig. 4.5 Inhibition of Microsomal 7-Ethoxycoumarin 
'• 0-Deethylase by ANF and Metyrapone.
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Fig. 4.7
Levels of a dose of in the blood (A)
and liver (B) of C3H/He mice fed semisynthetic 
diet (X) or diet containing PB at a dose of 
85 mg/kg/day (•). Large nodules (o) present 
in test livers were removed and the radioactivity 
present determined separately. PB
(0.1 mCi/kg, 0.43 mg/kg body weight) was given 
by i.p. injection.
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Fig. 4.8 Activity of 7-Ethoxyresorufin 0-Deethylase
In C3H/He Mice.
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Activity of hepatic 7-ethoxyresorufin 0-deethylase 
in control animals (C) or mice fed a diet 
containing 85 mg/kg/day PB for 70 and 90 weeks.
Livers from treated animals were separated into 
large nodules (N) and surrounding host tissue 
(HT). Some untreated mice (of ages equivalent 
to 0 and 90 weeks of PB treatment) were given 
40 mg/kg/day BNF for 3 days by i.p. injection.
Each point represents a tissue preparation from
a single animal except for large nodules which
were pooled from 1-3 mice. Bars represent group means
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Table 4.1 The effect of PB treatment on hepatic activity of 
succinate dehydrogenase and carnitine acetyltransferase in
C3H/He mouse
Duration
(weeks) Treatment
Parameter
Succinate Dehydrogenase Carnitine .acetyltransferase
praol/min/ 
g liver
pmol/min/100 g 
body weight
pmol/min/ 
g liver
pmoI/min/100 g 
body weight'
4 Control 12.4 ± 0.4b 49 ± 1 3.9 ± 1.3 4.6 1 0.6
PB^ 10.9 ± 0.2c 59 ± 2d 2.6 1 0.5c 3.9 1 0.4
(88) (119) (65) (85)
10 Control 14.7 ± 0.3 58 ± 2 6.7 ± 1.8 4.5 1 0.4
PB 11.5 ± 0.4c 59. ± 4 3.7 ± 0.9c 3.8 1 0.5
(78) (102) (55) (84)
25 Control 19.1 ± 0.6 51 ± 2 4.5 ± 0.3 4.6 1 0.3
PB 14.4 ± 0.5c 60 ± 2d 2.8 ± 0.2c 4.8 1 0.3
(75) (118) (62) (93)
40 Control 13.8 ± 0.4 55 ± 2 5.4 ± 0.2. 5.4 1 0.2
PB 9.2 ± 0.3c 52 i 3 3 . 1 1  0.3c 4.2 1 0.8
(66) (95) (58) (78)
55 Control 14.6 i 0.4 57 ± 2 7.4 1 0.4 6.4 1 0.5
PB 9.3 ± 0.7c 57 1 4 5.4 1 0.6d 8.0 1 1.1
(64) (100) (73)- (125)
70 Control 18.9 ± 0.8 67 1 4 5.8 1 0.7 5.7 1 0.6
PB 14.9 ± 0.7^ 103 ± 5c 3.0 1 0.4d 5.7 1 1.4
(79) (153) (52) (100)
^ PB was administered in the diet at a dose of 85 mg/kg/day.
^ Results are presented as the mean ± S.E.M. of 6 animals with percentage of
control values shown in parentheses.
^ Significantly different (Student's jt~test) from control ; _P <0.01.
^ Significantly different (Student's t-test) from control; JP <0.05.
1 34
lipid peroxidat ion in the C3H/He mouse
Weeks of treatment
Treatment^ 4 10 25 40 55 70
Control 17.8 ± 7.lb 55 1 7 155 ± 8 169 1 4 145 ± 6 113 ± 3
PB 24.5 ± 5.9 58 1 8 217 ± 15C 231 1 5C 137 ± 11 131 ± 7<
(138) (105) (140) (137) (94) (116)
PB was adminstered in the diet at a dose of 85 mg/kg/day.
Results are presented as the mean ± S.E.M. of 6 control and 6 test animals 
with percentage of control values in parentheses. Units are nmol of 
thiobarbiturate reacting substances produced/hour/mg microsomal protein. 
Significantly different (Student's _t-test) from control ; ^<0.01.
Significantly different (Student's t-test) from control; P <0.05.
135
Table 4.3 Covalent binding of [^^C] PB and Paracetamol
to hepatic microsomes from control and PB treated C3H/He mice
Treatment^
Substrate
[14c]
Control
PB
TCPOb [l^C] Paracetamol
4 week control n.d.^ n.d. 39 ± 4d
4 week PB n.d. n.d. 64 ±_6®
10 week control n.d. n.d. 32 ± 2
10 week PB n.d. n.d. 63 ± 6®
^ PB was adminstered in the diet at a dose of 85 mg/kg/day.
b TCPO; in the presence of 0.1 mM 3,3,3-trichloropropylene oxide. , ^
^ n.d., none detected- Minimum detectable level estimated to be 1 nmol 
bound/hour/mg microsomal protein.
d Data is presented as mean ± S.E.M. of four tissue pools. Units are nmol 
bound/hour/mg microsomal protein.
® Significantly different (Student's _t-test) from control; 2  <0.01.
1 3 6
Table 4.4' Effect of PB treatment on DNA content and [^H] thymidine 
incorporation in liver and liver nodules of C3H/He mice
Control PB&
Parameter Whole liver
Liver minus 
large nodules
Large
nodules
DNA (mg DNA/g liver) 4.22 ± 0.24b 3.68 ± 0 . 4 2  
(87)
3.74 ± 0.04 
(89)
[^H] Thymidine incorporation 
(d.p.m./mg DNA)
8540 ± 870 8530 ± 114 
(100)
13890 ± 740C 
(162)
^ PB was adminstered in the diet at a dose of 85 mg/kg/day for 70 to 72 
weeks.
^ Results are presented as mean i S.E.M. of 6 control, 3 host livers and 3 
large nodule preparations with percentage of control value in 
parentheses.
^ Significantly different (Dunnett's test) from control; P <0.01.
1 37
Table 4.5 Effect of PB treatment on some hepatic parameters in
liver and liver nodules in the C3H/He mouse
1 Treatment®
Control PB
Parameter Whole liver
Liver minus 
large nodules
Large
nodules
Non-protein sulphydryl groups 6.3 ± 0.2^ 
(pmol/g liver)
5.8 ± 0.2 
(92)
6.8 ± 0.5 
(108)
Succinate dehydrogenase^ 18.8 ± 0.6 13.7 ± 1.1® 
(73)
9.8 ± 0.5® 
(52)
Y— Glutamyl 
transpeptidase® 338 ± 14 840 ± 190® 
(249)
10400 ± 1200® 
(3000)
Glutathione reductase^ 93 ± 4 138 ± 6® 
(148)
273 ± 34® 
(249)
Glucose-6-phosphate^ 
dehydrogenase 8.9 ± 0.7 13.0 ± 1.3 
(146)
17.3 ± 1.5® 
(194)
Glutathione S-transferase 
-(substrate 1-chloro- 
2,4-dinitrobenzene)ê 7.0 ± 0.4 9.0 ± 0.9 
(129)
18.4 ± 1.2® 
(263)
-(substrate 1,2-epoxy- 
3-[nitrophenoxy] 
propane)8 0.379 ± 0.014 0.558 ± 0.057® 
(147)
0.679 ± 0.049® 
(179)
® PB was adminstered in the diet at a dose of 
weeks.
b Results are presented as mean ± S.E.M. of 6
85 mg/kg/day for 
to 16 control, 6
70 to 72 
to 9 host
liver and 3 to 7 large nodule preparations, with percentage of control 
values in parentheses.
^ Significantly different (Dunnett’s test) from control; ^<0.01.
^ In units of pmol/min/g liver.
® In units of nmol/hour/g liver.
^  In units of nmol/min/mg cytosolic protein.
8 In units of pmol/min/mg cytosolic protein.
1 3-3
Table 4.6 Apparent kinetic constants of Y-Glutamyl transpeptidase in 
large nodules and host tissue from mice fed 85 mg/kg/day PB for 72 weeks
and in similarly aged controls
Tissue
Kinetic constant®
Km (mM) Vmax (pmol/hour/g liver)
Control 0.152 ± 0.03lb 1.60 ± 0.08
PB Treated
Host Liver 0.214 ± 0.027 3.32 ± 1.15®
Large nodules 0.262 ± 0.048® 78.9 ± 21.7 d
® Enzyme activity was measured using Y“glutamyl-7-amino-4-methylcoumarin as 
substrate as described in Materials and Methods (2.25) over a concentration 
range of 1 mM to 10 pM. The concentration of methoxyethanol was 7% in all 
incubations.
b Data is presented as mean ± S.E.M. of three different tissue preparations. 
® Significantly different (Student's ^-test) from control; ^<0,05.
(
^ Significantly different (Student's ^-test) from control; ^<0.01.
1 3 9
Table 4.7 Effect of PB treatment on some hepatic parameters in
liver and liver nodules in the C3H/He mouse
Treatment®
Control ' PB
Parameter
Whole
liver
Liver minus 
large nodules
Large
nodules
7-Ethoxyresorufin 
O-deethylase^
4.7 ± 0.4b 21.6 ± 1.0® 
(460)
116 ± 18® 
(2470)
7-Ethoxycoumarin
O-deethylase^
255 ± 17 1478 ± 78®  ^
(580)
2577 ± 254® 
(1010)
Ethylmorphine
N-demethylase^
397 ± 36 4286 ± 295® 
(1080)
4175 ± 301® 
(1050)
NADPH-cytochrome 
c reductase®
278 ± 20 630 ± 73® 
(227)
769 ± 47® 
(277)
Cytochrome P-450
(nmol/mg microsomal 
protein) 0.68 ± 0.02 1.87 ± 0.13® 
(275)
2.2 ± 0.07® 
(323)
Cytochrome P-450 
X max.(nm) 450.5 ± 0.1 NDf 450.4 ± 0.1
Ethyl isocyanide spectra 
(peak height ratio 455 
nm/430 nm)
- At pH 7.0
- At pH 7.4
0.308 ± 0.022 
0.417 ± 0.016
0.172 ± 0.008® 
0.294 ± 0.069®
0.129 ± 0.013® 
0.228 ± 0.019®
NADPH- dependent
lipid peroxidation^ 113 ± 3 132 ± 11 
(114)
141 ± 12 
(122)
® PB was administered in the diet at a dose of 85 mg/kg/day for 70-72 wk.
b Results are presented as mean ± S.E.M. of 6 to 16 control, 6 to 9 host
tissue and 3 to 7 large nodule preparations, with percentage of control
value in parentheses.
® Significantly different (Dunnett's test) from control; ^<0.01.
^ In units of nmol/hour/mg microsomal protein.
® In units of pmol/hour/mg microsomal protein.
 ^ ND; not determined.
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Table 4.12. Some parameters in spontaneous nodules and 
non-nodular liver of untreated 102 week old C3H/He mice
Tissue®
Parameter
Control Nodules 
(n = 4)
Y-Glutamyl transpeptidase 
(nmol/hour/g liver)
327 ± 23b . 281 ± 32(n=2) 
1719 (n = 1)
Cytochrome P-450 
content (nmol/mg 
microsomal protein)
0.50 ± 0.06 0.41 ± 0.06 
(82)
Microsomal protein 15,1 ± 1.0 13.3 ± 0.9 
(88)
Glucose-6-phosphate
dehydrogenase (nmol/min/mg 
cytosolic protein)
20.2 ± 2.7 76.9 ± 10.7® 
(381)..
®Tissue was derived from animals fed semisynthetic diet. Control 
values are those of animals without large nodules combined with 
those that had been host to large nodules. Nodule preparations 
were from one to three nodules pooled.
boata is presented as mean ± S.E.M. with percentage of control 
value in parentheses.
^Significantly different (Student’s ^  test) from control; ^<0.01.
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CHAPTER 5
METABOLISM AND EXCRETION OF [^^cJPHENOBARBITONE 
IN THE RAT AND MOUSE.
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INTRODUCTION
Carcinogenesis is rarely a result of direct biologic 
interaction with a parent xenobiotic but is usually 
the result of metabolism to the ultimate carcinogen 
(Weisburger and Williams 1975). The rate and/or 
route of metabolism may affect the concentration of 
active metabolite and thus the carcinogenic effect 
(Zimmerman 1978). The variability in metabolism and 
disposition of a compound provides an explanation of 
differing interspecies susceptibility to toxic and 
carcinogenic effects. Phenobarbitohe (PB) does not 
produce hepatic tumours readily in either the rat or 
the C57B1 strain mouse, but nodules are stimulated in 
other, susceptible, strains of mouse (see Chapter 1.2.6).
Such differences might be the result of different routes 
of metabolism and/or disposition favouring the production 
of reactive or toxic intermediates.
As a result of widespread theraputic use of PB and its 
congeners several studies have attempted to define its 
metabolic fate in man and other animals. Butler et al 
(1954) demonstrated the presence of 5-ethyl-5-(4-hydroxyphenyl) 
barbituric acid (4-OHPB) in the urine of PB treated 
dogs, and later in humans (Butler 1956). These studies 
indicated that the dog extensively conjugated PB with
1 4 8
glucuronic acid, whereas in humans no apparent 
glucuronidation occurred and about 50% of a dose 
was excreted in the form of other conjugates. Subsequent 
work with the rat by Glasson and Benakis (1951) showed 
rapid urinary excretion and they identified 4-OHPB 
and its glucuronide as 19 and 27% of the excreted 
dose respectively, after 24 hours. Three other 
metabolites were separated, of which one was another 
conjugate of 4-OHPB. Harvey et al (1972) identified 
some minor metabolites from PB in man , rat and 
guinea pig including 5-(3,4-dihydroxy-1,5,eyelohexadien- 
1-yl)-5-ethyl barbituric acid. Such a metabolite 
suggests the formation of an arene oxide intermediate. 
Such epoj?:ides are known to be reactive and thus 
potentially cytotoxic (Mitchell and Jollow 1975).
Horning et al (1975) similarly identified a catechol, 
which also suggests an epoxide intermediate. These 
studies used computerised GC/MS and did not quantify 
the production of these metabolites. Using similar 
techniques Hooper et al (1981) reported small quantities 
of the 3-0-methyTcatechol of PB, which might also arise
■>
from an epoxide intermediate. A dihydrodiol of 
amobarbitone has also been identified in several species 
(Tang et al 1980) including the mouse.
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N-Hydroxylation of barbiturates was postulated as a 
route of metabolism (Tang et al 1975) but subsequent 
work has identified the putative N-hydroxy metabolite 
as barbiturate-N-glucoside (Tang et al 1978, 1979),
The major pathways of PB metabolism are shown in 
Fig. 5.1 and the possible routes of formation of 
reactive metabolites in Fig. 5.2.
In this study the elimination and metabolism of a 
[}^c]PB dose to rats and both C57B1/6 and C3H/He 
mouse strains was investigated. Tissues were examined 
to detect remaining levels of radioactivity. Urine 
samples were purified and some of the major metabolites 
identified in order to compare metabolism between the 
species and strains. The effect of acute PB pretreatment 
on metabolism was assessed with a view to undertaking 
parallel studies in animals treated for prolonged 
periods with PB. This aspect might be especially 
relevant in view of the prolonged administration of 
PB required to result in nodule formation.
MATERIALS AND METHODS 
Animals and Treatment.
Male C3H/He and C57B1/5 strain mice, and Sprague-Dawley 
rats were used for metabolic studies. Mice were aged
b  U
from 6 to 8 weeks and rats from 10- to 12 weeks at the 
start Qf treatment. Animals were fed SS2 semisynthetic 
diet, as described in Chapter 2. Animals were either 
pretreated by daily intubation with the maximally 
stimulating dose of PB (see Chapter 3); that is 
85 mg/kg/day to mice or 150 mg/kg/day to rats, or with 
aqueous vehicle (1.0 ml/lOOg body weight) for 14 days.
PB was administered to some C3H/He mice for 70 wee3<s 
at a dose of 85 mg/kg/day in the diet.
Animals were then given by intubation the maximally 
stimulating dose of pheno[2-^^c]barbitone, 6 pCi/animal 
to mice and 7.5 pCi/animal to rats. For metabolism 
studies animals were housed in all glass metabolism 
cages designed for the free collection of urine and 
faeces as described in Chapter 2.15. Radioactive 
content of collected samples was determined by liquid 
scintillation spectroscopy, as described in Chapter 2.15 
and 2.16.
Treatment of Urine
Urines collected at 24 and 48 hours from each animal 
were pooled. A 4ml aliquot from each 0- 48 hour urine 
was treated with 50 mg p-glucuronidase (B.C.3.2.1.31) 
and 50 mg sulphatase (B.C.3.1.6.1) in 1.0ml 0.5M 
acetate buffer pH 5.0 for 12 hours at 37°C. Both 
untreated and glucuronidase treated urines were purified
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by ion exchange chromatography (Tang et al 1979).
Amberlite XAD2 resin, washed three times sequentially 
with ethanol, acetone and water was packed in a 
1 X 2 0 cm column and further washed with water.
2 .0 ml of urine was applied and washed through slowly 
with two volumes of water. PB and its metabolites 
were eluted with methanol, until a recovery of greater 
than 95% was obtained. Solvent was removed by rotary 
evaporation under vacuum at room temperature and the 
residues stored at -2 0 °C.
Chromatography of Purified Urine.
Purified untreated and glucuronidase treated urines 
were applied to Silica gel GHLF plates and developed 
in n-butyl chloride/l,4-dioxan (1 : 1 v/v) followed by 
n-butanol/water (93:7 v/v) (Tang et al 1979). Plates 
were divided into 0.5cm strips, the silica scraped off 
into a scintillation vial and radioactivity determined 
as previously described (Chapter 2.16). Peaks of 
radioactivity were equated to U.V. quenching of 
authentic PB, 4-OHPB and 3-OHPB. Glucuronide and/or 
sulphate conjugates of 4-OHPB were estimated by 
subtraction of free 4-OHPB from the amount present 
after combined glucuronidase/sulphatase hydrolysis.
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RESULTS
Preliminary experiments showed that less than 
0 .,0 l% of a C^^cJPB dose was excreted as expired CO2 
in both control and PB treated rats and mice (data 
not shown). In subsequent experiments CO2 was not 
collected.
The elimination of radioactivity from untreated and 
PB treated rats following a (^^c]PB dose is shown in 
Fig. 5.3. Most of the radioactivity was eliminated 
within 4 days, with negligible amounts excreted from 
5 to 7 days. PB pretreatment enhanced the rate of 
elimination in urine as control rats excreted 56% of 
the dose in the 0-24 hour urine compared to 76% after 
PB treatment. Total urinary excretion was similar 
in control and treated rats after 7 days (Table 5.1). 
After 7 days negligible amounts of radioactivity 
remained in the tissues (Table 5.2).
As with the rat, the urine was the major route of 
elimination of [^^C]PB and its metabolites in untreated 
and PB treated C3H/He (Fig. 5.4) and C57B1/6 (Fig. 5.5) 
mouse strains. In untreated C3H/He strain mice only 
some 41% of the dose was eliminated in the 0-24 hour- 
urine, compared to 6 8 % in the C57B1/6 strain. Prior 
PB treatment markedly enhanced the rate of urinary
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excretion of radioactivity in C3H/He mice but had 
less effect on the C57B1/5 strain. There was more 
radioactivity excreted in the faeces of untreated 
C3H/He mice than in either untreated C57B1/5 mice 
or PB treated mice of either strain. There were 
negligible amounts of radioactivity present in either 
the gastro-intestinal tract contents (Table 5.1) or 
body tissues (Table 5.2) 7 days after C^^c]PB 
administration in either strain.
The excretion of radioactivity following a dose of 
f^^cJPB to C3H/He mice treated for 70 weeks with PB 
and similarly aged untreated mice is shown in Fig. 5.6. 
Excretion was mainly in the urine with a similar degree 
of faecal elimination in both control and pretreated 
mice, in contrast to results from young mice (Fig. 5.4). 
Urinary excretion was more rapid in pretreated animals 
with 84% of the dose cleared in the 0-24 hour urine 
compared to 45% in control mice.
The metabolite profile in 0-48 hour urine samples was 
examined in limited numbers of rats and mice by t.l.c. 
and results are given in Table 5.3. A typical separation 
of untreated and enzymically hydrolysed urine samples 
from control C3H/He strain mice is shown in Fig. 5.7.
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In the untreated rat PB was extensively metabolised, 
only 15% excreted unchanged in 48 hours. Metabolism 
was greater following PB pretreatment when 7% of PB 
was excreted unchanged. 4-OHPB was the major metabolite 
in the rat, PB pretreatment resulting in an increase of 
glucuronidation and/or sulphation of this metabolite. 
Authentic PB-N-glucoside was not available, but was 
tentatively identified by comparison of Rf value to 
metabolite P3 of Tang et al (1979), PB-N-Glucoside was 
estimated as 13% of the excreted dose in both test 
and control rats. A significant proportion of radioactivity 
was not resolved using this solvent system and was 
classified as polar products, which increased with 
PB pretreatment.
In control mice of both strains about 40% of PB was 
excreted unmetabolised. PB pretreatment reduced PB 
excretion to 26% and 15% in the C3H/He and C57B1/6 
strain mouse respectively. In both treated and control 
mice of both strains free 4-OHPB represented about 
2 0 % of the dose and although pretreatment did not 
change the amount of 4-OHPB conjugated in C3H/He mice 
(29%) it raised conjugation from 18% to 44% in the 
C57B1/6 strain mouse. The amount of N-glucoside was 
unchanged by PB pretreatment in both strains being 
about 7% of the metabolites. Polar products were
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increased by PB pretreatment from 8 to 16% and 
from 9 to 15% in C3H/He and C57B1/6 strain mice 
respectively.
Discussion.
As no was excreted it may be assumed that
the barbiturate ring was stable to, metabolic cleavage.
This is in accord with results of Parke (1968) and 
Caldwell et al (1977).
In agreement with the observations of Crayford and 
Hutson (1980) PB was excreted mainly in the urine 
within 48 hours in both the rat and mouse. The present 
study showed relatively little faecal excretion of 
radioactivity in the rat and C57B1/6 mouse independent 
of pretreatment, although pretreatment reduced faecal 
excretion inthe C3H/He mouse. Crayford and Hutson 
(1980) reported extensive (29%) faecal excretion in 
the rat after 3 days and this value was increased by 
pretreatment. These results may be the result of 
different rat strains or significant contamination of 
faeces by urine. It has been demonstrated in rats that 
a significant amount of a PB dose was excreted in the 
bile and thus some enterohepatic circulation may occur 
(Caldwell et al 1977). Crayford and Hutson (1980) reported
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less faecal excretion in the mouse, which was further 
reduced by PB pretreatment.
Pretreatment of both rats and mice with PB increased the rate 
of clearance of PB, and this may be partially due to the 
increased metabolism seen in treated animals. Crayford and 
Hutson (1980) saw only small changes in the rate of excretion 
of PB between control and pretreated rats but the pretreatment 
regimen used (40 mg/kg for 4 days) was probably not maximally 
stimulating enzyme induction as did the doses used in the 
present study (see Chapter 3).
In both strains of mouse metabolism of PB was less than that 
seen in the rat, but the increase in metabolism following PB 
induction was greater. No evidence (such as tissue retention) 
was found for the presence of a reactive metabolite of PB. 
Assuming that PB-3,4-oxide is an intermediate in the formation 
of 4-OHPB (Fig. 5.2) and that this arene oxide is a substrate 
for epoxide hydrolase then a change of the ratio of epoxide 
hydrolase to hepatic m.f.o. enzyme activities could lead to 
increased formation and/or longer exposure of hepatocytes to 
the reactive molecules. Other workers have demonstrated that 
epoxide hydrolase activity is higher in the rat than the 
mouse (Walker et al 1978; Birnbaum and Baird 1979). As more 
extensive metabolism of PB occurred in the rat, which is less 
susceptible to tumour formation, PB-3,4-oxide may spontaneously 
rearrange to 4-OHPB so rapidly that no tissue damage occurs. 
Some evidence for the possible formation of a PB arene oxide 
has been obtained by Spielberg et al (1981) in studies with 
human lymphocytes, which indicated that PB plus a mouse
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microsomal metabolising system were only toxic to cells in the 
presence of the epoxide hydrolase inhibitor 3,3,3-trichloro- 
propylene oxide (Oesch 1974). In the present study covalent 
binding of metabolites to proteins following in vitro
microsomal incubations in the presence and absence of 3,3,3- 
trichloropropylene oxide was not detected (Chapter 4, Table 4.3). 
Other workers have failed to detect any in vitro PB metabolism 
or covalent binding of metabolites (Crayford and Hutson 1980; 
Corsini et al 1972), thus the possibility of a reactive 
metabolite of PB is not resolved.
The rate of excretion of a C'^^cJPB dose from C3H/He mice treated 
for 70 weeks with PB and similarly aged control mice was very 
similar to that of young mice, except faecal excretion was low 
and the same in controljand jpretreated animals. This suggests 
that metabolic processes were still unimpaired by either age 
or treatment. Kapetanovic et al (1982) have shown that 24-34 
month old rats clear PB from plasma more slowly than young 
animals. Therefore it might have been expected for 78 week old 
mice (equivalent age to mice having received PB for 70 weeks) 
to have impaired metabolism and/or clearance of PB. Mice older 
than 70 weeks are needed to study any decline in metabolism and 
clearance with age. Certainly nodule formation occurs before 
any such decline (Chapter 4).
In summary both the rat and mouse eliminate C^ ^^ c] PB in the urine, 
the rat metabolising PB to a greater extent than the mouse. 
Pretreatment with PB increases both the rate of elimination 
and the degree of metabolism. No significant tissue retention 
was noted. The C3H/He mouse did not differ in its metabolism 
or disposition of ^c] PB in a way that might explain its 
susceptibility to hepatic tumour formation.
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Fig. 5,3 The Elimination of a [^^cjphenobarbitone Dose 
From Sprague-Dawley Rats.
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Elimination of radioactivity in the urine (0,e) and faeces (a ,a ) 
of untreated (closed symbols) and PB treated (open symbols) rats 
following a single oral 150 mg/kg dose (7.5 pCi/animal) of 
QI^cJpb. PB treated animals received unlabelled PB by daily 
gastric intubation for 14 days at a dose level of 150 mg/kg/day. 
Each point represents the mean ±S.E.M. of 5 rats.
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Fig. 5.4 The Elimination of a Phenobarbitone Dose
From C3H/He Mice.
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Radioactivity was measured in the urine (o,#) and faeces (A,^) 
of untreated (closed symbols) and PB treated (open symbols)' 
C3H/He mice following a single oral 85 mg/kg (5 ^Ci/animal) 
dose of PB treated animals received unlabelled PB
by daily gastric intubation for 14 days at a dose level of 
85 mg/kg/day. Each point represents the mean - S.E.M. of 5 mice
Fig. 5.5 The Elimination of a Phenobarbitone Dose
From C57B1/5 Mice.
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Radioactivity was measured in the urine (o,e) and faeces (a.,a ) 
of treated (open symbols) and untreated (closed symbols)
C57B1/5 mice following a single oral 85 mg/kg (6 pCi/animal) 
dose of [I'^CjPB. PB treated animals received unlabelled PB 
by daily gastric intubation for 14 days at a dose level of 
85 mg/kg/day. Each point represents the mean - S.E.M. of 5 mice
Fig. 5.6 The Elimination of a cjphenobarbitone Dose
From Old C3H/He Mice.
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Radioactivity was measured in the urine (O,#) and faeces (a 
of untreated (closed symbols) and PB treated (open symbols) 
C3H/He mice following a single oral 85 mg/kg (6 pCi/animal) 
dose of [i^cJPB. PB treated animals received unlabelled PB 
in the diet for 70 weeks at a dose of 85 mg/kg/day. Each 
point represents the mean - S.E.M. of 3 mice.
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Fig. 5.7 Analysis of,Urinary P  cjphenobarbitone and 
Metabolites by Thin Layer Chromatography.
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Urine samples, (0-48 hours after [ c]PB dose) were treated 
as described in the text and aliquots of the urine extract 
(15,000 d.p.m.) were chromatographed as silica gel GHLF 
plates and developed in n-butyl chloride/dioxan (l:l,v/v) 
(solvent A) and subsequently in n-butanol/distilled water 
(93:7,v/v) (solvent B). Radioactivity was determined in
0.5cm strips with a recovery of 93-98%.
The upper plot shows a urine sample from a C3H/He mouse given 
a single oral 85 mg/kg dose of C 03PB (6 pCi). The lower plot 
shows.the effect of comb^ined glucuronidase/sulphatase hydrolysis 
on an aliquot of the urine sample prior to .chromatography.
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Table 5.2 Tissuedistribution of radioactivity after administration of 
single dose of [^^C] PB to control and PB treated Sprague-Dawley rats 
and C3H/He and C57BL/6 strain mice
Percentage of administered radioactivity x 10 3
Sprague--Dawley rat& C3H/He mouse^ C57BL/6 mouse^
Tissue Control PB treated Control PB treated Control PB treated
Brain 0.9 0.1 1.0 0.9 0.6 6.3
Heart 0.5 0.2 1.0 0.3 0.2 0.2
Kidneys 4.0 0.7 4.0 3.0 1.0 2.0
Liver 21 3.0 10 8.0 9.0 7.0
Lungs 0.7 0.2 0.5 0.3 0.3 0.1
Spleen 0.3 0.1 0.3 0.1 0.1 0.1
Testes 1.0 0.2 0.6 2.0 0.3 0.2
Stomach 3.0 0.3 0.7 1.0 2.0 1.0
Small
intestine
27 1.0 6.0 4.0 4.0 13
Large
intestine
3.0 0.8 0.7 0.4 0.7 12
Caecum 17 0.6 0.1 0.1 6.0 3.0
Gall bladder - - 0,05 0.01 0.05 0.1
Urinary 
. bladder
n.d.c n.d. 7.0 5.0 T6 19
^ Rats were killed 5 days after a single oral dose of 150 mg/kg (7.5
pCi/animal) [^^C] PB and the radioactivity remaining in the tissues
determined. Each value represents the mean of either 3 untreated or 3 PB 
treated (150 mg/kg/day, by gastric intubation for 14 days) rats.
^ Mice were killed 7 days after a single oral dose of 85 mg/kg (6 pCi/animal)
[^^C] PB and the radioactivity remaining in the tissues determined. Each
value represents the mean of either 3 untreated or 3 PB treated (85 
mg/kg/day, by gastric intubation for 14 days) mice.
^ n.d., not determined
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Table 5.3 The urinary excretion of PB and PB metabolites in 
untreated and PB treated rats and mice
Species and 
strain Treatment^
Percentage of urinary metabolites^
PB 4-OHPB
4-OHPB
conjugates PB-N-Glucoside
Other 
polar products
Sprague-Dawley None (1) 16 47 10 13 . 14
rat PB (1) 7 16 34 13 30
C3H/He mouse None (2) 40 15 29 8 8
PB (2) 26 23 29 6 16
C57BL/6 mouse None (2) 42 24 18 7 9
PB (3) 15 18 44 8 15
Animals received either no treatment or PB at dose levels of either 150 
mg/kg/day or 85 mg/kg/day for rats and mice respectively by gastric 
intubation for 14 days. The number of animals used are shown in parentheses
Animals were given a single oral [^^CjPB dose of either 150 mg/kg (7.5 
pCi/animal) or 85 mg/kg (6 pCi/animal) for rats and mice respectively and
0-48 hour urine samples collected. The amounts of [I'^CJPB metabolites were 
determined by the procedure described in the text employing the combined 
t.l.c. solvent system of Tang et al. (1979).
CHAPTER 6
THE EFFECT OF PHENOBARBITONE ON 
SOME ENZYMES OF GLUTATHIONE 
METABOLISM IN THE RAT AND TWO 
MOUSE STRAINS.
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INTRODUCTION
Glutathione (Y-L-glutamyl-L-cysteinylglycine) is a tripeptide 
ubiquitous in mammalian tissues that has also been isolated 
from invertebrates, plants and unicellular organisms (Meister 
1983). The molecule exists in two forms, either with the 
sulphur atom of the cysteine moiety reduced (GSH) or forming 
a disulphide bond (oxidised) (GSSG) with another glutathione 
molecule. GSH synthesis is achieved in two steps from its 
three constituent amino acids, firstly catalysed by Y-glutamyl- 
cysteine synthetase and secondly by glutathione synthetase. 
Degradation of GSH is initially catalysed by Y-glutamyl 
transpeptidase (GGT) and then cysteinylglycinase. Thus GSH 
can be metabolised with preservation of its amino acids and, indeed, 
plays a role in translocation of amino acids (Meister 1978).
The maintenance of hepatic GSH levels is dependent firstly on 
the availability of amino acids, especially those containing 
sulphur such as methionine, cystine and cysteine (Fig. 6.1). 
Normally a high intracellular ratio (about 100:1) of GSH to GSSG 
is maintained by glutathione reductase (Meister 1983; Moron 
et al 1979). The concentration of hepatic GSH is subject to 
circadian variation, and overnight starvation reduced hepatic 
levels by up to 50% in mice (Strubelt et al 1981; Brooks and 
Pong 1981).
After the administration of a non-lethal dose of a hepatotoxin,
GSH levels become depleted and on resynthesis tissue 
concentrations may overshoot normal control levels (Mitchell 
et al 1973; Nakagawa et al 1984). In certain instances prolonged 
administration of hepatotoxic agents such as coumarin (Evans 
et al 1982) and _g-aminoazotoluene (Chapter 7) leads to enhanced
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hepatic reduced glutathione content. Biliary efflux of GSSG 
may be used as an index of oxidative load (Sies et al 1980). 
Breakdown of GSH is dependent on GGT resulting ultimately in 
formation of mercapturic acids from GSH conjugates, or the 
constituent amino acids.
GSH plays a major role in the detoxification of various reactive 
molecules. It has several modes of action, which are summarised 
in Fig. 6.2. It is apparent that GSH is capable of participating 
in detoxification reactions with and without enzymic direction.
GSH is important for the protection of the cell from reactive
oxygen species and this subject has recently been reviewed by
Bus and Gibson (1984). Oxygen toxicity has been linked with
the superoxide anion (OgT), hydrogen peroxide (#2 ^2 '^ the
1
hydroxyl radical (OH*) and singlet oxygen ( Og). Incomplete 
cycling of the cytochrome P-450 system is believed to result in 
the generation of O^T which may then form ^ 2^2 either 
spontaneously or catalysed by superoxide dismutase. These 
molecules may form the hydroxyl radical (OH*) by way of the 
reaction described by Haber and Weiss (1934) (equation 3). 
Although this reaction has ah apparently slow rate, iron salts 
or complexes may catalyse the process in biological systems 
(equations 1 to 3).
0^7 + Fe^* ----- ►  0 ^ + Fe^* (1 )
Fe^* + HgOg ----- ►  Fe^+ + OH* + OH” (2)
0^7 + H 2 O2  ►  O2 + OH* + 0H“ (3)
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Reddy and Lalwani (1983) have reported that H 2 O2 leak from
peroxisomes as a result of the p-oxidation process. Furthermore 
O2 T may be formed as a result of redox cycling of certain 
xenobiotics, such as Paraquat and Streptonigrin, or by 
autoxidation as in the case of alloxan. Singlet oxygen may be 
produced from photosensitised oxidations of xenobiotics (Bus 
and Gibson 1984).
As the hydroxyl radical is very reactive it is unlikely to exist 
for long after formation, thus any resulting damage will be 
near to the site of formation. This is in cohtrast to the 
superoxide anion and hydrogen peroxide which may exist long 
enough to translocate across the cell and thus potentially cause 
damage at another site, such as the nucleus (K. Cheeseman 
personal communication).
GSH can act as a reductant, catalysed by glutathione peroxidase, 
both of H 2 O2 and lipid hydroperoxides that may result from 
oxygen toxicity (Fig. 6.3) (Bus and Gibson 1984; Wendel and 
Feuerstein 1981). Polyunsaturated lipids may participate in 
a chain reaction of lipid peroxidation and the sequence can be 
terminated by antioxidants such as water soluble GSH and 
ascorbic acid, and lipid soluble vitamin E. GSSG is enzymically 
reduced to GSH with reducing equivalents derived from glucose- 
6 -phosphate dehydrogenase (review see Bus and Gibson 1979).
GSH can either spontaneously or enzymically conjugate with 
reactive products of microsomal xenobiotic metabolism (see 
Chapter 1 and Fig. 6.3). Such conjugations are mediated by the
1 7
glutathione S-transferase group of isoenzymes. The glutathione 
S-transferases are multifunctional in detoxification (review 
see Jakoby 1978). That is if a compound bears a sufficiently 
electrophilic centre it can bind with GSH; such compounds are 
substrates for the transferase enzymes. If the compound is 
very reactive, reaction may occur with GSH or irreversibly 
with the transferase itself. The cytosolic binding protein, 
of the rat (ligandin) is identical to glutathione S-transferase 
form B (Habig et al 1974b), although ligandin may exist in 
several forms (Hayes et al 1979). Similarly mouse binding 
protein (h-protein) is similar to the glutathione S-transferase 
isozymes (Sarrif et al 1978).
Most extensive work on purification of glutathione S-transferase 
isozymes has been performed in the rat and human (Habig et al 
1974a; Kamisaka et al 1975). Typically the transferase activity 
is purified by passing over a DEAE-cellulose column, then 
separated into several peaks of activity by elution from a 
carboxymethyl-cellulose column using a salt gradient. In the 
rat the major forms are called AA,A,B,C,D and E by order of 
elution. Human liver cytosolic glutathione S-transferases have 
been designated a,p,Y, 6 and e. In the mouse Lee and coworkers 
(1981) purified transferase activity into three major (F1,F2,F3) 
and one minor (F4) form. FI and F2 are charge isomers.
However the relative activities of the different forms of 
glutathione S-transferase in the mouse and rat are quite 
different (Table 6.1), the rat demonstrating higher activities 
to substrates other than l-chloro-2 ,4-dinitrobenzene than the 
mouse (Lee 1984).
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In the rat phenobarbitone (PB), 20-methylcholanthrene,
2,3,7,8 -tetrachlorodibenzo-p-dioxin (Baars et al 1978), DDT 
(Down and Chasseaud 1979), ethanol (Hetu et al 1982) and 
butylated hydroxytoluene (Awasthi et al 1983) are among known 
inducing agents of glutathione S-transferase. Similarly in 
the mouse PB (Shoemaker et al 1981), 2,3,7,8 -tetrachlorodibenzo- 
p-dioxin, 20-methylcholanthrene, p-naphthoflavone (Felton et al 
1980), and butylated hydroxyanisole (Morgenstern and Dock 1982) 
are inducers of glutathione S-transferase. In both species 
antioxidants are particularly effective inducers. In this 
study the effect of up to 28 days treatment with the maximally 
stimulating dose (see Chapter 3) of PB was studied on several 
parameters associated with glutathione metabolism, in both the 
rat and two mouse strains. Glutathione S-transferase activity 
was measured with respect to four different substrates. In 
addition NADPH-dependent microsomal lipid peroxidation was 
assessed during the treatment period, as an index of hepatic 
damage. Thus both the response in two species and possible 
differences in effect through either toxic metabolites, or 
through the generation of active oxygen species by stimulation 
of the hepatic microsomal cytochrome P-450 system might be 
evaluated. By comparison of results from a mouse strain (C3H/He) 
susceptible to both spontaneous and PB induced hepatic tumours 
with those from a non-susceptible strain (C57B1/6) and species 
(rat) the role of glutathione in nodule formation may be assessed.
MATERIALS AND METHODS
Male Sprague-Dawley rats and C3H/He and C57B1/6 mice were housed 
on grid floor cages and fed SS2 semisynthetic diet as described
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in Chapter 2.13. PB was administered to test animals by daily
i.p. injection at a maximally stimulating dose (150 mg/kg/day 
to rats, 85 mg/kg/day to mice) for up to 28 days. Control 
animals received 0.9% w/v saline vehicle alone (5 ml/kg to 
rats, 10 ml/kg to mice) . Animals were starved overnight before 
sacrifice. After 3, 7, 14 and 28 days of treatment hepatic 
non-protein sulphydryl levels, and the activity of GGT, 
microsomal cytochrome P-450 content, NADPH-dependent lipid 
peroxidation and activity of glucose-6 -phosphatase, and activity 
of cytosolic glutathione reductase and glutathione S-transferase 
towards four substrates was determined.
RESULTS
Induction by PB was monitored at 3, 7, 14 and 28 days of 
treatment by measurement of liver size, microsomal protein and 
cytochrome P-450 content. These parameters were significantly 
increased at all times, and typical values, obtained after 
28 days of PB administration are shown in Table 6.2. Furthermore 
the specific activity of microsomal glucose-6 -phosphatase was 
reduced by PB treatment in both species and strains (Table 6.2).
Parameters relating to glutathione metabolism were measured in 
either whole liver homogenate or cytosolic fractions. Hepatic 
non-protein sulphydryl content (Fig. 6 .4.A), shown largely to 
comprise reduced glutathione (Moron et al 1979), was little 
changed with PB treatment.
GGT activity of whole liver homogenates was unchanged by PB 
treatment in the rat, but was significantly depressed in the 
C57B1/6 mouse at 7 and 14 days and at all times of treatment
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in the C3H/He mouse strain (Fig. 6.4.B); control activities 
were similar in both species and strains (Table 6.2).
Cytosolic protein content was not affected by PB treatment in 
either species at any time point. Typical data from control 
animals, and those treated for 28 days with PB is shown in 
Table 6.3.
Glutathione reductase specific activity measured in the soluble 
fraction, was similar in both species (Table 6.2). PB treatment 
resulted in small stimulation of enzyme activity in the mouse 
at all times excluding 28 days in the C3H/He strain (Fig. 6.4.0). 
In the rat, activity increased to a maximum at 14 days which 
was maintained at 28 days. The increase to over 250% of control 
value was much greater than that seen in the mouse.
Glutathione S-transferase activity was measured towards four 
substrates. Highest specific activity in both species was 
measured to CDNB, although activity in the C3H/He mouse strain 
was more than 4-fold that in the rat (Table 6.3). In the 
C3H/He strain mouse PB treatment did not alter CDNB conjugation 
(Fig. 6 .5.A). In the C57B1/6 strain activity was stimulated 
less than 2 -fold at all times, but in the rat activity was 
increased to some 350% of control value from 7 to 28 days.
Glutathione S-transferase activity towards DCNB was increased 
in both species and strains at all times after PB treatment 
and although the initial response was greatest in the C57B1/6 
mouse strain, at 28 days both species and strains showed similar 
stimulation (Fig. 6.5.B).
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A similar profile of response was recorded towards NBC 
conjugation, with greatest induction again occurring in the 
C57B1/6 strain mouse (Fig. 6 .5.A). In control animals the 
specific activity to the epoxide substrate ENPP was considerably 
lower in the rat than mouse (Table 6.3). Over the treatment 
period both species and strains showed increased conjugation 
of ENPP, but the degree of stimulation was highest in the 
C57B1/6 mouse strain (Fig. 6 .6 .B).
The effect of PB treatment in both mouse strains and the rat 
on microsomal NADPH-dependent lipid peroxidation is shown in 
Table 6.4. Control rates of activity were lowest in the C3H/He 
strain mouse compared to the C57B1/6 strain mouse or the rat.
In the C57B1/6 strain mouse no change of activity was noted 
with treatment whereas in the C3H/He strain small but significant 
increases were recorded at 14 and 28 days. The rat also showed 
a small but statistically significant stimulation at 14 days.
DISCUSSION
In agreement with other workers (Moron et al 1979; Kaplowitz 
et al 1980), PB did not affect hepatic GSH levels in the rat 
or mouse. Furthermore it has been shown in the rat that PB 
does not affect the rate of GSH synthesis (Darby 1980;
Kaplowitz et al 1980). In this study PB treatment had no 
effect on GGT, which may suggest that there was no change in 
the rate of removal of GSH from the liver. However hepatic 
levels of GSSG were not investigated and PB has been shown to 
increase the degradation of GSSG in the rat (Jones et al 1978).
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It is noteworthy that PB greatly induces glutathione reductase 
in the rat compared to the mouse, If the rat is able to 
recycle GSSG more quickly, protection from reactive molecules 
may be maintained without loss of GSSG. Efflux of GSSG from 
the liver in bile can be used as a measure of oxidative stress 
(Sies et al 1980) . Whilst the induction of glutathione 
reductase was less in the mouse than in the rat, PB produced 
a similar effect in both mouse strains. Thus'in both the high 
and low spontaneous heptoma incidence mouse strain, generally 
similar effects were observed on hepatic GSH levels and two 
enzymes involved in glutathione metabolism.
The effect of PB treatment on glutathione S-transferase activity 
towards a number of substrates was investigated. In this study 
glutathione S-transferase was measured at 37°C at the pH 
optimal for enzymic conjugation of each substrate. Non-enzymic 
conjugation was corrected for by dual beam spectrophotometry. 
These methods resulted in slightly higher specific activities 
than some previously published values, where measurements were 
made at 25°C at a pH to minimise non-enzymic conjugation 
(Morgenstern and Dock, 1982; Habig et al 1974b).
In the present study PB. treatment induced rat glutathione 
S-transferase activity towards four substrates, the greatest 
induction was observed to CDNB, the lowest to ENPP. Using the 
known affinities of the major purified glutathione S-transferase 
in the rat (Habig et al 1974a)(Table 6.1) it is probable that 
transferase E is less induced by PB than other form(s). As 
activities to NBC and CDNB were similarly stimulated whereas
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the ratio of specific activities of the two major catalytic 
enzyme forms were 1 : 1 and 5:1 respectively it is probable that 
both transferase forms A and C were induced. More definitive 
statements on induction of different transferase forms would 
require purification of the enzymes.
In the mouse the degree of transferase enzyme induction by PB 
towards the substrates NBC, ENPP and DCNB was similar to that 
seen in the rat. However induction of activity towards CDNB 
appeared to be strain dependent, as induction was seen in the 
C57B1/5 strain, but not the C3H/He strain. Indeed other studies 
showed that activity to this substrate was not increased with 
10 weeks PB treatment in the C3H/He mouse strain (see Chapter 4). 
Lee and coworkers (1981) purified glutathione S-transferase 
from DBA/2J mice finding three major and one minor form 
following carboxyiriethyl-cellulose chromatography. All forms 
apparently conjugated CDNB about 100 fold more readily than 
other substrates, showing a marked difference of isozyme forms 
compared to the rat (Lee 1984). Levels of induction of CDNB 
conjugation by PB have been shown to be similar in CDFl mice 
(Shoemaker et al 1981) as those seen in the present study in 
C57B1/6 mice. It is interesting to note that in the present 
study in the rat where most induction of activity to CDNB was 
seen, control rates were lowest, and that the control rate 
was highest in the C3H/He strain mouse where no induction was 
seen. Whilst other workers have reported a small increase in 
transferase activity towards CDNB in a C3H substrain after 
3 days PB treatment, they also observed greater induction in 
other strains including C57B1/6J mice (Dragani et al 1983).
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The low- control rate of NADPH-dependent lipid peroxidation 
seen in C3H/He strain mice, and the lack of effect of PB in 
both species and strains suggests that neither turnover of 
the cytochrome P-450 electron transport chain during the 
in vivo metabolism of PB, nor the induction of microsomal 
proteins results in increased susceptibility to enzymic lipid 
peroxidation. Levin and coworkers (1973) also found no 
stimulation by PB of microsomal NADPH-dependent lipid 
peroxidation in rats. Indeed those workers and others (Miles 
et al 1980) have found many m.f.o. enzyme substrates, including 
PB, to be in vitro lipid peroxidation inhibitors. .In contrast 
Hahn and coworkers (1976, 1977) found that both enzymic and 
non enzymic lipid peroxidation were increased by PB. However 
these workers used 9000g supernatants from rats fed a 35% fat 
diet, and such a diet may influence the cellular fat content, 
the degree of saturation and thus in turn, lipid peroxidation. 
Although other, more sensitive techniques are available for the 
measurement of lipid peroxidation, such as measurement of 
fluorescent products or the formation of conjugated dienes, 
it is probable that any peroxidative effects resulting from PB 
treatment are unlikely to result in gross membrane damage, but 
to be of a more subtle nature.
In summary, whilst there were some differences observed, the 
administration of PB for 28 days produced generally similar 
effects on hepatic reduced glutathione content and some associated 
enzyme activities in the two species and two strains examined.
Thus the present studies do not indicate any metabolic deficiencies 
as a result of which C3H/He mice are more likely than C57B1/6 mice 
or the Sprague-Dawley rat to sustain PB induced liver injury 
resulting in nodule formation.
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Fig. 5.3 The Relationship between The Generation of Reactive 
Species by the Hepatic Cytochrome P-450 System, and 
Mechanisms of Cellular Protection by Enzymes 
Associated with Glutathione Metabolism.
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Fig. 6.4 The Effect of PB on Hepatic- Non-Protein Sulphydryl (A) , 
Y-Glutamyl Transpeptidase (B) and Glutathione 
Reductase (C).
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Fig. 5.5 The Effect of PB on Hepatic Glutathione
S-Transferase Activity to CDNB (A) and DCNB (B).
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Sprague-Dawley rats (■) at a dose of 85 mg/kg/day to mice 
and 150 mg/kg/day to rats. Data is presented as the mean 
± S.E.M. of 6 treated animals expressed as a percentage of 
6 control animals. Typical control data and units of 
expression are shown in Table 6.3. * Indicates values not
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Fig. 5.6 The Effect of PB on Hepatic' Glutathione
S-Transferase Activity to NBC (A) and ENPP (B).
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and 150 mg/kg/day to rats. Data is presented as the mean 
± S.E.M. of 6 treated animals expressed as a percentage of 
6 control animals. Typical control data and units of 
expression are shown in Table 6.3. All values significantly 
different (Student's t-test) from control (P<0.01).
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Table 6.1 Reported specific activities of purified glutathione 
S-transferase isoenzymes to different substrates compared to
l-chloro-2,4-dinitrobenzene in the Sprague-Dawley rat and DBA/2J mouse
' Relative activities (%) of rat
glutathione S-transferase^
Substrate A B C E
(Specific activity to CDNB^) (62) (11) (10) (0.01)
l-Chloro-2,4-dinitrobenzene 100 100 100 100
1,2-Dichloro-4-nitrobenzene 6.9 0.03 20 1
p-Nitrobenzyl chloride 18 1.0 102 41000
1,2-Epoxy-3-(^-nitrophenoxy)propane 0.2 0.5 1 67000
Relative activities (%) of mouse
glutathione S-transferase^
FI F2 F3 F4
^Specific activity to CDNB^) (104) (281) (143) -
l-Chloro-2,4-dinitrobenzene 100 100 100 100
1,2-Dichloro-4-nitrobenzene 0.9 0.1 1.5 0.5
p-Nitrobenzyl chloride 0.7 0.2 0.1 0.1
1,2-Epoxy-3-(p-nitrophenoxy)propane 0.2 0.2 0.3 4.8
^ Data from Habig et al. (1974a), J. Biol. Chem., 249, 7130 •
^ Data from Lee et al (1981), J. Biol. Chem., 256, 8110.
^ In units of pmol/min/mg cytosolic protein.
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CHAPTER 7
THE EFFECT OF o-AMINOAZOTOLUENE 
ADMINISTRATION ON. SOME XENOBIOTIC 
METABOLISING ENZYME ACTIVITIES OF 
LIVER AND LIVER NODULES IN TWO MOUSE 
STRAINS.
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INTRODUCTION
The carcinogenic potential of some azo dyes, including
o-aminoazotoluene (OAT,4-amino-2,3-dimethylazobenzene, 
see Fig. 7.1), has been known for many years. Indeed the 
first demonstration of carcinogenesis at a site remote from 
the place of application was reported by Yoshida (1932), who 
found that feeding OAT resulted in hepatocellular carcinoma. 
Thus in contrast to previous work inducing skin tumours in 
mice painted with coal tar (Yamagiwa and Ichikawa 1915), 
the structure of a carcinogen producing organ specific tumours 
was known. As a result the carcinogenicity of many other azo 
dyes has been investigated, mainly in the rat and mouse.
Aminoazotoluenes are more carcinogenic in mice than rats, 
while the opposite is true for the aminoazobenzenes (Terayama 
1967). Of the azo dyes 4-dimethylaminoazobenzene (DAB) and
3-methyl-4-dimethylaminoazobenzene (3-MeDAB) are among the 
most potent hepatocarcinogens and the most comprehensively 
studied.
Aminoazo dyes are mainly metabolised in the liver and the 
pattern of metabolism may differ according to species, strain, 
sex, age and nutritional status of the test animal (Terayama 
1967). In the rat metabolic reactions taking place on 
administered DAB include N—déméthylation, N-hydroxylation, 
ring hydroxylation and reductive azo cleavage (Terayama 1967). 
Following Phase I metabolism conjugation with sulphate, 
glucuronate or acetate may occur. A small proportion of
■190
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administered dye, or dye metabolites may bind covalently to 
cell macromolecules. Binding occurs to protein in practically 
all the subcellular fractions of rat liver, but the microsomal 
proteins are first to bind dyes and thus probably represent 
the initial site of metabolism (Gelboin et al 1958). Of the 
metabolic pathways occurring, ring hydroxylation, azo reduction 
and conjugation are considered to be detoxifying reactions.
For example the products of azo bond cleavage of DAB, aniline 
and N,N-dimethyIphenylenediamine were not carcinogenic 
(Terayama 1967). However N-hydroxylation of DAB is apparently 
correlated with carcinogenicity in the rat (Kimura et al 1982a). 
The same workers find that N-hydroxylation of 3-MeDAB in rats 
involves cytochrome ”P-448” (Kimura et al 1982b).
Some azo compounds have been found to induce cytochrome P-450. 
For example Hino et al (1982) reported the induction of 
cytochromes ”P-450** and "P-448" after feeding 3-MeDAB to rats. 
Fujita et al (1981) postulated the formation of an "azo-bay 
region" in napthol-azo compounds, resulting in the induction 
of cytochrome "P-448" with treatment (Fig. 7.2)a Indeed
l-m-tolueneazo-2-napWthol was a potent inducer of this cytochrome 
form in C57B1 mice (Fujita et al 1982).
The elucidation of all the metabolic pathways of OAT metabolism 
has yet to be achieved. N-Hydroxylation of OAT was inferred by 
Matsumoto and Terayama (1965) after identification of 
4,4 -bis(o-tolylazo)-2,2-dimethylazobenzene (BTDA), isolated 
from livers of rats after oral administration of OAT. BTDA 
could be formed as a condensation product of N-hydroxy-OAT and
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OAT. In recent in vitro rat studies, N-hydroxy-OAT,
4-hydroxy-OAT and some 2-hydroxymethyl-3-methyl-4-aminoazobenzene 
have been isolated (Degawa et al 1982). Again some BTDA was 
recovered as an artefact. The same study showed that formation 
of these metabolites was reduced by addition of inhibitors 
of cytochrome P-450, particularly ^-naphthoflavone, known to 
inhibit enzyme activities associated with cytochrome "P-448" 
(Wiebel et al 1971). In mice and rats both 20-methylcholanthrene 
and PB have been shown to increase azo reductase activity 
(Fujita and Peisach 1978). Thus the proportions of the various 
cytochrome types in the liver might influence both toxifying 
and detoxifying metabolic pathways.
There is little information on the effect of OAT or other azo 
dyes on microsomal cytochrome P-450 content or xenobiotic 
metabolism. Given as a single dose to rats DAB was found to 
decrease hepatic microsomal cytochrome P-450 content and 
aminopyrine déméthylation for several days (Arcasoy et al 1968). 
Both DAB and 3-MeDAB depressed microsomal N-demethylation and 
benzo(a)pyrene hydroxylation when fed in a low protein diet 
for up to 90 days at 0.06%, but no change was noted when the 
dyes were fed in a stock diet (Baldwin and Barker 1965).
However a more recent study has shown that 3-MeDAB induces 
cytochrome P-450 (Hino et al 1982).
In this study the effects of prolonged administration of OAT 
on microsomal cytochrome P-450 content and m.f.o. enzyme 
activities, and on some aspects of glutathione metabolism 
were measured. Two strains of mouse with low (C57B1/6) and
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high (C3H/He) frequencies of spontaneous hepatoma were tested 
(see Chapter 1.2.3), to ascertain any differences in response 
that might be relevant to nodule formation. Furthermore the 
response of C3H/He mice to the carcinogen OAT might be 
compared to that during prolonged PB treatment (see Chapter 4). 
Two experiments were performed; firstly a pilot study feeding 
0.04% OAT to C3H/He mice for up to 32 weeks and secondly, 
feeding 0.03% OAT to both strains of mouse for up to 32 weeks.
MATERIALS AND METHODS
OAT was administered in semisynthetic diet (see Chapter 2.13) 
at a concentration of 0.04% (w/w) to C3H/He mice. Groups of 
4 control and 4 test mice were killed at 8, 16, 24 and 32 weeks 
of treatment, and enzyme activities of Phase I and Phase II 
metabolism were measured by methods described in Chapter 2.
OAT was also administered in the diet at a concentration of 
0.03% (w/w) to both C3H/He and C57B1/6 mice. Groups of 6 control 
and 6 test mice were killed at 4, 8, 16, 24 and 32 weeks of 
treatment and DNA content, non-protein sulphydryl groups and 
several enzyme activities of Phase I and Phase II metabolism 
measured.
At 32 weeks of treatment some animals had large easily 
dissectable liver nodules. These were removed and assayed 
separately. Nodules from more than one animal were combined 
to form each tissue pool.
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RESULTS
Feeding 0.04% (w/w) OAT to C3H Mice
Feeding 0.04% (w/w) OAT to C3H/He mice (Table 7.1) resulted 
in a marked reduction of body weight at all times although 
the percentage reduction was progressively less from 8 to 
32 weeks. Over the whole treatment period relative liver 
weight was significantly increased above control values 
with the maximum increase at 16 weeks.
Hepatic non-protein sulphydryl groups (Table 7.1) were 
significantly increased at 8, 16 and 24 weeks of treatment, 
but not at 32 weeks. The maximum increase attained (190%) 
at 8 weeks progressively declined to 32 weeks of treatment. 
Cytochrome P-450, NADPH-cytochrome c reductase and m.f.o. 
activity to two substrates were also measured. Cytochrome 
P-450 was significantly reduced at 16 weeks of treatment, but 
unchanged at other times. NADPH-cytochrome c reductase 
activity was significantly raised at 8, 16 and 24 weeks of 
treatment, but not at 32 weeks. Maximum stimulation (177%) 
occurred at 8 weeks. At 24 weeks of treatment ethylmorphine 
déméthylation was significantly raised (243% of control); 
at other times there was no significant change. 7-Ethoxycoumarin 
metabolism and microsomal protein content were not changed a t  
any time.
Four nodule preparations were obtained at 32 weeks, and the 
results of biochemical determinations are shown in Table 7.2. 
Non-protein sulphydryl groups in nodules were significantly 
increased to 158% of control levels. Host liver, from which
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nodules were dissected, also had significantly elevated 
non-protein sulphydryl levels. Glutathione S-transferase 
activity to l-chloro-2,4-dinitrobenzene (CDNB) was elevated 
inboth host and nodular tissue to 142 and 239% of control 
values respectively but these increases were not significantly 
different from control. Activity to 1,2-epoxy-3-(£-nitrophenoxy) 
propane (ENPP) was not changed with treatment.
Cytochrome P-450 content of host tissue was slightly reduced 
from Control levels, but in nodules the level was 51% of 
control. In contrast NADPH-cytochrome c reductase activity 
was not significantly changed in either tissue preparation.
De aIkylation of both 7-ethoxycoumarin and ethylmorphine was 
not different from control in host tissue but in nodular tissue, 
although metabolism of 7-ethoxycoumarin was also unchanged, that 
of ethylmorphine was 59% of control.' Glucose 6-phosphatase 
activity was reduced in both tissues but only the reduction 
in nodules was significant.
Feeding 0.03% (w/w) OAT to C3H/He and C57B1/6 Mice
OAT was fed to both mouse strains for up to 32 weeks and the 
results of measurements made are shown graphically in Figures 
7.3 to 7,9, as percentage of control values. The effect of 
OAT treatment on body weight shows that treated C3H/He mice 
were significantly lighter than control throughout OAT 
administration whereas treated C57B1/6 mice were only lighter 
at 24 weeks (Fig. 7.3A). There was no apparent difference in 
the food consumption of test animals between strains indicating
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that the dose of OAT received was similar in both strains 
(data not shown). Livers of test mice became progressively 
more affected with treatment. The surface and edge of the 
liver lobes were rough and at 24 and 32 weeks of treatment 
liver nodules developed. Nodules were generally liver coloured 
in both strains and at 32 weeks large nodules were excised and 
treated as a separate tissue pool. At 32 weeks in C3H/He mice 
more large nodules were found at a dose of 0.04% than 0.03% OAT. 
The bile of C3H/He mice was often a cloudy white colour, whereas 
in the C57B1/5 mice it was clear and yellow.
Figure 7.3B shows that relative liver weight in C57B1/6 mice 
was significantly increased at all times of treatment. From 
4 to 16 weeks the increase was progressive, but there was little 
change from 16 to 32 weeks. Relative liver weight in C3H/He 
mice was not increased at 4 weeks, increased from 8 to 16 weeks 
and remained constant thereafter.
The DNA content of OAT treated livers expressed as a percentage 
of control is shown in Figure 7.4. ' Total hepatic DNA content 
per unit body weight was not changed ineither strain at 4 weeks 
but was significantly elevated at all other times (Fig. 7,4A)o 
DNA content in the C3H/He strain remained constant from 16 to 
32 weeks, but increased over this time in the C57B1/6 strain. 
Specific hepatic DNA content expressed per g liver was not 
changed in either strain at 4 weeks (Fig. 7.4B). Thereafter 
in both strains there was a significant increase, to a similar 
level of about 140% above control at 32 weeks.
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Non-protein sulphydryl levels were significantly raised at 
all times in both mouse strains (Fig. 7.5). In both strains 
levels increased to a maximum at 8 weeks and declined thereafter.
Biochemical assay of some enzyme activities often used as 
histochemical markers are shown in Figure 7.6. Figure 7.6A 
shows Y-giutamyltranspeptidase (GGT) was stimulated at all 
times in both mouse strains.
Glucose-6-phosphate dehydrogenase activity was variably induced 
in both mouse strains at all times of treatment (Fig. 7.6B). 
Glucose-6-phosphatase showed a significant depression of activity 
at all treatment times in both strains.
Glutathione reductase (Fig. 7.7A) was induced at all times of 
OAT treatment in both strains of mouse. Glutathione S-transferase 
activity to CDNB was induced in both strains at 4 and 8 weeks 
but at 16 weeks of treatment in C57B1/6 mice and at 16 and 
24 weeks in C3H/He mice there was no increase of activity above 
control (Fig. 7.7B). At 32 weeks some stimulation, was seen in 
both strains. GTutathione S-transferase activity to ENPP was 
essentially not changed from control, although a slight increase 
was observed in C57B1/6 mice at 8 weeks of treatment (Fig. 7.7C).
Microsomal protein content was not significantly changed from 
control in C57B1/6 mice, but in C3H/He mice there was a 
significant reduction at 4 and 8 weeks to 78% and 79% of control 
values respectively. At 32 weeks there was an increase in 
protein content to 118% of control value (data not shown).
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Microsomal m.f.o. enzyme activity was measured using the 
substrates'7-ethoxycoumarin (Fig. 7.8A), 7-ethoxyresorufin 
(Fig. 7.8B) and ethylmorphine (Fig. 7.9A). 7-Ethoxycoumarin 
dééthylation was significantly increased in the C57B1/6 strain 
at all times to about 200% of control. In the C3H/He mouse 
there was induction only after 16 weeks of treatment. 
7-Ethoxyresorufin dééthylation was highly induced at all times 
of treatment and in both strains. C57B1/6 strain mice responded 
to a higher degree (about 700% of control value ) than the 
C3H/He strain (about 400% of control value). Ethylmorphine 
N-demethylase was significantly elevated in both strains to 
a similar degree at 16, 24 and 32 weeks of treatment, but 
not at 4 or 8 weeks.
NADPH-cytochrome c reductase (Fig. 7.9B) was significantly 
increased from 4 to 24 weeks in the C3H/He mouse, but was not 
increased in the C57B1/6 strain at any time.
Cytochrome P-450 content (Fig. 7.9C) was only increased in 
both strains at 32 weeks of treatment. The cytochrome P-450 
Soret peak showed a hypsochromic shift of about 0.8 nm in 
test animals (data not shown).
Studies on Large Nodules
At 32 weeks of treatment preparations of nodular tissue were 
obtained from both strains of mice. Results of biochemical 
measurements are given in Tables 7.3 and 7.4 for C3H/He mice 
and Tables 7.5 and 7.6 for C57B1/6 mice.
1 98
GGT was increased in host tissue of both strains but to a 
greater extent (387%) in C3H/He mice. In this strain the 
activity in nodular tissue was induced to a lesser degree 
(242%). GGT activity in nodules of C57B1/6 mice was not 
measured due to lack of tissue sample.
Non-protein sulphydryl levels were significantly increased in 
nodular and host tissue of both strains being 119% and 132% 
of control respectively in C3H-/He and 155% and 155% of 
control respectively in C57B1/6 mice.
Glutathione S-transferase activity was not changed in nodules 
of C3H/He mice although there was some stimulation of activity 
to CDNB in host tissue. There was a large stimulation of 
activity to CDNB and ENPP in nodules from C57B1/6 mice. 
Activity in host tissue was stimulated to CDNB (197%) and 
not stimulated to ENPP.
The activity of nodular glutathione reductase was increased 
in both strains being 252% of control in C57B1/6 mice and 
352% of control in C3H/He mice. Host tissue glutathione 
reductase was induced to about 180% of control values in 
both strains.
Glucose-6-phosphate dehydrogenase activity was elevated 
in nodules of both strains to about 200% of control, as was 
activity in C57B1/5 host tissue, but activity in C3H/He 
host tissue was increased 3 fold over control values.
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Three m.f.o. substrates were assayed for microsomal metabolism. 
7-Ethoxyresorufin dééthylation was increased more than 
5 fold in nodules and host liver of both mouse strains.
With the substrate 7-ethoxycoumarin activity in nodules 
and host tissue in both strains was about 150-200% of control. 
Ethylmorphine N-demethylase was not significantly elevated 
in nodular tissue from C57B1/5 mice, but in C3H/He mice was 
significantly raised to 145% of control value. The values 
from host tissue were significantly raised in both strains, 
to 147% in C57B1/6 and 187% in C3H/He mice.
Glucose-5-phosphatase activity was reduced by treatment in both 
host tissue and nodules but these reductions were not 
significantly different in nodules from C3H/He mice.
NADPH-Cytochrome c reductase activity was little changed in 
nodules or host tissue. Cytochrome P-450 content of nodules 
was reduced and this was greatest in the C57B1/5 strain, 
where content was 55 or 70% of control level. However 
cytochrome P-450 content of host tissue was significantly 
increased in both strains.
Microsomal protein content was not changed in C57B1/6 mice but 
nodules from C3H/He mice protein content was significantly 
reduced to 79% of control and in host liver was significantly 
raised to 118% of control value.
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DISCUSSION,
The very low body weights of C3H/He mice fed 0.04% OAT 
suggests that the compound was toxic at this dose. In this 
strain body weight was also reduced at all times with 0.03%
OAT. However the C57B1/5 strain was only marginally lighter 
in body weight when fed the lower dose, indicating a possible . 
difference in toxicity between the two strains. The toxicity 
of OAT has been previously noted (Kirby 1945; Shelton 1955).
The different condition of the bile fluid may also indicate 
a different metabolic profile between the two strains. This 
point warrants further investigation.
Relative liver weight in the C57B1/6 strain increased throughout 
the treatment, but in the C3H/He strain reached a maximum 
after 16 weeks, at both the doses tested. Increase of liver 
size is a common response to xenobiotic treatment and may be 
a result of cellular hypertrophy and/or hyperplasia. The 
effect is commonly seen after administration of many types of 
chemicals (Schulte-Hermann 1974), including PB (Chapter 4). 
Grasso (1979) postulated that such increases in liver size 
with hepatic enzyme induction represented "work hypertrophy" 
but with no change or depression of hepatic enzymes represented 
liver damage. The azo dye Ponceau MX matched the latter 
criteria and indeed resulted in tumour formation. Changes in 
total hepatic DNA content (mg DNA/lOOg body weight) to a large 
extent mirrored the changes in liver size with OAT treatment; 
that is continuing increasing trend in C57B1/6 mice, but a 
plateau at 16 weeks in C3H/He mice. Thus the increase in liver 
size was accompanied by DNA synthesis showing hyperplasia, or 
perhaps changes in cellular ploidy. Hypertrophy, indicated
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by a fall in specific DNA content (mg/g liver), was not 
apparent; indeed the unit content of DNA was increased with 
treatment. However at 4 weeks there was no change in C3H/He 
mice and there w a s  an indication of a hypertrophic response 
in C57B1/6 mice. Lawson (1970) measured the incorporation 
of [^njthymidine into hepatic DNA of mice fed 0.1% OAT for 
up to 8 weeks. There was no change from control animals until 
6 weeks when a 3 fold increase was measured, and at 8 weeks 
over 4 fold. These data again indicate that there was no 
hyperplastic response until after 4 weeks of OAT administration.
Hepatic non-protein sulphydryl content was elevated by OAT 
treatment in both strains of mouse at all times. In the C3H/He 
mouse the two dose levels resulted in very similar changes and 
the profile of response in both strains was comparable. Calcutt 
et al (1961) claimed that hepatic sulphydryl levels were 
increased in mice for up to 72 days after a single 8 mg dose, 
but the data presented scarcely supported this view. These 
workers hypothesised that increased tissue sulphydryl was an 
"essential prerequisite for tumour formation". Neish et al 
(1964) investigated the effect of several azo dyes, including 
OAT, on hepatic glutathione content and found that elevation 
of this parameter correlated with carcinogenic potency. Later 
work led to the revision of the hypothesis to include that 
other factors might also be involved (Neish. 1971). It is 
noteworthy that in this study non-protein sulphydryl levels 
increased up to 8 weeks and declined thereafter. The increase 
in glutathione reductase activity might tend to increase 
reduced glutathione levels in the cell, but induction of this 
enzyme did not mirror changes in non-protein sulphydryl content.
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Compounds that give rise to reactive metabolites tend in 
the short term to deplete intracellular reduced glutathione, 
by binding and subsequent excretion as mercapturic acids 
(Lake 1984j see Chapter 6). On prolonged challenge sulphydryl 
content may rise above control levels, reflecting toxicity 
(Evans et al T982). Ketterer et al (1979) have identified 
glutathione adducts of some DAB metabolites and it would 
be of interest to repeat that work using OAT.
Conjugation of glutathione may also be directed by the glutathione 
S-transferase group of isozymes. These enzymes are differentially 
induced by OAT as activity to CDNB is increased in both strains 
with 4, 8 and 32 weeks of treatment, but activity to ENPP is 
essentially unchanged with treatment. Mouse liver glutathione
S-transferase has been separated into at least 4 types 
(Lee et al 1981), labelled FI, F2, F3 and F4. CDNB is a substrate 
to all four transferases, but F4 has a high specific activity 
to ENPP and thus may not be induced by OAT.
Considerationcf the effect of OAT on cytochrome P-450 content 
and associated xenobiotic metabolising enzymes shows a
generally similar response in both strains of mouse. Cytochrome
■
P-450 content and ethylmorphine N-demethylase show no large 
strain differences and in spite of little change in cytochrome 
P-450, some increase of the enzyme activity develops with 
prolonged treatment. However the cytochrome "P-448" linked 
dééthylation of 7-ethoxyresorufin and also 7-ethoxycoumarin 
are induced in the C57B1/5 strain at all times of treatmenti 
These enzymes are not changed or are increased to a lesser
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extent in the C3H/He mouse. As both strains are classified 
as "responsive” to polycyclic hydrocarbon type induction,
(Nebert et al 1975) it may be concluded that OAT is similar 
to polycyclic hydrocarbon type inducers. However the late 
stimulation of ethylmorphine N-demethylase in both strains 
is not typical of cytochrome "P-448" induction. As has been 
shown earlier (Chapter 4, Tables 4.9 and 4.10) with cytochrome 
"P-448" induction ethylmorphine N-demethylation is not ' 
increased. A change of cytochrome types is confirmed by the 
hypsochromic shift in the wavelength of absorption of the 
reduced cytochrome P-450-C0 complex. Hino et al (1982) 
reported increased cytochrome P-450 after 3-MeDAB in rats, 
but no apparent wavelength change, and using the Ames test 
detected "P-448" at high doses but not low, suggesting biphasic 
induction. Cytochrome "P-448" induction would, according to 
Hernandez et al (1967), potentially stimulate azoreductase 
by a CO insensitive pathway, thereby aiding detoxification.
As previously stated cytochrome "P-448" enhances the formation 
of N-hydroxy-OAT (Degawa et al 1982) which has been positively 
correlated with carcinogenicity in the rat (Kimura et al 1982a). 
The stimulation of NADPH-cytochrome c reductase in C3H/He 
but not C57B1/6 mice by OAT may have some relevance to toxicity 
and tumour formation, as it is at least partly involved in 
the reductive cleavage of DAB (Hernandez et al 1967). However 
stimulation of cytochrome c reductase did not protect the 
C3H/He mice to any appreciable extent. The metabolism of 
OAT has many pathways and by altering the cytochromes present 
in the mouse liver OAT must alter its own metabolism. The 
precise effect that this may have cannot be ascertained from
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these data. However, it seems that stimulation of the 
cytochrome P-450 system can lead to increased reactive metabolites 
for in the Ames test both "anti-P-448" and "anti-P-450" 
antibodies reduced mutagenicity of OAT (Kawajiri et al 1980).
After feeding 0.06% of DAB for several weeks little change 
(Takamiya et al 1973) or reduction (Autrup et al 1975) of 
enzyme activities have been reported. The latter group 
reports DAB-nitroreductase, DAB-azoreductase, NADPH-cytochrome 
c reductase, N,N-dimethylaniline N-oxidation, DAB N-demethylation 
activities, cytochrome P-450 content and body weight all 
reduced below control values from 2 to 24 weeks with some 
recovery at about 12 weeks. It can be seen from comparing 
data from mice fed 0.04% OAT with those from mice fed 0.03%
OAT that there tended to be greater stimulation of m.f.o. 
enzymes and a slightly higher Cytochrome P-450 content at 
the lower dose. Thus 0.04% OAT in the diet probably had a more 
toxic affect on the mice and this is confirmed by comparing 
the body weights of test and control animals. The lack of 
enzyme stimulation previously seen with other azo compounds 
may be partly due to toxicity.
This finding was repeated when comparing the enzyme activities 
of nodular tissue from C3H/He mice fed 0.03 or 0.04% OAT,
While non-protein sulphydryl was elevated more at the higher 
dose, glutathione S-transferase activities were largely 
unchanged from control. At the higher dose the activity of 
nodular m.f.o. enzymes and cytochrome P-450 content were
205
equal to or below control levels, but at the lower dose 
they were equal to or higher than control. When fed DAB 
at 0.06% nodular enzyme levels were far below control 
activities (Adamson and Fouts 1961), Indeed nodular tissue 
resulting from various treatments has often been found lacking 
in m.f.o. enzyme activities (seeChapter 4).
When considering nodules from the two strains of mouse the 
response to OAT was in many respects similar. For instance 
the m.f.o. enzymes were similarly induced with the greatest 
increase of 7-ethoxyresorufin 0-deethylase. However there was 
a considerable elevation of non-protein sulphydryl groups 
in the C57B1/6 strain and there was a clear difference of 
activity in glutathione S-transferase which was highly induced 
in C57B1/6 mice, and may thus represent a protective mechanism 
present only in nodules of this strain. Kitahara et al 
(1983) have found increased glutathione S-transferase types A 
and B in rats fed 0.06% 3-MeDAB for 2 weeks. This point 
could be further investigated by purification of the isozymes 
present from the various tissues.
Treatment of mice with OAT did not lead to the consistent 
reduction of parameters measured with the exception of body 
weight and glucose-6-phosphatase. Many parameters were 
stimulated to varying extents showing OAT to be a weak mixed 
type inducing agent. Nodules resulting from OAT treatment 
tended to have similar enzyme activities to their host tissue. 
The carcinogenic process resulting from feeding OAT to mice 
does not, therefore, arise from failure of m.f.o. enzyme 
activities.
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Fig. 7.1 Structure of o-aminoazotoluene, OAT.
,CH CH.
N=N NH.
Fig. 7.2 Bay region structure of l-arylazo-2-naphthol
B, Bay region
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Fig., 7.3 The Effect of OAT Administration on Body
and Liver Weight.
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OAT was administered in the diet at a concentration of 
0.03% (w/w) for up to 32 weeks to C3H/He (•) C57B1/6 (a) 
strain mice. Body weight (A) in g and relative liver weight 
(B) in -g/lOOg body weight are presented as the mean - S.E.M: 
of 6 treated mice expressed as a percentage of 6 »untreated 
mice. Typical control values for body weight are 26.6 - 0,4 and 
25.6 - 0.5g and for relative liver weight 3.4 * “0.1 and 3.5 * 0.1 g/lOOg 
of C3H/He and Ç57B1/6 mice, respectively.
* Indicates values nob significantly different (Student's 
t-test) from control (P>0.05) .
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Fig. 7.4 The Effect of OAT Administration on Hepatic DNA Content.
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Fig. 7.5 The Effect of OAT Administration on Hepatic
Non-Protein Sulphydryl Groups.
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OAT was administered in the diet at a concentration of 
0.03% (w/w) to C3H/He (•) and C57B1/6 (A) strain miçe for 
up to 32 weeks. Results are presented as the mean - S.E.M. 
of 6 treated mice expressed as a percentage of 6 untreated 
mice. Typical control values and units of expression are shown 
in Tables 7.3 and 7.5 All values significantly different 
(Student's t-test) from control(P<0.01).
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Fig. 7.6 The Effect of OAT Administration on Hepatic
Y-Glutamyl Transpeptidase (A), Glucose-6-Phosphate 
Dehydrogenase (B) and Glucose-6-Phosphatase (C).
400-1
300-
>
■*— >
o 200-
<
o 100-
&_ 
4—' 400-
c
o
O 300-
s—
o
200-
o
D)
03 100-
C 100-]
Q)
O
L_ 50-
(D
CL
n -
C3H
. 8
C 5 7
C3H
T 1T
""s m  2 4
W e e k s  of Treatment
C 5 7
C3H
32
OAT was administered at a concentration of 0.03% (w/w) 
t-o'CBH/He (•) and C57B1/6 (a) strain mice for up to 
32 weeks. .Results are presented as the mean - S.E.M. 
of 6 treated mice expressed as a percentage of 6 untreated 
mice. Typical, control values and units of expression are 
shown in Tables 7.3 to 7.6. All values significantly 
different (Student's t-test) from control (P <0.05).
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Fig. 7.7 The Effect of OAT Administration on Hepatic
Glutathione Reductase (A) and Glutathione
S-Transferase Activity to CDNB (B) and ENPP (C).
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OAT was administered at a concentration of 0.03% (w/w) in 
the diet to C3H/He (•) and C57B1/6 (a ) strain mice for up 
to 32 weeks. Results are presented as the mean - S.E.M. 
of 6 treated mice expressed as a percentage of 5 untreated 
mice. Typical control values and the units of expression 
are shown in Tables 7.3 and 7.5. * Indicates values not
significantly (Student's t-test) different from control (P>0.05)
Fig. 7.8 The Effect of OAT Administration on Hepatic 
Microsomal 7-Ethoxycoumarin 0-Deethylase (A) 
and 7-Ethoxyresorufin 0-Deethylase (B).
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OAT was administered in the diet at a concentration of 0.03% 
(w/w) to C3H/He (•) and C57B.1/6 (^ ) mice for up to 32 weeks. 
Results are presented as the mean * S.E.M, of 6 treated mice 
expressed as a percentage of 6 untreated mice. Typical 
control values and the units of expression are shown in 
Tables 7.4 and 7.5. * Indicates values not significantly
different (Student's t-test) from control (P>0.05).
Fig. 7.9' Effect of OAT Administration on Hepatic Microsomal 
Ethylmorphine N-DemeVhylase (A), NADPH-Cytochrome c 
Reductase (B) and Cytochrome P-450 Content (C).
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OAT was administered at a concentration of 0.03% (w/w) in 
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GENERAL DISCUSSION •
This general discussion will review the data gained on enzyme 
induction and nodule formation in this study, consider it in 
conjunction with other available information, and conclude with 
some speculation on the process of nodule formation.
It is generally accepted that the predisposition of the mouse 
to hepatic tumours makes interpretation of results indicating 
positive tumourigenesis difficult, and extrapolation to man- 
dubious (Grasso and Crampton 1972, Nutrition Foundation 1983). 
Furthermore the differing susceptibilities of various mouse 
strains to tumourigenesis by epigenetic carcinogens suggests a 
fundamental difference, not only between the mouse and other 
species, but within the species. Thus comparisons of several 
effects of short term treatment with phenobarbitone (PB) to 
two mouse strains of differing susceptibilities, and the rat 
were made. Although the rat tolerated nearly twice the daily 
dose of PB compared to both mouse strains, induction of cytochrome 
P-450 and related m.f.o. enzymes was similar in degree. PB also 
increased enzymes of Phase II metabolism in both species and 
strains, although some minor differences were noted. The rate 
of excretion of PB and its metabolites was increased by 
pretreatment of both species and strains. However PB was more 
extensively metabolised in the rat than either mouse strain, and 
pretreatment with PB further increased metabolism in both 
species and strains. Thus while minor differences of both 
constitutative and PB induced enzyme activities were observed 
between the rat and two mouse strains in these studies, none 
of these differences appeared to be responsible for the known 
differences in susceptibility to hepatoma formation.
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Long term treatment of PB to C3H/He mice resulted in sustained 
induction of several enzymes of Phase I and II metabolism.
The excretion of [^^c]PB from mice treated for 70 weeks was 
similar to that from mice treated for 2 weeks. Nodules in PB 
treated mice were seen from 40 weeks, and thus hepatic nodule 
formation was initiated between 25 and 40 weeks. These nodules, 
which developed into large masses, were eosinophilic. This 
indicates a difference from nodules seen in untreated mice, 
which developed later and were basophilic (Evans et al 1985). 
Previously PB has been reported to increase the incidence of 
spontaneous tumours (Perainio et al 1973; Ponomarkov et al 
1976; Becker 1982). However other compounds have been shown to 
produce nodules histologically different from spontaneous nodules 
(Hoover et al 1980). Thus the suggestion of previous workers 
(Frith et al 1980; Lipsky et al 1981; Ward and Vlahakis 1978) 
that hepatic nodules progress to carcinoma may be erroneous.
Xenobiotic metabolising enzyme activities were also induced in 
these nodules, and few functional differences were observed 
between liver nodules and host tissue. Y-Glutamyl transpeptidase 
(GGT) was stimulated to a large degree in all nodules from treated 
mice, but in only some nodules from mice given PB for 60 weeks 
and then control diet for 34 weeks, or from untroated mice. 
Although GGT was considered to be a marker for preneoplastic 
tissue in the mouse (Cameron et al 1978) as activity was not 
shown to be elevated in spontaneous tumours, but showed a positive 
relationship with time during chemical carcinogenesis. By these 
criteria PB induced nodules were equivalent to preneoplastic 
lesions resulting from treatment with a carcinogen, In contrast 
nodules resulting from OAT treatment did not show the great
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stimulation of GGT. These equivocal results demonstrate that 
GGT should not be used as a marker of carcinogenesis without 
consideration of other factors. For example GGT is mainly 
associated with the plasma membrane, and activity is 1000 times 
higher in foetal liver compared to adult. Thus the question 
arises as to whether expression of this enzyme is associated 
with rate of cell growth or division, rather than damage by 
carcinogens.
As with several other hepatocarcinogens o-aminoazotoluene is 
capable of forming adducts with cellular macromolecules, 
including DNA (see Chapter 7), and thus affecting gene expression, 
The present study (Chapter 4) and other work (Corsini et al 
1972) have failed to demonstrate the covalent binding of PB 
to cell macromolecules. Thus a mode of action remains to be 
found for PB in the generation of mouse hepatic nodules.
Although acute PB treatment stimulates DNA synthesis and cell 
division and thus may result in the incorporation of unrepaired 
genetic damage into DNA (Craddock 1978) acute PB treatment alone 
is insufficient to result in tumourigenesis. Indeed PB has 
been shown to be a promoter for various carcinogens where genetic 
changes are presumably involved (Perainio et al 1971). As 
prolonged treatment is required for both nodule generation and 
promotion following a carcinogen the process may involve subtle 
changes that accumulate. Possible target molecules include 
RNA, histones, polyamines, enzymes of DNA metabolism and cell 
and organelle membrane components. PB treatment Stimulates 
RNA function resulting in increased protein syntbes is. P'B may 
also affect DNA indirectly by altering its metabolism. Increased 
DNA polymerase activity has been reported in several rat 
hepatomas (Ove et al 1969) and these enzymes utilised denatured
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DNA as template more efficiently than native DNA. The same 
study reported decreased deoxyribonuclease activity in , 
hepatomas. Furthermore the fidelity with which DNA polymerase 
enzymes can join nucleotides to a synthetic template has been 
shown to be decreased during 2-acetaminofluorjejne 
hepatocarcinogenesis (Chan and Becker 1979). Fidelity of 
mitochondrial DNA polymerase was reduced following administration 
of diethylnitrosamine and PB to mice (Mulcahy and Cans 1983).
Thus PB may cause an accumulation of errors in DNA (as opposed 
to DNA adducts or damage), which may ultimately result in 
tumourigenesis or allow the expression of a prexisting oncogenic 
factor as has been previously suggested (Boutwell 
1974; Peraino et al 1973). The fidelity of the DNA polymerase 
enzymes in mouse strains having differing susceptibilities to 
both spontaneous and induced hepatic nodules awaits determination.
APPENDIX
ANIMAL HEALTH
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APPENDIX 
Animal Health
During the course of chronic treatment of PB in the diet to 
C3H/He mice described in Chapter 4, some animals died during 
the early part of the study (Appendix Table 1). Apparently 
healthy mice became sick and might die within one or two days* 
Some sick mice were sent to the Medical Research Council 
for bacteriological studies, but no significant pathogens 
were found. Subsequently the presumed infection abated. 
Control and treated mice were equally affected.
At approximately 25 weeks into the study some mice were noted 
to have significant fur loss and a hunched back. Thefur loss 
was found to be directly attributable to the diet, as affected 
mice fed stock diet regained fur. Both test and control 
mice were equally affected. Over the study to 70 weeks the 
death rate was higher than expected and the major part of the 
experiment was terminated at 70 weeks. Some animals returned 
to control treatment and some test and control animals were 
kept to 94 weeks.
Three possible explanations are put forward to explain the 
health of these mice:-
1) The diet was not analysed for quality, and may have 
deteriorated or been inadequate in some way, prior to use,
2) The early infection suffered by the mice may have had 
profound and lasting effects, possibly leaving the mice unable
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to obtain adequate nutrition from the diet.
3) The diet formulation was unsuitable for long term 
nutrition in this mouse strain. However the diet (RHM) 
differed little from SS2 diet (Chapter 2.13), which was 
used successfully for up to 32 weeks in the C3H/He and 
C57B1/6 mouse strains (Chapter 7).
These factors may have contributed singly or together to 
the effects seen. It is felt, however, that this problem 
did not invalidate the results obtained because a) liver 
architecture was histologically normal at all treatment 
times in control mice and a typical response to PB was 
observed, and b) enzyme activities of control mice were 
in normal ranges and the response to PB was compatable 
with known f acts.
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